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Cationic lipids are commonly used and relatively safe vectors for plasmid 
(pDNA) delivery.  In search for an optimal lipid-based formulation for siRNA 
delivery to the lungs, cationic lipid-based carriers were investigated for the delivery 
of siRNA in comparison with pDNA delivery. The aim was to determine whether the 
factors that influence cationic-lipid mediated pDNA delivery would similarly affect 
siRNA delivery. 
Plasmid DNA encoding for luciferase and GAPDH siRNA were complexed 
using three model cationic lipid-based systems; DOTAP:DOPE, 
DOTAP:DOPE:DMPE-PEG5000, DOTAP:DOPE:protamine.  Cationic lipid/pDNA 
(+/-) charge ratio of 2 or greater complexed pDNA most efficiently, while much 
higher  ratios  (≥  10) were still less efficient in complexing siRNA.  pDNA complexes 
were larger (up to 4 µm) and formed aggregates in physiological buffer, compared to 
water, whereas siRNA complexes remained small (<300 nm).   Gene silencing in 
bronchial and alveolar cell lines Calu-3 and A549 revealed a dependency on high 
lipid/siRNA (+/-) charge ratio (> 8) compared to the delivery of pDNA complexes 
(0.5-1).  Confocal microscopy and endocytic inhibitors studies indicated that the 
cellular uptake of siRNA/lipid complexes was via a temperature-dependent pathway, 
which lead to the vesicular localisation of siRNA in the peri-nuclear region.   Gene 
silencing activity was not dependent on the endocytosis-mediated uptake of the 
complexes. In conclusion, important differences in the factors that affect of siRNA 
versus pDNA delivery were revealed: the optimal properties of gene silencing were 
different depending on the nucleic acid and the lipid used.  DOTAP:DOPE:DMPE-
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absence (grey bars) or presence of the inhibitor (white bars) for 6 h.  Gene silencing 
and cell viability were measured 72 h post-tranfection using KDalert assay.  Data 
represent the mean of three independent experiments (mean±SEM).  *Statistically 
significant ((p<0.05, unpaired t-test) .....................................................................192 
Figure 4.16  (A) Gene silencing and (B) cell viability of A549 cells when exposed to 
LpegR complexes after pretreatment with inhibitors of non-clathrin mediated 
endocytosis.  Pre-treatment with nystatin 25 µg/ml, amiloride 8 µg/ml or 
cytochalasin D 10 µg/ml for 1 h, followed by transfection with LpegR complexes in 
the absence (grey bars) or presence of the inhibitor (white bars) for 6 h.  Gene 
silencing and cell viability were measured 72 h post-tranfection using KDalert assay. 
Data represent the mean of three independent experiments (mean±SEM).  
*Statistically significant ((p<0.05, unpaired t-test) ................................................193 
Figure 4.17  A) Gene silencing and B) cell viability of A549 cells after pre-treatment 
with combinations of the endocytic inhibitors.  Pre-treatment for 1 h, followed by 
transfection with LpegR complexes in the presence of the inhibitors.  Gene silencing 
and cell viability were measured 72 h post-tranfection using the KDalert assay. (Data 
represent mean±SEM, n=3).  Statistically significant (*p<0.05, *** p<0.001, One-
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1.1. Nucleic acid therapy, gene expression and gene silencing  
Gene therapy involves the transfer of genetic information into cells to modify 
their function or behaviour and therefore altering the disease state or preventing the 
occurrence of a disease (Lasic, D.D. and N.S. Templeton, 1996, Tomlinson, E. and 
A.P. Rolland, 1996).  Because inherited or acquired genetic diseases are often 
associated with a defect or absence of a particular gene, most gene therapy has been 
based on inducing gene expression by introducing nucleic acid that contains a 
specific gene to replace the defective or missing gene.  Examples of such genetic 
diseases are cystic fibrosis, alpha 1-antitrypsin deficiency and sickle cell anaemia 
(Lasic, D.D. and N.S. Templeton, 1996).  The genetic material is delivered to 
humans in two ways. One method consists of using modified viruses which contain 
the gene of interest and which are able to efficiently deliver their genomes in cells 
and express their content.  The other approach consists of combining the gene of 
interest, in many cases by inserting it into a bacterial plasmid construct with a non-
viral carrier.  Plasmids are easily manipulated to include any gene of interest and the 
preparation of large quantities in the pure form is simple.   
Studies in gene therapy have been ongoing for many years in order to improve 
transfection efficiencies to levels required for clinical trials.  Meanwhile, there has 
been a growing interest in developing ways of altering cell function by the 
suppression of gene expression, and the idea of silencing pathogenic genes has 
become an attractive approach for the treatment of many diseases including viral 
infections, such as HIV and influenza, cancer and inflammatory diseases such as 
rheumatoid arthritis and Crohn’s  disease (Opalinska, J.B. and A.M. Gewirtz, 2002).  
The most widespread approach employed to downregulate gene expression consists 
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of the use of antisense oligonucleotides.  Over 20 antisense drugs have entered 
clinical studies (Chan, J.H. et al., 2006, Juliano, R. et al., 2008).   However despite 
the success of the antisense approach in studying gene function, this methodology is 
not the most attractive therapeutic gene silencing approach because it requires 
extensive experimental work to define effective target sites within the gene of 
interest, which is expensive and time consuming (Thomas, M. et al., 2007, Behlke, 
M.A., 2006). Ribozymes are catalytically active RNA composed of three helices that 
chop single-stranded regions of their own or other RNAs by transesterification or 
hydrolysis.     They   haven’t   been   highly   investigated   for   therapeutic use due to their 
low stability in serum of only seconds to minutes (Reischl, D. and A. Zimmer, 2009, 
Dorsett, Y. and T. Tuschl, 2004).  
The discovery of RNA interference (RNAi) in the 1990s opened up an entirely 
new field of gene silencing methodology. Although RNA interference was first 
observed   in   the   early   90’s   in   plants   (Napoli, C. et al., 1990), the mechanism 
remained unexplained until 1998 when Fire and co-workers showed that the injection 
of double standed RNA (dsRNA) several hundred bases in length, caused an 
important gene silencing in Caenorhabditis elegans.  They identified RNAi as a 
fundamental pathway in which sequence specific stands of RNA can target and 
induce the cleavage of complementary messenger RNA (mRNA).   After the display 
of RNAi in mammalian cells (Elbashir, S.M. et al., 2001) it was rapidly recognized 
that this highly specific mechanism of sequence-specific gene silencing might be 
explored to develop a new class of drugs that interfere with disease-causing or 
disease-promoting genes (Shrivastava, N. and A. Srivastava, 2008, Wu, S.Y. and 
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N.A. Mcmillan, 2009, Cejka, D. et al., 2006) and therefore a lot of efforts have been 
made to understand the RNAi mechanism. 
1.2. RNA interference (RNAi) 
RNAi is a naturally occurring gene silencing pathway. In eukaryotic cells this 
sequence-specific silencing mechanism is essential for the suppression of genes that 
determine cell differentiation and survival.  In plants and microorganisms, this RNAi 
pathway protects the genome from viral infections (Tijsterman, M. et al., 2002, 
Dykxhoorn, D.M. and J. Lieberman, 2006, Spelios, M. et al., 2010).  In mammalian 
cells, Elbasir et al (2001) showed that introducing synthetic 21-nucleotide siRNA 
duplexes to different cells specifically suppressed the expression of endogenous 
genes.  RNA interference is initiated by long dsRNAs that are cleaved by the Dicer 
enzyme into short duplexes (~21-25 nucleotides) with 2-nucleotide   3’overhangs  
(Tijsterman, M. et al., 2004). These are known as short interfering RNA (siRNA).   
RNA interference occurs when components of the RNAi machinery specifically 
recognize these short RNA duplexes and then integrate a single siRNA strand into a 
protein complex known as the RNA induced silencing complex (RISC (Angaji, S.A. 
et al., 2010).  RISC contains the endonuclease (Ago2) (Hammond Sm, B.S., Caudy 
Aa, Kobayashi R, Hannon Gj, 2001) that cleaves the target messenger RNA bearing 
a complementary sequence to the incorporated siRNA strand and the second strand 
of the duplex is degraded (Aigner, A., 2007, Angaji, S.A. et al., 2010, Schroeder, A. 
et al., 2010). 
siRNA is a highly potent gene silencing tool compared to antisense 
oligonucleotides and riboenzymes, because it uses the physiological gene silencing 
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machinery (Figure 1.1).  The observation that long dsRNAs are cleaved by the Dicer 
enzyme, encouraged researchers to identify endogenous interfering RNA that is 
encoded by the genome itself.  Endogenous molecules termed microRNAs have been 
found and are the most characterised short RNA molecules.  These are single 
stranded RNA (ssRNA) of 21-22 nucleotides and are effector molecules derived by 
the cytoplasmic processing of pre-microRNAs (~70 nucleotides) by the dicer enzyme 
(Cejka, D. et al., 2006).  These micro-RNAs suppress gene expression by cleaving 
mRNAs or inhibiting their translation (Scherer, L.J. and J.J. Rossi, 2003, 
Karagiannis, T.C. and A. El-Osta, 2005). 
Introduction of long (>30 nucleotides) dsRNA into mammalian cells leads to 
the initiation of the antiviral interferon (IFN) response and global protein expression 
shutdown (Akhtar, S. and I.F. Benter, 2007).  Short siRNA duplexes (21-23 
nucleotides) avoid the non-specific activation and causes highly efficient gene 
silencing (Yadava, P. et al., 2007).  Therefore for safer therapeutic applications 
RNAi can be initiated through delivery of shorter siRNAs that are produced 
synthetically ex vivo and can result in highly specific and potent gene silencing in 
mammalian cells.  Although siRNAs are expensive and the induced RNA 
interference is short lived this approach is simple and effective (Gary, D.J. et al., 
2007, Aigner, A., 2007). 
1.2.1. siRNA as a therapeutic tool 
Because RNAi is present in all cells and any gene can be targeted with good 
specificity, siRNA has become an attractive strategy for the treatment of many 
diseases caused by over-expression of a gene or multiple genes such as cancer 
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(Takeshita, F. and T. Ochiya, 2006, Garbuzenko, O.B. et al., 2009), neurological 
disorders (Davidson, B.L. and H.L. Paulson, 2004), inflammation and infections 
(Ponnappa, B.C., 2009).  Before the discovery of RNA interference, antisense 
oligonucleotides were the primary tools for targeted gene silencing; but studies into 
the inhibitory effect of the different gene silencing nucleic acids have found that the 
effect of siRNA is more potent at low concentration than antisense oligonucleotides 
and riboenzymes (Scherer, L.J. and J.J. Rossi, 2003). Bertrand et al (2002) also 
reported that siRNA is 1000-fold more effective than antisense ODNs in silencing 
target genes.   In addition, gene silencing using siRNAs is cheaper and faster 
compared to the conventional gene silencing technologies (Thomas, M. et al., 2007).  
Because of these advantages, pharmaceutical companies are now aiming to exploit 
this new molecule commercially and despite its recent discovery, the first siRNA- 
based drugs have already reached phase II clinical trials (Schroeder, A. et al., 2010).  
Examples of such drugs include Bevasiranib and Cand5 siRNA, which targets the 
VEGF ligand for the treatment of age-related macular degeneration (AMD).  
However the therapeutic application of RNA interference is highly dependent on its 
delivery, since the siRNA sequences need to be delivered to the host in an efficient 






Figure 1.1  The mechanism of RNA interference (RNAi) in mammalian cells induced by either (A) long dsRNA molecules expressed from DNA 






1.3. Delivery vectors for nucleic acids 
The perquisite for successful gene therapy or gene silencing is efficient and 
safe delivery of pDNA or siRNA to target cells.  Due to their hydrophilic nature, the 
negative charge of the phosphate backbone and their susceptibility to degradation by 
nucleases, these molecules are not able to efficiently enter the cells due to the 
physical barriers of the negatively charged cellular membrane.  Therefore carriers are 
necessary for delivery of pDNA or siRNA.  Present delivery vectors for nucleic acids 
are divided into two major classes, viral and non-viral vectors. 
1.3.1. Viral vectors 
Viruses are highly efficient delivery vectors because they are extremely 
infectious and have very good endosomal escape mechanisms (Lasic, D.D. and N.S. 
Templeton, 1996); retroviruses, adenoviruses and adeno-associated viruses.  
Retroviruses infect only dividing cells and permanently integrate genes into the host 
chromosomal DNA, which makes it difficult to stop or modify therapy in case of 
intolerance to the side effects.  In addition, permanent incorporation of genes may 
lead to the stimulation of oncogenes or inhibition of tumour suppressor genes leading 
to cancer (Kay, M.A., 2007, Lasic, D.D. and N.S. Templeton, 1996, Tomlinson, E. 
and A.P. Rolland, 1996).  Another disadvantage of retroviruses is the inability to 
make high concentration of the virus and their low stability in blood (Kaneda, Y., 
2001, Kay, M.A., 2007, Lasic, D.D. and N.S. Templeton, 1996).  Unlike retroviruses, 
adenoviruses transduce non-dividing cells and have high titres, but they have been 
associated with immune and inflammatory responses, which prevents repeated 
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administration (Kovesdi, I. et al., 1997).  In addition, there is the risk of developing 
host resistance to transduction after repeated exposure to the viral vector as well as 
the generation of an infectious form of the virus during production or use. Adeno-
associated viruses are safer when compared to other viruses because of the removal 
of all viral genes (Driskell, R.A. and J.F. Engelhardt, 2003), but due to its small 
transgene size there is a limit to the size of DNA that can be packaged (Kaneda, Y., 
2001, Kay, M.A., 2007). 
1.3.2. Non-viral vectors 
Despite the popularity of viruses as vectors for in vitro and in vivo gene 
delivery, in the past decade non-viral vectors have evolved as safer and effective 
gene delivery systems for in vivo applications.  These systems include cationic lipids, 
polymers, and peptides (Martin, M.E. and K.G. Rice, 2007, Lasic, D.D. and N.S. 
Templeton, 1996).  Cationic lipids and polymers are the most promising non-viral 
vectors (Zhang, Y. et al., 2010) and despite their low transfection efficiency in vivo 
compared to viral vectors, they offer many advantages over viruses.  They are easy to 
prepare and can carry an unlimited size of DNA, and they are less likely to cause 
immunogenic and inflammatory responses (Akhtar, S. and I.F. Benter, 2007).  
Moreover the risk of developing the infectious form or inducing oncogenic mutations 
is very low because the genes delivered have low integration capacity and are unable 
to replicate or recombine (Birchall, J.C. et al., 1999). 
There is massive literature on the different non-viral vectors used to deliver 
nucleic acids.  Some recent examples include cationic lipids, Lipidoids, 
Polyethyleneimine, dendrimers, and polysaccharides.  Although they have all been 
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successfully explored for pDNA and siRNA delivery, they all share the same major 
obstacles for in vivo application and these consist on physical and colloidal stabilities 
as well as toxicity.  
Cationic polymers.  Linear or branched cationic polymers including peptides 
readily bind pDNA to form a complex known as a polyplex capable of gene delivery.  
Unlike cationic lipids, they do not contain a hydrophobic moiety and are completely 
soluble in water.  In addition they have the advantage of compacting pDNA into 
small nanoparticle which favourable for delivery (Lv, H.T. et al., 2006).  Their 
common feature is that they exhibit proton sponge effect, which allows endosomal 
escape and release of nucleic acid in the cytosol (Juliano, R. et al., 2008).  
Polyethyleneimine (PEI) has been extensively and successfully used for both pDNA 
and siRNA transfection provided that the correct architecture and molecular weight 
polymer is selected to avoid high toxicity.  It was shown that branched low molecular 
weight PEI  (< 25 Kda), rather than linear are more transfection efficient and that 
high molecular weight PEI result in higher toxicity (Akhtar, S. and I.F. Benter, 2007, 
Tseng, Y.C. et al., 2009).  It has been shown that PEI have two types of toxicity, an 
immediate toxicity that occurs when free PEI enters the circulation and causes 
destabilisation of the plasma membrane.  The delayed toxicity is associated with 
cellular processing of PEI/pDNA complexes, as after the release of the nucleic acid 
free PEI is restored and it interacts with cellular components resulting in the 
inhibition of normal cellular process.  Some efforts are being made to tackle the 
toxicity challenge (Lv, H.T. et al., 2006).  In terms of siRNA delivery in vivo, 
microarrays of tumors treated with linear and branched PEI revealed that both 
architectures induced multiple gene changes in vivo that might contribute to off 
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target effects of siRNA and also have an effect on gene silencing activity ((Akhtar, S. 
and I.F. Benter, 2007, Tseng, Y.C. et al., 2009).   
Poly(l-lysine) polymers are linear polymers with the amino acid Lysine as the 
repeat unit.  They were the first cationic polymers used for gene delivery and their 
biodegradable nature gives them an advantage for in vivo applications .  However it 
has been shown that DNA condensation and transfection efficiency is favored by the 
use of high moleclular weight polymers  which was linked with high toxicity.  Also 
their disadvantage is the rapid clearance from circulation due to interaction with 
plasma proteins leading to poor delivery efficiency.  In addition they need the co-use 
of a lysosmotropic agent to minimise their lysosomal degradation, which has been 
associated with increased toxicity (Lv, H. et al., 2006). 
Cationic polysaccharides.   Another group of cationic polymers desirable for 
nucleic acid due to their biocompatible, biodegradable and low toxic nature.  
Chitosan is a naturally occurring linear polysaccharide, which has been widely 
applied for pDNA delivery with encouraging results however limited research with 
siRNA ((Gary, D.J. et al., 2007).  These polymers have the ability to compact the 
nucleic acid in nano-sized polyplexes, but the stability and properties of the 
complexes depends on the structure and molecular weight of the chitosan.  In 
addition, interactions of chitosan and nucleic acid is pH sensitive and decreases with 
increasing pH ((Akhtar, S. and I.F. Benter, 2007, Tseng, Y.C. et al., 2009).  So far, 
chitosan nanoparticles have been modified and stabilised in many ways to optimise 
gene delivery but one of the major obstacles is physical and colloidal stability in 
particular in vivo.  
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Dendrimers.  The branched, nanometer sized, spherical modular structures can 
be engineered to have specific molecular weight and defined molecular shapes and 
sizes able to overcome biological barriers in vivo.  Dendrimers of positive charge can 
be generated to bind to nucleic acid.  This family of polymeric vectors were initially 
designed for pDNA delivery but are emerging as potential carriers for siRNA.  The 
advantage with dendrimers is that the small sized siRNA can be positioned as a 
polyplex on a positively charged dendrimer surface or well hidden within the sphere, 
which prevents aggregation.  Increasing efforts have been made to develop various 
dendrimers and dendritic structures for siRNA delivery.  In parallel, various 
chemical alterations have been required to increase bio- compatibility and delivery 
efficiency, reduce toxicity and promote targeted delivery via surface group 
modification (Lv, H.T. et al., 2006).  
Lipidoids.  A new class of delivery vectors, which have been generated 
recently to allow rapid synthesis of large libraries of lipid like carriers and therefore 
expand the diversity of delivery vectors.  The range of the previous vectors is 
restricted due to the long multi-step process of their sythesis.  Lipidoids are 
generated by conjugate addition of alkyl acrylamide or acrylacylate to primary or 
secondary amine groups, this reaction does not require the presence of solvent or 
catalyst and therefore skips the protection or de-protection step as well as 
concentration or purification.   After the synthesis the library is screened for ability 
to deliver siRNA and a number of vectors with a certain characteristics were 
identified to be effective for gene delivery in vitro and in vivo, but further studies are 
necessary to characterise these systems (Mahon, K.P. et al., 2010) 
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1.3.3. Cationic lipids as gene delivery vectors 
Cationic lipids are amphipathic mono- or polycationic molecules made up of a 
positively charged head group attached to a hydrophobic moiety via a linker group 
(Brown, M.D. et al., 2001, Wasungu, L. and D. Hoekstra, 2006).  The hydrophobic 
anchor group is responsible for the formation of liposomes and interaction with the 
cell membranes, the positively charged head group (amine group) interacts with the 
nucleic acid, and the linker group is a determinant of lipid stability and 
biodegradability (Mahato, R.I. et al., 1997).  Because of their amphiphilic nature, 
cationic lipids easily form liposomes or micelles in aqueous media.  Cationic lipids 
were introduced as carriers for DNA (Felgner, P.L. et al., 1987, Zhang, S. et al., 
2007) and RNA (Malone, R.W. et al., 1989) over 20 years ago.  They have been 
extensively used as a transfection reagent in vitro and in vivo (Akhtar, S. and I.F. 
Benter, 2007, Tseng, Y.C. et al., 2009) and some formulations have already been 
used in clinical trials (Brown, M.D. et al., 2001).  However generally, gene 
expression has been found to be at a low level and transient (Kay, M.A., 2007).  1,2 
Dioleoyl-3-Trimethylammonium-Propane (methyl sulfate salt) (DOTAP), a double 
chain quaternary ammonium surfactant, is one of the most widely used cationic 
lipids.  It is relatively cheap, and is efficient in both in vitro and in vivo transfection 
(Ciani, L. et al., 2004, Felgner, P.L. et al., 1987). DOTAP can be used alone as a 
cationic carrier for transfection (Birchall, J.C. et al., 1999, Lasic, D.D. and N.S. 
Templeton, 1996) or in combination with an equal amount of the neutral lipids such 
as 1,2-Dioleoyl-sn-Glycero-3-Phosphoethanolamine (DOPE) or cholesterol to 
improve transfection.  
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1.4. Delivery of pDNA vs siRNA using cationic lipids 
Plasmid DNA (pDNa) and siRNA share many similar characteristics; i.e. they 
are both double stranded nucleic acids, share the negative phosphodiester backbone 
structure and can both interact electrostatically with cationic lipids.  However, there 
are a few key differences in their physicochemical properties and mode of action that 
are important when considering how they should be formulated for delivery to cells 
(Table 1.1).  pDNA has a molecular topography which allows it to condense into 
small particles once the negative charge has been neutralised by the cationic lipid 
and.  On the other hand, siRNA, which is shorter in length and has a more rigid 
structure, is not likely to condense. Interaction with cationic lipid may result in 
incomplete condensation and formation of large aggregates (Spagnou, S. et al., 
2004).  Unlike pDNA, which contains the sugar deoxyribose, siRNA has a hydroxyl 
group in the second position of the pentose ring instead of hydrogen.  The presence 
of hydroxyl groups makes the siRNA backbone more susceptible to hydrolysis by 
serum nucleases (Juliano, R. et al., 2008, Keller, M., 2005, Schroeder, A. et al., 
2010).  Adequate protection from nucleases is required for both nucleic acids.  The 
difference in site of action gives siRNA an advantage as entry into the nucleus is not 
required since mRNA molecules are released from the nucleus following 






Table 1-1 Main differences between plasmid DNA (pDNA) and short interference 
RNA (siRNA). 
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1.4.1. Cationic lipid/nucleic acid complex formation  
Cationic lipid/nucleic acid complexes are self-assembling nanosystems, which 
are prepared by simply mixing cationic liposomes and nucleic acid in aqueous 
solution.  Counterion release from the nucleic acid, a related decrease in hydration 
and increase in entropy are the driving force for the spontaneous electrostatic 
interaction between the negatively charged nucleic acid and the positively charged 
nucleic acid (Wasungu, L. and D. Hoekstra, 2006). As cationic lipid/nucleic acid 
complex formation is dependent on charge neutralization, the ratio of positive 
charges on the cationic lipid and negative charges of the nucleic acid generally 
defines the characteristics of the formed complexes (Zuhorn, I.S. et al., 2002b). 
1.4.2. Structure of the complexes 
The spontaneous electrostatic interaction leads to the formation of supramolecular 
assemblies whose structure is difficult to determine, although extensive studies have 
been undertaken with this aim (Desigaux, L. et al., 2007).  A fairly uniform picture 
has emerged from different studies using small angle X-ray scattering (SAXS) where 
it has been found that pDNA complexes display a highly ordered lamellar structure 
or non-bilayer inverted hexagonal structure according to the co-lipid and the salt 
concentration used in the preparation (Prasad, T.K. et al., 2003, Wasungu, L. and D. 
Hoekstra, 2006).  The lamellar structure consists of aligned strands of helical pDNA 
sandwiched between bilayers of cationic lipid.  However, when neutrally charged 
lipids such as DOPE are included a remarkable transition to the two-dimensional 
hexagonal phase occurs, where the buried apolar side chains of lipid extend outward 
from pDNA chain forming a uniform apolar coat around each strand of pDNA 
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(Tranchant, I. et al., 2004). The transition to hexagonal structure is enhanced in the 
presence of physiological salts as it has been shown that in water complexes exist in 
lamellar phase but when suspended in salt solution of physiological concentration, 
the system converts to the hexagonal phase (Labatmoleur, F. et al., 1996).  The 
presence of salt or neutral lipids reduces the net charge density of the cationic bilayer 
and weakens electrostatic interaction between DNA and bilayer, which induces the 
order to disorder transition (Prasad, T.K. et al., 2003). The hexagonal phase has been 
shown to possess higher transfection efficiency than the ordered lamellar phase as it 
facilitates nucleic acid release once inside the cells (Smisterova, J. et al., 2001, 
Middaugh, C.R. and J.D. Ramsey, 2007, Hoekstra, D. et al., 2007). 
For siRNA, there are very few reports concerning interactions with cationic 
lipid and the resulting structures.   Desigaux and colleagues (2007) reported the 
results of cryo-transmission electron microscopy (cryo-TEM) and SAXS 
experiments showing that self-assembled siRNA-lipidic complexes formed ordered 
lamellar domains with an even spacing. 
1.4.3. Physicochemical properties 
The physicochemical properties of cationic lipid/nucleic acid complexes such 
as size, charge and packing efficiency are believed to play a significant role in gene 
delivery efficiency.  Therefore a lot of effort has been made using different methods 
to characterise these complexes.   
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1.4.3.1. Complexation efficiency 
Protection of nucleic acid against degradation by nucleases depends strongly 
on the positive/negative (+/-) charge ratio and is associated with high transfection 
efficiency (Eastman, S.J. et al., 1997, Xu, Y. et al., 1999).  Displacement of 
intercalating dyes, such as ethidium bromide, from nucleic acid is one of the most 
commonly used techniques to determine the amount of unbound or uncondensed 
nucleic acid.  Typically, the fluorescent dye used has the ability to intercalate 
between nucleic acid bases and therefore competes with cationic lipids.  The 
reduction in fluorescence of the dye indicates inaccessibility of the dye to the nucleic 
acid, which is interpreted as condensation (Gershon, H. et al., 1993). 
1.4.3.2. Particle size 
The particle size of complexes can be characterized using dynamic light 
scattering, which is a well-established technique for measurement of particle size 
over a scale range of nanometers to micrometers.  In suspension, particles scatter 
light, which fluctuates depending on size.  Therefore the intensity of fluctuations in 
scattered light (due to Brownian motion of particles in solution) are analysed by an 
autocorrelation method to yield a diffusion constant and ultimately a particle size 
expressed as the mean hydrodynamic diameter (Yang, S.T. et al., 1994).  Although 
the polydispersity of cationic lipid/nucleic acid complexes make the analysis of the 
resulting data difficult, a mean diameter can still be obtained.  The particle size 
(diameter) of a lipid/ nucleic acid complex has been reported to influence the 
deposition of the complexes after administration as well as their uptake by target 
cells (Wiethoff, C.M. et al., 2004, Rejman, J. et al., 2004).  Because large molecules 
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are poorly endocytosed, it has been suggested that transfection complexes with small 
particle size (100 nm) are more efficient for transfection and provide better 
extravasation to target cells.  In contrast, more recent reports have shown that larger 
particles (micron range) are preferred for in vitro transfection (Zhdanov, R.I. et al., 
2002, Esposito, C. et al., 2006, Bouxsein, N.F. et al., 2007).  This was associated 
with quicker sedimentation at the cell surface compared to smaller complexes and a 
suggestion that large complexes reach the lysosomes relatively slowly compared to 
smaller particles.  Cationic lipid/siRNA complexes are usually smaller than cationic 
lipid/pDNA complexes (nano range, from 50 to 800 nm), however, transfection 
efficiency has not been restricted to small or large particle size as complexes of small 
size (200 nm) or larger aggregates (500-800 nm) have both been reported to be 
efficient in delivering functional siRNA (Spagnou, S. et al., 2004, Zhang, Y. et al., 
2010).    
1.4.3.3. Zeta potential 
The surface charge of nucleic acid/lipid complexes is an important property 
that affects its interaction with cells and non-cellular components such as serum 
proteins (Wolff, J.A. and D.B. Rozema, 2008).  Dynamic light scattering in the 
presence of an electrical field can estimate the zeta potential of the complexes, as 
particles in suspension will migrate toward the electrode of opposite charge with 
velocity proportional to zeta potential.  The zeta potential is used to assess the charge 
stability of a disperse system as it can give an estimate of the surface charge of 
particles in suspension.  It has been reported that complexes with positive charge are 
formed when the cationic lipid is in excess in comparison to the nucleic acid and at 
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these ratios the complexes are more transfection efficient in vitro (Tomlinson, E. and 
A.P. Rolland, 1996, Sakurai, F. et al., 2000a).  However, non-specific interactions 
between negatively charged components in vivo and the positively charged 
complexes affects the stability of the complexes.  Several strategies have been 
developed to reduce these non-specific interactions, but the most common is the use 
of hydrophilic uncharged polymers such as polyoxyethylene glycol (PEG) attached 
to the lipid in order to shield the positive charge and provide a steric barrier (Lee, M. 
and S.W. Kim, 2005). 
1.4.4. Influence of charge ratio on physical properties 
All the physical properties discussed in the previous sections are strongly 
dependent on the +/- charge ratio.  Both pDNA and siRNA complexes have been 
reported to follow a three zone model of colloidal stability; zone A which represents 
a region of colloidal stability for complexes with excess negative charge ratio (excess 
nucleic acid) and uncondensed nucleic acid surrounding lipids; one B which 
represents colloidal instability where complexes are uncharged and tend to form 
large aggregates; and zone C where colloidally stable complexes of excess positive 
charge and highly complexed nucleic acid are observed (Tranchant, I. et al., 2004, 
Desigaux, L. et al., 2007).  Although pDNA and siRNA follow the same three-zone 
model, the charge ratio at which these zones occur varies between the two nucleic 
acids (Zhang, Y. et al., 2010).  In addition the pH and salt concentration influence 
these physical properties as at high ionic strength complexes are unstable and tend to 
form large aggregates (Boffi, F. et al., 2002, Rejman, J. et al., 2004, Wiethoff, C.M. 
et al., 2004, Gopal, V. et al., 2006).  
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1.5. Challenges of gene delivery  
Gene delivery is a multi-step process in which a number of barriers must be 
overcome including internalisation and intracellular barriers such as cell entry, 
endosomal escape and nuclear entry (Morille, M. et al., 2008, Wasungu, L. and D. 
Hoekstra, 2006).  siRNA has an advantage over pDNA in that it does not require 
nuclear localization for its action as it acts in the cytoplasm.  The challenges of 
cationic lipid-mediated pDNA/siRNA delivery are considered below. 
1.5.1. Cellular binding and internalisation 
Due to their polyanionic and macromolecular nature, nucleic acids cannot enter 
the cells freely.  The polyanionic characteristic limits cellular entry and interferes 
with uptake via endocytosis.  The bulky nature of the nucleic acid hinders uptake via 
passive diffusion.  Both issues can be surmounted by the use of cationic carriers 
(Grayson, A.C. et al., 2006), which as described earlier, effectively condense the 
nucleic acid into small positively charged complexes.  It is generally accepted that 
binding to cells occurs via an interaction between the positive headgroup of the 
cationic lipids and the negatively charged cell surface components (Pires, P. et al., 
1999, Labatmoleur, F. et al., 1996).  Passive fusion of complexes with the cellular 
membrane has been suggested as a first pathway to deliver nucleic acid directly into 
the cytoplasm with endocytosis and endocytosis-like pathways being proposed as the 
main cellular internalisation pathways (Elouahabi, A. and J.M. Ruysschaert, 2005). 
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1.5.2. Endosomal escape 
Once inside the cells the complexes will follow the endocytic pathway and 
endosomal escape should occur rapidly before the nucleic acid passes into lysosomes 
and degraded by lysosomal nucleases (Wattiaux R, L.N., Wattiaux-De Coninck S, 
Jadot M, 2000).  As a consequence the main challenge to date for gene delivery has 
been to get the nucleic acid out of the endosome (Wasungu, L. and D. Hoekstra, 
2006) and de-assembly of the complex to release the nucleic acid.   
A mechanism for endosomal escape for cationic lipid/DNA complexes has 
been described by  Xu and Szoka (1996) and consists of the formation of ion pairs 
between complexes and the anionic endosomal membrane, which leads to disruption 
of the endosomal membrane.  The ion pair formation weakens the electrostatic 
interaction between nucleic acid and the cationic lipid and promotes the formation of 
non-bilayer hexagonal structures, which in return enhances endosomal disruption and 
facilitates the release of the nucleic acid from the complex (Koltover, I. et al., 1998, 
Hafez, I.M. et al., 2001). Elouahabi et al (2005) proposed another endosomal escape 
mechanism whereby endosomal escape occurs through a detergent-like 
destabilisation mechanism of the endosomal membrane and the dissociation of 
complexes after interaction with the cytosolic network.  This idea came from the 
assumption that not all pDNA could be dissociated and released into the cytoplasm 
during endosomal escape (verified by electron microscopy showing undissociated 






1.5.3. Nuclear translocation and entry   
The last physical barrier to nucleic acid delivery is translocation to, and entry 
into, the nucleus.  Overcoming this barrier is only necessary for pDNA, which unlike 
siRNA that exerts its effects in the cytoplasm requires entry into the nucleus in order 
to be transcribed.  The stability of DNA in the cytoplasm is threatened by the 
presence of nucleases (Lechardeur, D. et al., 1999).  It is thus not surprising that the 
nuclear translocation efficiency of pDNA is low with an estimate of 1 of 1000 
plasmids making it into the nucleus (Pollard, H. et al., 1998).  
Endocytosis may play a role in the transport of DNA from near the plasma 
membrane to the perinuclear zone.  Another possibility is that the positively charged 
lipoplex-containing endosomes might interact and eventually fuse with the 
endoplasmic reticulum resulting in the release of DNA into the lumen of the 
reticulum.  The DNA could then easily access the nucleus through the continuous 
network existing between nuclear and reticulum membranes.  Kamiya et al (2002) 
suggested that complexes delivered into the cytoplasm of cells fused directly with the 
nuclear membrane to release DNA into the nucleus.   
In terms of nuclear entry, the nuclear membrane is known to contain highly regulated 
transport structures known as nuclear pores with a diameter of approximately 25 nm.  
The small diameter of the pores is expected to constrain the entry of pDNA as only 
small molecules (40 KDa) can enter via passive diffusion through the nuclear pores. 
Therefore two pathways for nuclear entry have been proposed; either via a passive 
entry into the nucleus during cell division when the nuclear membrane is temporarily 
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disintegrated (Escriou, V. et al., 2001) or via an active transport of DNA through the 
nuclear pores (Pires, P. et al., 1999). 
1.5.4. Stability of the complexes 
Efficient delivery complexes require both chemical and physical stability.  The 
complexes need to be chemically stable to protect the nucleic acid from from 
enzymatic degradation until taken up by cells, but also susceptible to dissociation in 
the endosomal compartment to allow release of the nucleic acid in the cytoplasm. In 
terms of physical stability, highly charged complexes tend to form aggregates in 
presence of polyelectrolytes and physiological salt due to reduced repulsive forces, 
this needs to be minimised either by electrostatic or steric stabilisation.    In vivo, the 
main disadvantage of cationic lipid/DNA complexes is their instability in the 
presence of negatively charged serum proteins.  Several studies used serum, which 
contains a large number of plasma proteins, to mimic the in vivo situation (Zhang, Y. 
and T.J. Anchordoquy, 2004).  The binding of serum proteins to cationic lipid/DNA 
complexes can cause structural reorganization, aggregation and dissociation of the 
complexes (Li, S. et al., 1998, Nchinda, G. et al., 2002).  Aggregation will lead to 
reduced binding of the complexes with cellular membrane, rapid clearance of the 
complexes and increased toxicity.  Complex de-assembly can also lead to DNA 
degradation by serum nucleases, and decreased association of the complexes with the 
target cells (Yang, J.P. and L. Huang, 1998, Sakurai, F. et al., 2001).  The strong 
inhibitory effect of serum has been observed to affect gene expression efficiency of 
cationic lipid/pDNA complexes in vitro (Escriou, V. et al., 2001), whereas others 
reported contradictory results in which serum did not inhibit transfection efficiency 
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in vitro (Zuhorn, I.S. et al., 2002a, Zuhorn, I.S. et al., 2002b, Han X, L.S., Qiangyi 
Fang, Dongxiao Li, Xianghui Gong, Yuyin Wu, Shengli Yang, Bing Q. Shen, 2007).  
These differences could be due to the fact that different lipidic systems were used in 
each study and suggests that the susceptibility to serum inhibition is related to the 
type of cationic lipid used as cationic lipid.  In addition, (Yang, J.P. and L. Huang, 
1998) reported that at high charge ratios DOTAP:DOPE and DC-Cholesterol:DOPE 
complexes were more resistant to serum inhibition compared to lower charge ratios.  
Several strategies have been developed to surmount the inhibitory effect of serum 
including modification of charge ratios, using alkaline pH and salt during preparation 
and reducing interaction with negatively charged molecules by including pegylated 
lipids (Rejman, J. et al., 2004, Schroeder, A. et al., 2010) or neutral lipid such as 
cholesterol (Zhdanov, R.I. et al., 2002, Hong, K. et al., 1997, Bennett, M.J. et al., 
1995) in the formulation.   
1.5.5. Toxicity 
Although cationic lipids are not immunogenic like viral vectors, they are not 
without any toxicity. They can be cytotoxic and the extent to which this is 
manifested differs between different reagents and cell types. The prospect of toxicity 
is determined by the nature of the cationic carrier as well as the cationic lipid/nucleic 
acid complex (Lv, H.T. et al., 2006).  In terms of cationic lipid/nucleic acid 
complexes, the toxicity may, in part, be caused by the large size of the complexes, 
and the high positive zeta potential required for their uptake (Li, S. et al., 1998, Lv, 
H.T. et al., 2006).  Therefore the toxicity is also associated with the charge ratio 
between the cationic lipid species and the nucleic acids, as well as the dose of 
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lipoplexes administered.  Higher +/-charge ratios are generally more toxic due to the 
high positive zeta potential as well as the presence of free (i.e., empty) liposomes 
(Xu, Y. et al., 1999).  Free liposomes are present at high charge ratios when lipid is 
in excess to nucleic acid but their role in transfection efficiency remains unclear.  
However, Xu et al (1999) showed that their removal did not increase transfection 
efficiency but did allowed prevention of a decrease in transfection-associated 
toxicity.  Free liposomes may also compete with nucleic acid complexes for 
interaction with negatively charged membranes and uptake in cells. 
1.6. Cellular uptake mechanisms 
The analysis of the uptake pathways for non-viral gene delivery vectors has 
mainly been focussed on studies with DNA complexes, with endocytosis being 
established as the main uptake pathway (Labatmoleur, F. et al., 1996, Zuhorn, I.S. et 
al., 2002a, Zuhorn, I.S. et al., 2002b, Friend, D.S. et al., 1996).  However non-
endoyctic pathways have also been suggested as an alternative route for the 
internalisation of delivery vectors. 
1.6.1. Endocytic uptake pathways 
Endocytosis is a broad term that covers multiple distinct pathways used by 
cells to internalize a variety of macromolecules and can be classified into two 
categories; phagocytosis and pinocytosis.  Phagocytosis is only performed by 
specialized cells such as macrophages, neutrophils and monocytes and is used to 
eliminate large molecules including cellular debris and large pathogens such as 
bacteria and yeast (Conner, S.D. and S.L. Schmid, 2003).  The second pathway is 
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called pinocytosis and is present in almost all mammalian cells and includes several 
pathways; so far four pathways have been identified, their common feature being the 
uptake of macromolecules in transport vesicles.  However, they differ in the protein 
composition and size of the vesicles as well as the intracellular trafficking (Conner, 
S.D. and S.L. Schmid, 2003, Lamaze, C. and S.L. Schmid, 1995).  As most of these 
pathways share several characteristics, it remains difficult to identify which pathway 
the delivery vectors follow especially since the endocytic pathways themselves are 
not well understood.  Endocytosis-interfering drugs have been used to distinguish 
between the different pathways and to determine the type of pathway involved.  
However cautious interpretation of data is recommended, as there are concerns about 
specificity of these drugs as well as their effect on cell viability. 
1.6.1.1. Clathrin-mediated endocytosis  
The major and best characterized pathway is clathrin-mediated endocytosis 
(Takei, K. and V. Haucke, 2001, Lamaze, C. and S.L. Schmid, 1995), which 
commonly mediates the uptake of plasma membrane receptors such as receptors of 
transferrin, epidermal growth factor  (EGFR) and low density lipoproteins (LDLR) 
(Ivanov, A.I., 2008).  This uptake process is receptor-mediated as it involves specific 
receptors located in invaginations of the plasma membrane known as clathrin-coated 
pits.  These vesicles are characterized by the presence of a polyglonal clathrin coat 
and range in size from approximately 100 to 150 nm (Takei, K. and V. Haucke, 
2001).  They carry ligand-bound receptors inside the cell involving GTPase dynamin 
activity (Benmerah, A. and C. Lamaze, 2007) and they are transformed into early 
endosomes where the ligand is separated from the receptor.  The ligand is then 
transferred to late endosomes for potential degradation in lysosomes.  The receptors 
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are recycled and transported back to the cellular membrane (Khalil, I.A. et al., 2006).  
Genes internalized through the clathrin pathway end up in lysosomes for potential 
degradation, thus for a successful delivery of biologically active genes, lysosomal 
escape and release in the cytoplasm is crucial.  This receptor-mediated endocytosis is 
energy-dependent and can be strongly inhibited by lowering temperature (Haylett T, 
T.L., 1991, Wiliam A. Dunn, A.L.H., And Nathan N. Aronson, 1980) or by depletion 
of the ATP pool using metabolic inhibitors (Khalil, I.A. et al., 2006).  In addition 
reagents that prevent the assembly of the clathrin lattice on the membrane 
specifically inhibit this pathway.  Such treatments include potassium depletion 
(Larkin, J.M. et al., 1983, Ivanov, A.I., 2008), hypertonicity, cytosol acidification 
and the cationic amphipathic drug chloropromazine (Wang, L.H. et al., 1993, Khalil, 
I.A. et al., 2006, Ivanov, A.I., 2008).  
1.6.1.2. Caveolin-mediated endocytosis  
Similar to the clathrin-coated vesicles, caveolae vesicles also originate from 
cholesterol-enriched invaginations of the plasma membrane. They invaginated as 
flask-shaped vesicles within the plane of the plasma membrane, or as detached 
vesicles.  In addition, caveolae can fuse to form grape-like structures and tubules 
with sizes larger than 100 nm (Smart, E.J. et al., 1999, Pelkmans, L. et al., 2001).  
Caveolae are mainly composed of cholesterol and sphingolipids and accumulate 
cholesterol binding-proteins known as caveolins, on the cytosolic face of the vesicles 
(Smart, E.J. et al., 1999, Matveev, S. et al., 2001, Harris, J. et al., 2002).  Caveolae 
play a role in endocytosis of certain viruses such as simian virus 40 (SV40), as well 
as some bacteria and bacterial toxins such as cholera toxin (Khalil, I.A. et al., 2006) 
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and like the clathrin pathway, calveolae require GTPases activity for the pinch off of 
vesicles.   
After internalisation, caveolae-derived vesicles fuse with caveosomes (Nichols, 
B.J. and J. Lippincott-Schwartz, 2001, Pelkmans, L. et al., 2002), which are pre-
existing, stable, organelles with a neutral pH and it is believed that this uptake 
mechanism does not lead to lysosomal degradation (Parton, R.G., 2004).  
Macromolecules internalized via this route are transported to the endoplasmic 
reticulum (ER) (Pelkmans, L. et al., 2001) or to the trans-Golgi network (TGN) 
(Norkin, L.C. and D. Kuksin, 2005) and therefore avoid lysosomal degradation.  Due 
to its non-degradative nature (Ferrari, A. et al., 2003, Harris, J. et al., 2002), caveolar 
endocytosis represents an attractive pathway for gene delivery, even though this 
process is considered slow and has a small phase volume making it unlikely to be a 
primary uptake route.  This uptake is also energy dependent so it can be inhibited by 
lowering temperature or by ATP depletion.  In addition, drugs that specifically bind, 
sequester, or deplete cholesterol such as filipin, nystatin, and methyl-β-cyclodextrin, 
respectively, inhibit internalization by the caveolae (Lamaze, C. and S.L. Schmid, 
1995, Schnitzer, J.E. et al., 1994).  The caveloae pathway is actin-dependent and 
therefore drugs that affect the actin cytoskeleton such as cytochalasins are used to 
inhibit caveloae pathway without affecting the clathrin-mediated endocytosis, 
although these drugs do also inhibit macropinocytosis (Parton, R.G., 2004). 
1.6.1.3. Macropinocytosis 
Unlike clathrin and caveloae pathways, macropinocytosis is not a receptor-
dependent mechanism.  It involves the formation of large, irregular endocytic 
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vesicles generated from actin-driven membrane ruffles known as macropinosomes 
(Swanson, J.A. and C. Watts, 1995, Amyere, M. et al., 2002).  These vesicles are not 
coated and their intracellular trafficking is not very clear and depends on cell type.  
For example in macrophages the macropinosomes merge with lysosomes (Meier, O. 
and U.F. Greber, 2003), whereas in other cell lines they do not interact with other 
endosomal compartments (Swanson, J.A. and C. Watts, 1995).  The macropinosomes 
vary in size and can reach up to 5 m in diameter (Khalil, I.A. et al., 2006) and 
therefore they represent an efficient route for non-selective endocytosis of large 
solutes (Conner, S.D. and S.L. Schmid, 2003).  In addition the vesicles are leaky in 
nature, which facilitates the escape or release of gene delivery vectors.  The ruffling 
is dependent on actin cytoskeleton and on protein kinase C.  Thus, drugs that inhibit 
the Na+\K+ exchanged in the plasma membrane such as amiloride and its analogues 
can be used to block this pathway (Hewlett, L.J. et al., 1994).  Actin cytoskeleton 
depolymerising drugs such as cytochalasins inhibit the uptake through 
macropinocytosis (Parton, R.G., 2004). Other drugs have also been used to inhibit 
this pathway, such as genestein (another kinase inhibitor) but with low specificity 
(Fishman, P.a.O.a.P.H., 1998) and wortmannin, a phosphatidyl inositol-3-phosphate 
inhibitor.  
1.6.1.4. Caveolae and clathrin-independent endocytosis 
Receptor-mediated pathways that do not involve clathrin coats or caveolae 
proteins have been suggested as possible entry routes (Khalil, I.A. et al., 2006).  
These pathways are still poorly characterised, it has been suggested that each of these 
pathways could have a specific function in the cell and vary in the vesicles they 
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form, type of macromolecules they transport, intracellular fate and how the entry is 
regulated.  Targeting receptor-mediated endocytosis holds a promising strategy for 
delivering genes to defined cell populations.  An example of this is transferrin, an 
iron-binding glycoprotein, which is highly expressed in rapidly dividing cells and has 
been used to target tumour cells for gene delivery systems (Kakudo, T. et al., 2004, 
Wagner, E. et al., 1990). The folate receptor is another example of receptors 
overexpressed in tumour cells, and it can be used for targeting (Lee, E.R. et al., 1996, 
Cho, K.C. et al., 2005).  However, most of the currently used ligands are internalized 
by clathrin-mediated endocytosis, and the poor intracellular trafficking associated 
with this significantly limits the transfection activities of the systems.  Therefore, 
identifying and investigating new receptors that can be internalized by clathrin-
independent endocytosis might provide more efficient delivery. 
1.6.2. Non-endocytic pathways 
Work has suggested that pDNA/lipid complexes enter cells via fusion with the 
cellular membrane and direct release of pDNA into the cytosol before entering the 
endosomal compartment (Felgner, J.H. et al., 1994).  This mechanism has an 
advantage over endocytosis in that it can avoid lysosomal degradation.  However 
fusion has been found to only participate minimally in the uptake of gene delivery 
vectors (Friend, D.S. et al., 1996, Brooks, H. et al., 2005).  Another non-endocytic 
process is an energy-independent direct penetration of the lipid bilayer, which has 
been used as an internalisation route for pDNA/peptides complexes (Thoren, P.E. et 
al., 2003, Trehin, R. and H.P. Merkle, 2004).  Recently Lu and colleagues (2009) 
suggested that although 95% of siRNA/lipid complexes entered the cells via 
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endocytosis, they were not functional in inducing gene silencing and it was the 5% of 
complexes that entered via a different mechanism that resulted in efficient gene 
silencing.  They suggested that the mechanism followed by the functional complexes 
was passive diffusion across the cellular membrane. 
1.7. Formulation startegies to improve delivery of nucleic acids 
1.7.1. Helper lipids 
The inclusion of the helper lipid DOPE with cationic lipids has been shown to 
improve transfection efficiency of pDNA (Legendre J, S.F., 1992, Gao, X. and L. 
Huang, 1991, Farhood, H. et al., 1995)) and decreased the toxicity.  Electron 
microscopy showed that DOPE has the ability to induce fusion and endosomal 
disruption by changing the membrane bilayer packing from lamellar to hexagonal, 
which facilitates DNA entry into the cell and release into the cytosol after 
endocytosis (Zhdanov, R.I. et al., 2002).  The lamellar phase binds stably to anionic 
lipids while the unstable hexagonal phase fuse easily with anionic membranes and 
facilitates endosomal escape.  The transition to non-bilayer structures does not occur 
upon inclusion of DOPE in the cationic lipid system, but upon charge neutralization 
by salts or upon ion pairing with the anionic endosomal membrane as this decreases 
surface charge (Elouahabi, A. and J.M. Ruysschaert, 2005).  DOPE shields some of 
the positive charge of the cationic lipid and may lead to looser binding of the cationic 
lipid with the nucleic acid compared to DOPE-devoid complexes as reflected by 
ethidium bromide intercalation into DOPE-containing complexes even upon 
complete pDNA binding.  The weak binding facilitates complex disassembly.  
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Therefore DOPE can be used to enhance transfection in vitro (Gustafsson, A. and P. 
Sonesson, 1995), whereas cholesterol has more commonly been used as a helper 
lipid in vivo as it provides resistance to serum inhibition (Zhdanov, R.I. et al., 2002, 
Hong, K.L. et al., 1997, Bennett, M.J. et al., 1997). 
1.7.2. Polyoxyethylene glycol polymers 
Polyoxyethylene glycol is a flexible hydrophilic polymer that extends 
approximately 3-5 nm from liposomal surfaces depending on the length and 
concentration (Vp, T., 1994).  In addition it is non-ionic, water-soluble and is usually 
associated with phosphatidylethanolamines such as DSPE or DMPE serving as a 
bilayer anchor (Webb, M.S. et al., 1998).  The addition of a polymer such as 
polyethylene glycol is known to improve the stability of nucleic acid complexes and 
increase their in vivo half-life (Rejman, J. et al., 2004, Schroeder, A. et al., 2010).  
When they are added to a conventional liposome they form a steric barrier on the 
surface of the complexes, which inhibits opsonisation and thus prolongs the 
circulation time of the liposomes in the blood (Harvie, P. et al., 2000).  These 
pegylated-lipid/pDNA complexes have also been shown to be stable and to protect 
DNA from nuclease degradation in the plasma (Harvie, P. et al., 2000, Song, L.Y. et 
al., 2002). In addition incorporation of a PEG lipid prevents aggregation during 
storage and it preserves their transfection activity (Kim, J.K. et al., 2003). Sanders et 
al (2002) showed that exposure of the conventional DOTAP:DOPE lipoplexes to 
cystic fibrosis mucus components (albumin, mucin, DNA and phospholipids) 
reduced their transfection activity in vitro and this was associated with lipoplex 
aggregation, but it did not affect the transfection efficiency or activity of the 
pegylated complexes.  However the hydrophilic nature of pegylated-lipid may 
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present a disadvantage in terms of transfection efficiency as it can reduce cell 
binding and membrane fusion (Harvie, P. et al., 2000, Song, L.Y. et al., 2002).  
However, it has been shown that the reduction in transfection caused by pegylated-
lipid is concentration dependent, and efficient transfection can still occur with 
complexes prepared with less than 2 mol% of pegylated-lipid.  In addition, the length 
of the PEG chain is also a factor and it was shown that by using short length chains 
there was less inhibition of transfection (Harvie, P. et al., 2000).   
1.7.3. Pre-condensation with a polycation 
Many studies have shown that the pre-condensation of DNA with polycationic 
peptides such as protamine sulphate and poly-(L)-Lysine, enhances cationic lipid-
mediated gene transfer (Birchall, J.C. et al., 1999, Zhdanov, R.I. et al., 2002).  These 
small polycations are known to condense DNA in a small and stable structure via 
charge-charge interactions.  The commonly used condensing agent, protamine 
sulphate, is transfection inefficient on its own therefore the addtion of cationic lipids 
is necessary.  The high proportion of amine groups of these polypeptides make them 
able to neutralize a number of charge sites on the DNA molecule, and therefore 
facilitating condensation by cationic lipids.  These lipid-polycation-DNA (LPD) 
systems are stable at lower cationic lipid to DNA charge ratios and are small, 
homogenous (small polydispersity in size) and less susceptible to aggregation that 
can occur with the conventional cationic lipid/DNA complexes.  It has been reported 
that the transfection activity of LPD complexes was higher than that of those formed 
in the absence of protamine, especially after storage (1-2 months) as compared to 
freshly prepared complexes (Hong, K. et al., 1997).  Moreover in another study it 
was revealed that pre-condensation of DNA with protamine (3:2 mass ratio) resulted 
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in smaller compact and homogeneous lipoplexes whose structure remained 
unchanged by jet nebulisation, even when compared to high ratio (12:1) 
DOTAP:DOPE/DNA complexes (Gill, D.R. et al., 2004).  The LPD system 
displayed better protection of DNA during nebulisation. 
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1.8. Aims and objectives of the thesis 
The aim of this thesis was to investigate formulation strategies reported for the 
delivery of pDNA for the delivery of siRNA and identify what adaptations were 
required for optimal delivery of the shorter nucleotide sequences.  Three 
formulations for DNA delivery were characterised before they were adapted for the 
formulation of siRNA.  The mechanism by which these formulations delivered of 
siRNA into cells was investigated.  Finally, the requirement to formulate the siRNA 
delivery system for pulmonary delivery was considered. 
The specific objectives addressed in this thesis were to: 
 Optimise three cationic lipid-based formulations for complexing pDNA by 
systematically varying the charge ratio and measuring the physicochemical 
properties of the formulations and their transfection efficacy. 
 Formulate siRNA using the systems characterised for pDNA delivery and 
measure the effect of charge ratio on the physicochemical properties of the 
formulations and their efficacy in gene silencing, 
 Investigate the mechanism of cellular uptake of siRNA lipoplex systems by 
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Cationic lipids have received considerable attention as potential gene delivery 
agents and reached clinical trials stage (Gene Therapy Clinical Trials Worldwide, 
2011).  However, despite the large amount of research in cationic lipid mediated 
gene delivery, with literally thousands of different formulations examined the 
efficiency of these carriers is still lower than desirable as compared to their 
counterpart viral vectors.  The optimization of these systems remains a result of trial 
and error and in order to improve the clinical efficacy of cationic lipid formulations, 
it is necessary to comprehend the role of the parameters that affect the 
physicochemical properties of these systems, which in turn affect their biological 
activity.   
Since the interaction between cationic liposomes and pDNA is of an 
electrostatic nature, it is expected that the biophysical characteristics of the 
lipid/pDNA complexes formed would depend significantly on the apparent charge 
ratio (+/-) of the cationic amines on the liposomes and the negative phosphates 
groups on pDNA.  Mixing pDNA and cationic lipids at different charge ratios will 
result in the formation of complexes with distinct size, surface charge and colloidal 
stability (Boffi, F. et al., 2002, Zuidam Nj, B.Y., 1998, Hirsch-Lerner, D. and Y. 
Barenholz, 1999, Zuidam, N.J. et al., 1999). 
Although several studies have examined the effect of physicochemical 
properties on efficient pDNA delivery and some generalisations were made (Yang, 
J.P. and L. Huang, 1998, Zuhorn, I.S. et al., 2002a, Zuhorn, I.S. et al., 2002b, Ross, 
P.C. and S.W. Hui, 1999b) (Ross, P.C. and S.W. Hui, 1999a, Simberg, D. et al., 
2001), a detailed comparison between different works is difficult because of the 
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different experimental conditions and different cell lines used.  This is particularly so 
when taking into account that even within a group of structurally related compounds 
within one class a small change in structure may lead to a dramatic change in 
activity.  In this study the transfection efficiency and toxicity of three different 
cationic lipid -based vectors were investigated comparatively using the same 
experimental conditions and the same cell line in an attempt to determine a 
relationship, if any, between the physicochemical properties and transfection 
efficiency.   
2.1.1. Cationic lipid formulation used in this study 
The equimolar combination of cationic lipid DOTAP and neutral lipid DOPE 
liposomes was used in this study; because this cationic lipid/neutral lipid 
combination is one of the most widely used lipidic systems for pDNA delivery 
(Ciani, L. et al., 2004) and extensively described in terms of their physical 
properties, examination of the basis of their relative transfection efficiencies may 
provide further insight into the physical basis of effective gene delivery.  
DOTAP:DOPE was also modified by incorporating either a polycation such as 
protamine sulphate or a polyethylene glycol-associated lipid both of which have been 
shown to enhance the stability and transfection efficacy of DOTAP (Kim, J.K. et al., 
2003, Rejman, J. et al., 2004, Birchall, J.C. et al., 1999, Sanders Nn, D.S.S., Cheng 
Sh, Demeester J, 2002, Hong, K.L. et al., 1997).  The structure of the lipids used in 







Figure 2.1 Chemical structures of the neutral lipid (DOPE), cationic lipid (DOTAP) 
















Table 2-1  A summary of the formulations used in this study.   
Formulation Components Abbreviation 
DOTAP:DOPE  
(1:1 molar ratio)/pDNA 
















2.1.2. Physicochemical characterization of pDNA complexes 
It has been reported that the composition of the suspending medium in 
particular the ionic strength, affected the physicochemical properties including size 
and charge of the nucleic acid/lipid complexes (Eastman, S.J. et al., 1997).  However 
it is common that, the physicochemical properties of the complexes are determined 
in water or in weak electrolyte solutions and the transfection experiments are carried 
out using cell cutlture media (transfection media) of physiological salt concentration 
(Kim, J.K. et al., 2003, Spagnou, S. et al., 2004, Zhang, Y. et al., 2010, Wiethoff, 
C.M. et al., 2004);(Birchall, J.C. et al., 1999)).  Therefore this study also aimed at 
illustrating the effect of type of media used on the complexation efficiency as well as 
the physical properties of the cationic lipid/pDNA complexes. 
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2.1.3. Transfection of respiratory epithelial cells by pDNA 
The respiratory epithelium is the first target for gene delivery to the lungs 
because it is the surface encountered by inhaled particles in the conducting airways 
of the lungs (trachea, bronchi and respiratory bronchioles) as well as the alveolar 
region (Forbes, B. and C. Ehrhardt, 2005, Florea, B. et al., 2003)).  This is why most 
efforts have been concentrated on optimising gene transfer to epithelial cells by 
making it more efficient, less immunogenic and less inflammatory and having 
prolonged expression.  In order to develop suitable gene delivery vectors, an in vitro 
model that correlates with the in vivo situation is required.  The airway epithelium 
comprises three major cell types: ciliated cells, secretory (mucous, goblet, serous or 
clara) and basal cells (Mathias, N.R. et al., 1996).  The alveolar epithelium is 
composed of a monolayer of two types of cells Type I and Type II cells that display 
different morphologies (Mathias, N.R. et al., 1996).  These different cell types with 
distinct properties make the epithelium a complex barrier to pulmonary delivery. A 
simpler in vitro model of the epithelium would consist of a monoculture of the cell 
line that contributes to the majority of the epithelial surface area (Forbes, B. and C. 
Ehrhardt, 2005).  Several human-derived cell lines are currently utilized as in vitro 
models of the airway epithelium.  These include the bronchial epithelial cells Calu-3, 
16HBE14o- and BEAS-2B, and the type II like alveolar epithelial cells, A549 
(Steimer, A. et al., 2005).   
2.1.3.1. Calu-3 cells 
This cell line derived from a bronchial adenocarcinoma of the airway has been 
considered to be an appropriate in vitro model of the bronchotracheal airway 
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epithelium (Forbes, B. and C. Ehrhardt, 2005, Florea, B. et al., 2003) These cells 
were found to be the only cell type derived from a lung cancer to have mRNA and 
protein content similar to the airway epithelium, which indicated that they are one of 
the well differentiated cell lines (Mathias, N.R. et al., 1996).  Calu-3 cells have been 
shown to possess many of the features relevant to drug absorption and metabolism as 
those found in the native epithelium.  These features include the formation of tight 
junctions, secretion of mucus, expression of transport and efflux pumps and the 
development of apical ciliated cells.  These cells also express the cystic fibrosis 
transmembrane conductance regulator (CFTR) protein (Mathias, N.R. et al., 1996, 
Foster, K.A. et al., 2000, Florea, B.I. et al., 2002).  Moreover Calu-3 cells are readily 
available and differentiate in monolayers of polarized cells of different phenotypes 
(Florea, B. et al., 2003). Because of these properties, Calu-3 cells have been 
extensively evaluated for use as a tool to study drug transport, metabolism and 
toxicity (Foster, K.A. et al., 2000).  However little work has been done in terms of 










2.1.4. Aim and objectives 
The ultimate aim of this work was to characterize formulations for the delivery 
of pDNA and develop methods for their characterization, which could subsequently 
be adapted for the delivery of siRNA.  Specific objectives related to pDNA delivery 
were: 
 Measure the impact of using biorelevant media (HBSS vs water) on the 
physicochemical properties of the formulations, 
 Investigate the effect of charge ratio on the formulation properties and 
transfection efficacy in Calu-3 respiratory epithelial cells, 
 Compare the physicochemical properties of the formulations with their 


















Plasmid pGL3-control vector, Bright Glo 
luciferase assay kit and Glo lysis buffer 
1X 
Promega, Southampton, UK 
Endofree Plasmid Mega Kit, GelPilot 
loading dye 5X  
Qiagen West Sussex, UK 
Quant-iTTMPicoGreen dsDNA Reagent 
and kit, Bright GloTM Luciferase assay, 
Lipofectamine 2000 
Invitrogen Paisley, UK 
DOPE, DOTAP, DMPE-PEG5000 Avanti Polar Lipids, Inc Alabama, USA 
Agarose gel  Bioline London, UK 
The Bio-Rad DC protein assay  Bio-Rad Laboratories Hertfordshire, UK 
GelRed (100001x in DMSO) Biotium Inc Cambridge, UK 
Luria-Bertani (LB) agar  Fluka BioChemica Buchs, Switzerland 
Black 96-well microplates PerkinElmer, UK 
Calu-3 cells ATCC Rockville, USA 
L-glutamine (200mM), Penicillin-
Streptomycin solution (100x), non-
essential amino acids, Dulbecco´s 
modified Eagle´s medium/Nutrient 
Mixture F-12 HAM (DMEM), Trypsin-
EDTA (0.25%),   Hank’s   balanced   salt  
solution (HBSS), Foetal bovine serum 
Sigma-Aldrich Ltd, Dorset, UK 
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(FBS), Protamine Sulphate, MTT [3-(4, 
5- dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide), 
Dimethylformamide (DMF) and SDS 





















2.3.1. Plasmid DNA preparation  
2.3.1.1.Plasmid pDNA amplification and purification 
The pGL3 control vector encoding for luciferase gene was amplified using an 
electro-competent E.coli JM109 strain cultured on Ampicillin LB (Luria-Bertani) 
agar for 8 h and then subcultured in LB broth for 12-16 h.  The bacterial cells were 
harvested and the pDNA yield was then extracted and purified using a Qiagen 
Endofree  Plasmid  Mega  Kit  according  to  the  manufacturer’s   instructions  (appendix  
1).  The resulting DNA was stored in 1X TE buffer (10 mM Tris (pH 8), 1 mM 
EDTA) 
2.3.1.2. Plasmid pDNA verification and quantification 
Sequencing: The presence of the luciferase gene was verified by gene 
sequencing (Lark Company).  The samples were sent to Lark Pharmaceuticals that 
used Applied Biosystems 3730xl sequencing instrument.  Results confirmed the gene 
sequence of the prepared plasmid pDNA. 
UV spectroscopy:  The purified DNA was also characterized quantitatively by 
UV spectrophotometery (measurement was taken at a wavelength of 260 nm (A260) 
and 280 (A280) using a Perkin Elmer UV/Vis Spectrophotometer Lambda 2S). The 
ratio between absorbance at 260 nm and absorbance at 280 nm (A260/A280 ratio) 




Gel electrophoresis:  The pDNA purity was assessed by agarose gel (1%) 
electrophoresis stained with Gel Red dye (5%) in 1X TAE buffer and the gel was 
subjected to 110 V for 75 min, and the DNA bands were viewed under UV light.  
Picogreen assay:  Picogreen dsDNA quantitation reagent is a very sensitive 
fluorescent nucleic acid stain for quantitating double-stranded DNA (dsDNA).  It 
determines DNA concentration as low as the picogram range.  This assay was also 
used to quantitate pDNA.  A standard curve was prepared as follows:  2 µg/ml stock 
solution of purified pGL3 control vector was used to prepare the following 
concentrations (0, 0.001, 0.01, 0.1 to 1 µg/ml).      
Qaunt-iT PicoGreen reagent (1 ml) was added to each sample and mixed well.  
After 2-5 min incubation, fluorescence was measured using a spectrofluorometer and 
fluorescein wavelengths (excitation 480 nm, emission. 520 nm).     (The   instrument’s  
gain was set at 38 for all measurements).  The fluorescence value of the reagent 
blank was substracted from that of each of the samples.  The corrected data was then 
used to generate a standard curve of fluorescence versus pDNA concentration.  The 
sample DNA concentration was then calculated from the standard curve (Appendix).   
2.3.2. Liposome preparation 
The lipids used in this work were DOTAP, DOPE and DMPE-PEG5000 (Figure 
1).  DOTAP and DOPE were used at a molar ratio of 1:1.  Many studies have shown 
that maximal gene expression is obtained when DOPE is mixed with DOTAP at this 
ratio and thus it was adopted for this work (Ciani, L. et al., 2004, Felgner, P.L. et al., 
1987).  The two lipids were dissolved in a chloroform/methanol 1:1 (v/v) mixture to 
obtain a final total lipid concentration of 1 mg/ml.  1ml of each component were 
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aliquoted in a glass vial using a glass syringe and thoroughly mixed to obtain a 
2mg/ml total lipid concentration.  The solvents were carefully evaporated by air 
blowing in a fume hood to produce a thin lipid film.  Residual solvent was removed 
via freeze-drying the samples under vacuum (Edwards, UK), by first placing the lipid 
cake containers in -70C freezer for 30 min and then placing the frozen lipid cake on 
a vacuum pump for for 4 h.    After removal of all traces of solvent the dry lipid film 
was re-suspended in sterile water to a final total lipid concentration of 2 mg/ml and 
the dispersion was vortexed for 5 min and the liposomes were left to stand overnight 
prior to downsizing to make sizing easier and improve the homogeneity of the size 
distribution.  The hydration step was carried out at a temperature above the gel-liquid 
transition temperature of the lipids used (DOTAP  -0C and DOPE  -16C).  To 
obtain liposomes of around 100 nm particle size the hydrated lipid dispersion was 
extruded at room temperature 10 times through an Avanti mini-extruder (Avanti 
Polar Lipids, USA) containing a 0.1 µm filter membrane. The 
DOTAP:DOPE:DMPE-PEG5000 complexes were prepared in the same way but at the 
molar ratios of 1:1:0.05 respectively.  The particle sizes of the liposomes were 
measured after extrusion using a Brookhaven instrument ZETAplus (particle sizer 
software).  
2.3.3. Preparation of cationic liposomes and pDNA complexes 
In this study three lipidic systems were used to complex plasmid DNA as 
described in table 2-1.  Plasmid DNA and liposomes were mixed at room 
temperature and were incubated for 30 min to allow complexation.  DOTAP:DOPE 
and DOTAP:DOPE:PEG5000 complexes were formed by the addition of pDNA to 
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sterile water for 5 min, and then the appropriate amount of liposome was added to 
obtain the different charge ratios.  To calculate the mean theroretical charge ratio, it 
was assumed that 1 µg pDNA is 3 nmol of negatively charged phosphate and that 1 
positive charge is displayed by DOTAP. 
LPD complexes were prepared by the addition of protamine (1 mg/ml) to 
pDNA at a 2:1 mass ratio with 10 min incubation, followed by the addition of 
DOTAP:DOPE.  For the three systems, different amounts of lipids were added to 
DNA to obtain cationic lipid/pDNA charge ratios ranging from 1 to 4.   
2.3.4. Physicochemical characterization of cationic liposome/pDNA 
complexes 
2.3.4.1. Assessment of complexation efficiency 
Picogreen assay.  The accessibility of the fluorescent intercalating reagent 
Picogreen to the pDNA associated with cationic liposomes was evaluated to 
determine the amount of complexed pDNA (Ferrari, M.E. et al., 2001).  Picogreen 
assay was applied as described in section 2.3.1.2.  The fluorescence scale was 
calibrated such that the initial fluorescence of Picogreen (100 µl of 1:200 solution 
added to wells containing 100 µl of water) was set as background fluorescence.  The 
fluorescence obtained upon addition of pDNA in 100 µl (20 µg/100 µl) minus 
background fluorescence was set as the control and reference fluorescence value 
(100% free pDNA).  100 µl of cationic lipid complexes containing 20 µg pDNA 
were prepared in water and added to each well containing 100 µl of Picogreen 
solution.  The amount of pDNA available for intercalation with the Picogreen was 
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calculated by subtracting the values of background fluorescence from those obtained 
for each measurement, and expressed as a percentage of the control according to the 
following formula: % free pDNA= fluorescence of complexes/fluorescence of 
control*100.   In order to investigate the effect of high ionic strength on 
complexation, the complexes were also incubated in HBSS for 1 hour before 
performing picogreen assay as described above.   
Gel elctrophoresis.  Agarose gel electrophoresis of cationic lipid/pDNA 
complexes was used to assess the complexation of lipid and DNA as a function of 
the cationic lipid/pDNA charge ratio.  
Cationic   lipid/pDNA   (2   μg   pDNA   per   sample)   complexes   were   prepared   at   the  
different   charge   ratios   in   100   μl  water.      After   1   h   incubation,   1   μl   of   the   loading  
buffer was added to each sample and mixed.  Each   sample   (5μl)   was   then  
electrophoresed on a 1% Agarose gel stained with Gel Red dye (5%) in 1X TAE 
buffer at 110V for 75 min.  The stained pDNA bands were then visualized and 
photographed on a UV transilluminator (Herolab, Germany). 
2.3.4.2. Light scattering and zeta potential measurements 
Particle sizes of the complexes were determined within one hour of their 
preparation using a Brookhaven instrument ZETAplus (particle sizing software). 
ZETAplus uses electrophoretic light scattering and the Laser Doppler Velocimetry 
(LDV) method to determine particle velocity and, from this, the zeta potential. It also 
offers the option of particle size analysis in the same instrument.  Measurements 
were made in water.   In order to determine the effect of ionic solution on the particle 
size of the lipoplexes, the prepared liposome/DNA complexes were incubated in 
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Hank’s   balanced   salt   solution   (HBSS)   15  min   before  measuring   their   particle   size.    
HBSS is the medium in which the lipoplexes would be added to cells in the 
transfection experiments.  The size distribution of the complexes at the different 
charge ratios was also determined in water and HBSS.  Five measurements with 10 s 
intervals between each measurement were taken for each sample; the measurements 
were performed on three separate occasions (n=3). 
The zeta potential of the lipoplexes was evaluated in both water and HBSS, 
using a Brookhaven instrument ZETAplus, Zeta potential analyzer.  Five 
measurements with 10 s intervals between each measurement were taken for each 
sample; the measurements were performed on three separate occasions (n=3). 
2.3.5. Cell culture 
Calu-3 cells, passage number 38-48, were grown in 162 cm2 flasks in 
Dulbecco’s   modified   Eagle’s   medium/Nutrient   Mixture   supplemented   with  
penicillin-streptomycin solution (5%), L-Glutamine (5%), non-essential amino acids 
(5%), and foetal bovine serum (50%) at 37°C in a humid atmosphere containing 5% 
CO2.  The cell culture medium was changed every 2 days and the cells were 
observed under a microscope to assess the degree of confluency and to confirm the 
absence of contaminants.  Once the cells reached 80-90% confluency, they were 
trypsinised using Trypsin-EDTA (0.25%), and either passaged to new flasks or 
plated in 96-well plates for transfection and toxicity experiments.  
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2.3.6. Transfection experiments 
One day before the transfection experiment, cells were seeded into 96-well 
plates at a density of 1x104 cells per well in standard cell culture media (plating 
volume 100 µl) and cultured overnight at 37°C.  Just before transfection, the medium 
was removed and 100 µl of HBSS buffer was added to each well.   After 30 min 
HBSS was removed and an equal volume of the complexes LD, LpegD and LPD of 
different charge ratios (0.5, 1, 2, 3, 4) were added to each well in filtered HBSS.  The 
final DNA concentration was 0.2 µg per well.  The cells were transfected for 6 h 
before removal of the complexes and each well was then supplied with 100 µl 
standard cell culture medium.  Cells were incubated for 48 h to allow gene 
expression to proceed.  The negative control group consisted of naked DNA alone in 
HBSS.  Lipofectamine (0.05 µl/well) complexed to DNA (0.2 µg/well) was used as a 
positive control because of its reported high transfection activity.  This commercial 
transfection reagent is suitable for in vitro transfection of suspended or adherent cells 
and it has been optimised for the delivery of both DNA and siRNA in a wide range 
of cell lines including Calu-3.   
2.3.6.1. Luciferase activity 
After 48 h incubation, the medium was removed and the cells were lysed by 
adding 100 µl of Glo lysis buffer,1X, to each well for 5 min.  The cells lysate (5 µl) 
was assayed for protein content using the Bio-Rad DC protein assay kit I.  The rest 
of the cell lysate was transferred to a white 96-well plate and the luciferase activity 
was measured using the Bright-Glo™   Luciferase   Assay   System   (according   to   the  
manufacturer’s  protocol)  and  the  Microtiter  plate  luminometer  (Dynex  technologies,  
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UK).  An excitation/emission wavelength of 560 nm was used to measure luciferase 
activity (a luciferase expressed will oxidise the added luciferin, which will emit 
photons at 560 nm).   All the luminescence values expressed as relative light units 
(RLU) were normalized per amount of protein. 
2.3.6.2. Protein Assay 
A standard curve was constructed using a protein standard (bovine gamma-globulin 
standard) between the concentration range of 0.32 and 1.32 mg/ml.  The standards (5 
µl) were pipetted into a 96-well plate (6 replicates for each concentration) followed 
by 25 µl of the reagent A (provided with the kit) and then followed by 200 µl of 
reagent B.  The plate was agitated to mix the reagents.  The same procedure was 
applied to the samples obtained from the cell lysis step of the transfection 
experiment.  After 15 min, absorbance of both the standards and the samples were 
read at 750 nm using the SpectraMax 190 Microplate Spectrophotometer (Molecular 
Devices, USA).  The amount of protein expressed by the cells was determined from 
the calibration curve (Appendix).    
2.3.6.3. MTT toxicity studies 
A relatively simple assay for cytotoxicity is the MTT (3[4, 5-dimethylthiazol-
2-yl]-2, 5-diphenyltetrazolium bromide) test.  The MTT is a tetrazolium dye that is 
reduced by mitochondrial enzymes and its colour changes from yellow to blue. This 
reaction takes place only in cells with viable mitochondria; therefore the colour 




2.3.6.4. Calibration curves for MTT test 
Cell counting:  Under sterile conditions 100 µl of cell suspension was mixed 
with an equal volume of Trypan blue dye by gentle pipetting.  Trypan blue dye only 
stains dead cells.  The number of viable cells was counted in a pre-cleaned 
haemocytometer and the concentration of viable cells was determined using the 
following equation: 
Concentration of viable cells (cells/ml) = A x B x C 
Where A is the mean number of viable cells counted, B is the dilution factor and C is 
the correction factor (104). 
Before performing an MTT test, calibration curves were constructed to 
determine the optimal cell seeding density for the experiment.  The cells were seeded 
into a 96-wells plate at concentrations of 5x105, 2.5x105, 1.25x105, 6.25x104, 
3.125x103, 1.56x103, 7.81x102, 3.91x102 and 1.95x 101 cells/ml. The experiment 
blank consisted of 100 µl of medium only.  The cells were incubated for 24hrs at 37 
ºC, 5% CO2. 
Solutions:  A 1 mg/ml MTT solution was made by dissolving 40 mg of MTT 
powder in 40 ml sterile PBS (the mixture was sonicated for a few seconds to aid 
dissolution) and stored in the fridge (2-8 C).  SDS solution was prepared by 
dissolving 4g of SDS powder in 20 ml pure water.  After sonication, 20ml of DMF 
was added to the SDS solution to give a final concentration of 10% SDS. After 24 hr 
incubation, 25 µl of filtered MTT solution (1mg/ml) mixed with 25µl medium was 
added to each well and the cells re-incubated for 4hrs.  Normally the dissolved MTT 
is converted to insoluble purple formazan crystals by cleavage of the tetrazolium ring 
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by dehydrogenase enzymes in viable cells. This water insoluble formazan is 
solubilized using SDS.   At the end of the incubation period, the medium was 
removed from the plate and the converted dye was solubilized by the addition of 100 
µl of SDS solution to each well (including the blank).   The cultures were incubated 
overnight and absorbance was measured at two wavelengths; 570 and 650 nm.  A 
calibration curve was constructed by plotting number of cells against the mean 
absorbance (Appendix).       
2.3.6.5. Cytotoxicity of pDNA/lipid complexes 
After determining the optimal seeding density of Calu-3 cells by calibration 
curves, cells were seeded into a 96-well plate at 1x104 cells/ well then incubated for 
24 hr (100 µl plating volume).  At the end of the incubation period the medium was 
removed, and lipoplexes were added at different lipid:DNA charge ratios (0.5:1, 1:1, 
2:1, 3:1, 4:1).   After 6 hr incubation, MTT assay was carried out as described above. 
2.3.7. Statistical tests 
A statistical package for social sciences (SPSS version 11.0) software was used 
to perform Independent samples t-test, One-way ANOVA and Post-Hoc   Tukey’s  
tests.  Statistically significant differences were assumed when p values were less than 
0.05.   
Independent samples t- test was performed to compare the difference in the 




One-way ANOVA and Post-Hoc  Tukey’s   tests  were   performed   to   determine  
whether there was a significant difference in luciferase production at the different 
charge ratios for each lipidic system including the control lipofectamine and to 
compare the level of luciferase expression between the three lipidic systems at the 




2.4.1.  pDNA characterization 
All pDNA preparations showed a major band of circular DNA and a minor 
band of nicked plasmid DNA (Figure 2.2) and the bands of the sample pDNA were 
similar to the marker (pure pGL3 control vector).   
The concentration of pDNA was determined using both UV spectroscopy and 
picogreen assay.  One unit of UV absorbance was equivalent to 50 µg plasmid DNA 
per ml.  All DNA samples were obtained in concentrations ranging between 0.8-1.5 
mg/ml. This result was confirmed by picogreen assay as the sample DNA 
concentration was calculated from the standard curve (Appendix) and was found to 
be in the same range.  The pDNA purity was assessed by the A260/A280 ratio, and 
all  preparations  had  an  A260/A280≥1.  
 
  1   2 
 
 
Figure 2.2  Gel electrophoresis of a sample of pGL3 control vector after extraction 
and purification using Qiagen Endofree Plasmid Mega Kit. 1) Pure pGL3 obtained 
from (Sigma Pharmaceuticals) was used as a marker, 2) sample pGL3 control vector. 
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2.4.2. Complexation efficiency as a function of charge ratio 
The influence of +/- charge ratio on the complexation of pDNA by cationic 
lipid was investigated using picogreen intercalation assay and agarose gel 
electrophoresis.  The extent of picogreen intercalation depended on the cationic 
lipid/pDNA charge ratios.  Upon addition of DOTAP:DOPE (LD) to pDNA a 
significant decrease in fluorescence intensity of picogreen was detected with 
approximately 50% remaining pDNA available for intercalation, which indicated 
association of 50% pDNA with the cationic lipid (Figure 2.3A).  This correlated with 
the presence of faint fluorescent bands on agarose gel at charge ratio 0.5  
corresponding to the ones observed in naked pDNA lane (Figure 2.3B) At charge 
ratios  ≥   2,   high   pDNA  condensation  was   achieved  with   less   than   20%  pDNA  was  
available for interclation.  However, gel electrophoresis showed absence of 
fluoresent  bands  at  ratios  ≥  1,  which  indicated  that  all  pDNA  was  bound  to  the  lipidic  
system. .  Although picogreen data showed that less than 40% free pDNA was 
available at charge ratio 1, agarose gel electrophoresis showed absence of free pDNA 
at this ratio.  Picogreen data after incubation of the complexes in HBSS, showed an 
increase in fluorescence intensity (represented by % free pDNA) suggesting greater 
dissociation of pDNA from the lipid in particular at low charge ratios (0.5 to 2) 
compared to incubation in water.  High pDNA condensation was achieved at high 
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Figure 2.3  A) Picogreen intercalation assay of LD complexes in water and HBSS.  
The percentage free pDNA represent the fraction of pDNA in the sample available 
for intercalation with picogreen reagent (n=3, mean ±SEM).  B) Gel electrophoresis 
of LD complexes prepared at different charge ratios in water; purre pGL3 control 




LpegD complexes showed more or less similar complexation profile as LD 
complexes both in water and HBSS.  In water the fluorescence intensity of picogreen 
decreased significantly after addition of DOTAP:DOPE:DMPE-PEG5000 (LpegD) to 
pDNA as shown by  the decrease of percentage free pDNA from 100% to ~ 60% at 
the 0.5 charge ratio.  Increasing the charge ratio caused a further decrease in 
percentage free pDNA to approximately 10% at charge ratio 4 (Figure 2.4A).  
Incubation of LpegD complexes in HBSS caused an increase in the fluorescense 
intensity of picogreen and therefore an increase in percentage free pDNA at low 
charge ratio (0.5 to 2) indicating dissociation or less effective condensation of 
pDNA.  As the charge ratio increased the percentage of free pDNA was comparable 
to the one observed in water.  In agarose gel, free DNA bands were observed in the 
until a charge ratio of 2:1 (Figure 3B), after this ratio no bands were observed 
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Figure 2.4 A) Picogreen intercalation assay of LpegD complexes in water and 
HBSS.  The percentage free pDNA represent the fraction of pDNA in the sample 
available for intercalation with picogreen reagent (n=3, mean ±SEM).   B) Gel 
electrophoresis of LpegD complexes prepared at different charge ratios in water; 




In the case of LPD complexes, the percentage of pDNA available for 
intercalation decreased by 90% at charge ratio 0.5 and remained the same despite 
increasing the lipid/pDNA charge ratios (Figure 2.5A) indicating complexation at 
low charge ratios.  Unlike the LD and LpegD other complexes, incubation of the 
LPD complexes in HBSS had no significant effect on the percentage of free pDNA.  
This data was supported by gel electrophoresis where LPD complexes showed 
complexation at all charge ratios indicated by the absence of free pDNA bands on the 
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Figure 2.5  A) Picogreen intercalation assay of LPD complexes in water and HBSS.  
The percentage free pDNA represent the fraction of pDNA in the sample available 
for intercalation with picogreen reagent (n=3, mean ±SEM).   B) Gel electrophoresis 
of LPD complexes prepared at different charge ratios in water; purre pGL3 control 
vector was used as a marker (M) 
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2.4.3. Changes in particle size and zeta potential as a function of 
charge ratio 
The particle size of LD complexes varied as a function of charge ratios.  When 
DNA was mixed with the liposomes, the mean size of the formed complexes 
increased from that of the original liposomes.  The largest particles were obtained at 
a charge ratio of 1 and smaller particles were obtained at charge ratios below or 
above 1 (Figure 2.6A).  The smallest diameter (150.2 nm) was observed at charge 
ratio 4.   Zeta potential was negative (-22.91 mV) when pDNA was in excess at the 
charge ratio of 0.5, then became positive (20-28 mV) at   charge   ratio   ≥1   (Figure  
2.6B).  After incubation in HBSS, there was a significant increase in size of the LD 
complexes at all charge ratios with up to a 10-fold increase at the charge ratio of 1 
(~3.8 µm) (Figure 2.6A).  The trend of particle size as a function of charge ratio was 
not observed in HBSS as the variability in size increased between different 
measurements.  LD complexes prepared at charge ratio 0.5 were the smallest 
complexes and their diameters remained in the nano range (500 nm).  The zeta 
potential of the LD complexes in HBSS showed a similar profile to the one observed 
in water; the zeta potential was negative at ratio 0.5 then became positive at charge 
ratio  charge  ratios  ≥1  to  reach  35  mV  at  ratio  4  (Figure  2.6B).    However  as  with  the  










Figure 2.6  (A) Particle size, and (B) zeta potential of LD complexes prepared at the 
indicated charge ratios.  The particle size (diameter) and zeta potential of the 






DOTAP:DOPE:DMPE-PEG5000 had a particle size of  150 nm which 
increased upon addition upon mixing with pDNA.  The LpegD complexes appeared 
larger than LD complexes with diameters reaching 500 nm or more.  However there 
was high variance in size (Figure 2.7A).  The LpegD complexes had a negative zeta 
potential (-38 to -6  mV)   at   charge   ratios  ≤2,  which   became  positive   as   the   charge  
ratios increased.  A zeta potential close to zero (charge neutrality) was obtained at 
charge ratio 2 (Figure 2.7B).   Similar to particle size measurements, high variability 
was also observed between different zeta potential measurements.  Incubation of the 
LpegD complexes in HBSS also resulted in a significant increase in particle size as 
compared to measurements in water, and the diameters of the complexes went from 
the nano range to the micro range except complexes at charge ratio 0.5 where the 
complexes remained small (~300 nm) (Figure 2.7A).  Incubation in HBSS 
significantly increased the positive charge of the LpegD complexes (Figure 2.7B).  
However similar trends as in water were obtained, the zeta potential shifted from 
negative to positive at charge ratios greater than 1 to become highly positive at 
charge  ratio  ≥  2  (~39-40 mV) when lipids were in excess.  A zeta potential close to 














Figure 2.7  A) Particle size, and B) zeta potential of LpegD complexes prepared at 
the indicated charge ratios.  The particle size (diameter) and zeta potential of the 








Figure 2.8  A) Particle size, and B) zeta potential of LPD complexes prepared at the 
indicated charge ratios.  The particle size (diameter) and particle size of the 




The exception to the changes in particle size as a function of charge ratio was 
the LPD complexes.  The particle sizes of the LPD complexes were similar to the 
size of the original DOTAP:DOPE liposomes (100-120 nm) and remained fairly 
constant despite the increase in +/- charge ratios (Figure 2.8A).   Unlike LD and 
LpegD complexes, the zeta potentials of the LPD complexes were highly positive 
(~25-30 mV) at all charge ratios tested.  Incubation in HBSS resulted in a significant 
increase in particle size in particular at low charge ratios 0.5 and 1 (Figure 2.8B).  
LPD complexes at higher ratios (3-4) were smaller and remained in the nano range 
(500-600 nm).  An important increase in the zeta potential values of the LPD 
complexes (~45-50 mV) was observed at all ratios as compared to measurements 
made in water.  
2.4.4. Transfection efficacy 
To assess the transfection efficiency of the three lipidic systems, the levels of 
luciferase gene expression were measured 48 h after delivery of LD, LpegD and LPD 
complexes at different charge ratios and normalised per amount of protein. Cells 
transfected with LD complexes showed a significant increase in luciferase expression 
as compared to naked pDNA (p<0.05, ONE-WAY ANOVA and Tukey tests) (Figure 
2.9).  Luciferase expression induced by LD was dependent on charge ratio with those 
prepared at 2 (+/-) producing significantly greater gene expression (p>0.05, ONE-
WAY ANOVA and Tukey tests) than complexes prepared at ratios above this ratio.   
The LD complexes prepared in the charge ratio range of 0.5 to 2 were as effective as 
the control lipofectamine/pDNA complexes in inducing luciferase expression 
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(p>0.05, ONE-WAY ANOVA and Tukey tests).  However at higher charge ratios 3 
and 4, a significantly lower gene expression was obtained, almost half of that 
achieved with lipofectamine, (p<0.05, ONE-WAY ANOVA and Tukey tests). 
In the case LpegD complexes, a significant luciferase expression was obtained 
at all ratios as compared to transfection with naked pDNA. (p<0.05, ONE-WAY 
ANOVA and Tukey tests) (Figure 2.10).  Again gene expression was determined by 
charge ratio with maximal expression at charge ratios 0.5 and 1 where the complexes 
were as effective as the positive control lipofectamine/DNA complexes (p>0.05, 
ONE-WAY ANOVA).  One the other hand At charge ratios 3 gene expression 
levels were significantly lower than those achieved at charge ratio 1 and those 
obtained with cells transfected with lipofectamine/pDNA complexes (p<0.05, ONE-
WAY ANOVA and Tukey tests). 
As with LD and LpegD complexes, cells tansfected with LPD complex showed 
a significant increase in luciferase expression as compared to naked DNA 
irrespective of the charge ratio tested (p<0.05, ONE-WAY ANOVA and Tukey tests) 
(Figure 2.11).  The complexes at all charge ratios were as effective as 
lipofectamine/DNA complexes in inducing gene expression (p>0.05, ONE-WAY 
ANOVA and tukey).  
When the transfection efficiency of the three complexes were compared, there 
was no significant difference in gene expression between the three systems at low 
charge ratios 0.5 to 2 (p>0.05, ONE-WAY ANOVA and tukey).  However, at charge 
ratios 3 and 4, the LPD complexes resulted in significantly higher gene expression 





Figure 2.9 Transfection of Calu-3 cells with LD complexes containing luciferase 
pDNA prepared at the indicated cationic lipid/pDNA charge ratios.   Luciferease 
activity was measured 48 h post-transection and luminescence (RLU/mg) represents 
the level of luciferase gene expression.  Lipofectamine/pDNA complexes were used 
as a (+) control and naked pDNA (charge ratio= 0) represent (-) control. (n=3, mean 











Figure 2.10 Transfection of Calu-3 cells with LpegD complexes containing 
luciferase pDNA prepared at the indicated cationic lipid/pDNA charge ratios.   
Luciferease activity was measured 48 h post-transection and luminescence 
(RLU/mg) represents the level of luciferase gene expression.  Lipofectamine/pDNA 
complexes were used as a (+) control and naked pDNA (charge ratio= 0) represent   












Figure 2.11  Transfection of Calu-3 cells with LPD complexes containing luciferase 
pDNA prepared at the indicated cationic lipid/pDNA charge ratios.   Luciferease 
activity was measured 48 h post-transection and luminescence (RLU/mg) represents 
the level of luciferase gene expression.  Lipofectamine/pDNA complexes were used 
as a (+) control and naked pDNA (charge ratio= 0) represent (-) control (n=3, mean 
±SEM).   
 
 
2.4.5. MTT toxicity study 
MTT test was carried out to determine the effect of increasing cationic 
lipid/pDNA charge ratio i.e. amounts of cationic liposomes, on the viability of Calu-
3 cells.  Untreated cells were considered as having 100% cell viability.  The cell 
viability remained above 70% for all three systems irrespective of the charge ratios 
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tested.  Both LD and LpegD complexes resulted in about 20-30% reduction in cell 
viability irrespective of the charge ratio used.  There was no significant difference in 
cell viability between low and high charge ratios (Figure 12A&B).  LPD complexes 
on the other hand showed no reduction in cell viability at lipid/pDNA charge ratio 
0.5 and resulted in less than 10% reduction at charge ratio 1 (Figure12C).  However, 






















Figure 2.12  Cytotoxicity of  LD (A), LpegD (B) and LPD (C) complexes in Calu-3 
as assessed by MTT assay. The relative cell viability as compared to untreated cells 




2.5.1. Effect of charge ratio on physicochemical properties of pDNA 
complexes 
Transfection efficiency of pDNA complexes is known to depend on many 
factors, among the main ones are complexation efficiency, size and surface charge of 
complexes.  Therefore prior to exploring transfection efficiency, these parameters 
were determined both in water and in bio-relevant media at different cationic lipid to 
pDNA charge ratios. 
2.5.1.1. Characterization in water 
A strong correlation between complexation efficiency, size and zeta potential 
data was observed and displayed a consistent trend as a function of charge ratio.  
Previously, it has been suggested that when liposomes are titrated into pDNA, the 
vesicles encounter excess pDNA and become coated with pDNA, which leads to the 
formation of negatively charged small complexes where pDNA was protruding from 
the surface (Eastman, S.J. et al., 1997).  This suggestion is consistent with the data 
from this study; at low +/- charge ratios where pDNA was in excess (0.5), LD 
complexes had a negative zeta potential indicating that charge neutralization did not 
occur, which was confirmed by the picogreen assay where more than half of pDNA 
was still available for intercalation with picogreen reagent and by the presence of 
free pDNA bands on agarose gel.  At these ratios LD complexes had small diameters 
(150-180 nm) because the repulsion by the negative charges prevented the formation 
of aggregates.  Larger LD complexes was observed when the charge ratio 
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approached neutrality because at this ratio there is almost an equal amount of 
negative versus positive charges and the interaction between complexes could occur 
easily due to the small zeta potential leading to the formation of aggregates and this 
is known as the colloidal instability zone (Sakurai, F. et al., 2000a).  In a previous 
study, Atomic Force Microscopy (AFM) images of DOTMA:DOPE:DNA 
complexes, showed that very large and heterogeneous aggregates were formed when 
the net charge became zero (Sakurai, F. et al., 2000a).  After the neutrality zone 
(charge ratios 1) and where cationic lipid is in excess complete condensation of 
pDNA by the cationic carrier occurred and this was accompanied by the significant 
fall in the percentage free pDNA, reduced particle size and the shift from negative to 
positive zeta potential indicating the formation of more stable complexes.  In the 
report by Sakurai and co-workers, AFM images demonstrated that at high +/- charge 
ratios when cationic lipid was in excess pDNA complexes appeared compact and the 
pDNA completely shrunk. 
In the case of LpegD complexes, picogreen intercalation data showed that 
pegylation did not significantly affect complexation efficiency as LpegD system 
showed similar percentage free pDNA trends as LD complexes.  However, unlike 
with LD complexes, LpegD gel electrophoresis data showed the presence of free 
pDNA at charge ratio 1, suggesting that the LpegD complexes required higher 
cationic charge ratio than LD complexes to achieve full charge neutralization.  The 
complexation data also correlated with changes in zeta potential, with a high 
percentage of free pDNA when the zeta potential was negative and then a reduction 
in the percentage of free pDNA when the zeta potential became positive, indicating 
negative charge neutralization.  This agrees with a study where it was found that 
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stabilization by the addition of 1% PE-PEG did not much change the morphology of 
freshly prepared complexes (Sternberg, B. et al., 1998).  In addition, Shi and co-
workers showed that the inclusion of 5-10% mole pegylated lipids (DSPE-PEG or 
Ceramide-PEG) did not affect oligonucleotide (ODN) association with cationic lipids 
(Shi F, W.L., Nomden a, Stuart M C a,  Polushkin E, Engberts J and  Hoekstra D, 
2002).   However, LpegD complexes appeared larger (300-500 nm) than LD 
complexes (150-300 nm) probably due to external PEG chains as reported by 
Sanders and co-workers who illustrated that the addition of Pegylated-lipid resulted 
in an increase in size of GL67-pDNA complexes as compared to non-pegylated LD 
complexes (Sanders Nn, D.S.S., Cheng Sh, Demeester J, 2002).  Surprisingly, the 
presence of PEG chains increased the heterogeneity of the system as compared to LD 
complexes, although it was difficult to distinguish any trend in particle size as a 
function of charge ratio because the differences in particle diameter were not 
statistically significant. 
The physicochemical properties of LPD complexes were completely different 
from those of LD and LpegD complexes.  Protamine sulphate is recognized as an 
effective condensing agent of pDNA (Collins, E. et al., 2007).  The pre-condensation 
of pDNA with the polycation before the addition of the lipid resulted in charge 
complete charge neutralisation even at low cationic lipid/DNA charge ratio very little 
pDNA was available for intercalation with picogreen.  Similarly on agarose gel, there 
were no free pDNA bands apparent at all charge ratios.  This was matched by a small 
particle size (100-150 nm) and a positive zeta potential  indication the formation of 
stable complexes irrespective of the cationic lipid +/- charge ratio used.  Sternberg 
and co-workers showed that pre-condensation leads to the formation of new 
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structures with a size of one or two liposomes (100-200 nm) (Sternberg, B. et al., 
1998).  The high proportion of amine groups in these polypeptides reduces the 
number of charge sites for interaction with cationic liposomes, therefore pDNA 
complexes formed by pretreatment with protamine sulphate were stable at lower 
cationic lipid to pDNA charge ratio without aggregation as observed with LD and 
LpegD complexes (Zhdanov, R.I. et al., 2002) (Hong, K.L. et al., 1997).  Birchall 
and co-workers used negative stain transmission microscopy to show that pre-
condensation of pDNA resulted in the formation of small spherical complexes as 
compared   to   the   larger   ‘’fingerprint-like’’   complexes   formed   by   LD   complexes  
(Birchall, J.C. et al., 1999). 
2.5.1.2. Characterization at physiological salt concentration 
Due to the electrostatic nature of the pDNA/lipid interaction, the presence of 
salt was expected to alter the dynamics for the formulations.  However many 
physicochemical characterization of pDNA/lipid complexes are reported in water or 
at low strength media as reported in section 2.1.2 which does not correlate with cell 
culture media in vitro or physiological environment in vivo.  Therefore in this study 
it was considered crucial to characterize the complexes in the media in which the 
transfection experiments were performed (HBSS).   The change in the properties of 
the different lipidic systems after incubation in high salt medium was measured. 
Complexation efficiency.  Eastman and co-workers reported that high ionic 
strength increased the accessibility a fluorescent dye to pDNA by decreasing 
association and compaction of pDNA (Eastman, S.J. et al., 1997).  The picogreen 
intercalation data indicated that this occurred for the LD and LpegD complexes as 
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incubation in HBSS increased percentage of pDNA available for intercalation at 
charge ratios (0.5 -2).  Mechanistically, this may be explained by the ionic strength 
reducing the release of counter ions from pDNA and cationic lipid, which are the 
driving force for complex assembly (Kawashima, T. et al., 2006).  However, in this 
study the decrease in binding efficiency was mainly apparent at low charge ratios 
while at higher ratios (3-4), there was no significant change in complexation as 
compared to water.   This indicated that at high charge ratios pDNA remained 
condensed and was not affected by the presence of anions.  Whietoff and co-workers 
reported that positively charged LD complexes (at high charge ratios) are generally 
more resistant to poly-anion mediated disassembly than those at low charge ratios 
(Wiethoff, C.M. et al., 2004).  In this study, the LPD complexes were not 
significantly affected by the high salt concentration even at low cationic lipid/pDNA 
charge ratios.  This is due to the presence of a constant amount protamine, which 
increased the pDNA compaction and made the complex more stable. 
Particle size.  The addition of ions extends the aggregation zone and changes 
the structure of the complex (Tranchant, I. et al., 2004).  Other work reported that 
pDNA/lipid complexes form compact lamellar structures in water but after exposure 
to high salt concentration, the complexes are more likely to form non-bilayer 
structures, which are believed to promote transfection (Sternberg, B. et al., 1998).  In 
this work, the size of all three systems increased significantly after incubation at 
physiological salt concentration irrespective of the charge ratio tested except at 
charge ratio 0.5, where the increase in particle size was less marked.  The low 
aggregation at this ratio with LpegD complexes can be explained by the effective 
shielding of cationic charges by the negatively charged free pDNA as well as the 
 109 
 
steric barrier caused by PEG chains in the case of LpegD complexes.  However with 
LPD complexes the negative charge of pDNA was already neutralized by the 
polypeptide and therefore aggregation was observed from charge ratio 0.5.  Despite 
the increase in size, the LPD complexes were less heterogeneous than LpegD and LD 
complexes due to the pre-compaction with a constant amount of the polypeptide.  
Interestingly, although the high ionic strength had no significant effect on the 
complexation efficiency of the LPD system, but it did cause a significant increase in 
particle size and formation of large aggregates.  This was due to the fact that the 
presence of electrolytes causes agglomeration of like-charged nanoparticles due to 
reduced screening of repulsive forces (Gary, D.J. et al., 2007). 
Zeta potential.  In terms of surface charge (zeta potential), the findings of this 
study were contradictory to what has been reported previously (Eastman, S.J. et al., 
1997) where it was shown that as the high salt concentration shields some of the 
positive charge of liposomes and therefore lowers the zeta potential of the 
complexes.  Here, the zeta potential stayed the same or became slightly more 
positive for all three systems after incubation in HBSS as compared with 
measurements in water in particular with the LPD and LpegD complexes where the 
increase was significant.  Nonetheless, the trends of zeta potential as a function of 
charge ratio in HBSS remained similar to those observed in water.  The increase in 
zeta potential with LPD can be explained by the presence of more free liposomes.  
With the LpegD system the reason for the increase in zeta potential is unclear. 
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2.5.2. Relationship between physicochemical properties and 
transfection  
With the exception of LPD complexes, there was a marked influence of the 
cationic lipid to DNA charge ratio on transfection efficiency and a tendency to a 
higher transfection at low charge ratios.  The influence of this parameter on 
transfection is related to the effect on either the size of the complexes, surface charge 
or complexation efficiency or on all of them.  LD complexes at low charge ratios 
0.5-2 were more effective in inducing luciferase expression in Calu-3 cells than 
complexes formed at charge ratios of 3-4.   This is in agreement with the work done 
by Masotti and co-workers who showed that a charge ratio 1 maximized transfection 
efficiency of LD complexes and that this was because at this ratio the particle size 
was greatest (Masotti, A. et al., 2009).  However other work has shown that LD 
complexes were most effective at high charge ratios (3-4) in C6 cell line (Esposito, 
C. et al., 2006).  These differences are probably due to different experimental 
conditions and cell lines used. 
Similar results were obtained with LpegD complexes, which produced higher 
gene expression at low charge ratios (0.5-2) when compared to higher ratios (3-4).   
Several studies support the assumption that transfection efficiency is determined by 
particle size of the complexes and that large complexes (micron-range) favour 
transfection (Esposito, C. et al., 2006, Bouxsein, N.F. et al., 2007, Ross, P.C. and 
S.W. Hui, 1999a).  Although, the findings of the current study confirmed that large 
pDNA complexes (micron range) can transfect cells efficiently, the difference in 
luciferase expression between high and low charge ratios was not directly associated 
with the particle size because incubation in HBSS prior to transfection resulted in the 
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formation of very heterogeneous systems and there was no significant difference in 
particle diameters of the complexes prepared at the different charge ratios.  Wiethoff 
and co-workers reported that although LD complexes showed no differences in 
particle size, they produced different levels of gene expression and concluded that 
size is not a controlling variable in gene expression (Wiethoff, C.M. et al., 2004).  
This agrees with the results of the current study.  In addition, LPD dependence on 
charge ratio was apparent as the same level of gene expression at almost all charge 
ratios was observed despite differences in diameters of the complexes as a function 
of charge ratio.  Thus it can be concluded that large pDNA complexes (micron 
range) resulted in efficient transfection in vitro, but particle size was not the only 
determinant of transfection efficiency and other factors in addition to size play a role 
in transfection. 
It has been assumed that a positive surface charge is necessary for the 
interaction of lipoplexes with cellular membrane and therefore entry into cells 
(Brown, M.D. et al., 2001).  In addition, the interaction of positively charged pDNA 
complexes with endosomal membrane anionic lipids through formation of ion pairs, 
lateral diffusion, and lipid mixing are mechanisms that have been speculated to 
facilitate the DNA release (Xu, Y. and F.C. Szoka, Jr., 1996).  However, there is 
evidence that neutral or negatively charged complexes are effective in transfection 
and result in high gene expression (Wiethoff, C.M. et al., 2004, Patil, S.D. et al., 
2004).  The data presented here, showed an increased gene expression at low charge 
ratios where LD or LpegD complexes had a negative or small zeta potential (close to 
neutrality) and a decrease in gene expression at higher charge ratios where zeta 
potential was positive.  This supports the contention that a positive surface charge is 
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not essential for transfection efficiency, which may be because negatively charged 
LD complexes trigger internalization via a different endocytic pathway than 
positively charged complexes as suggested by Wiethoff and co-workers.  Their work 
showed that when cholesterol was used instead of DOPE as the neutral lipid, 
negatively charged pDNA complexes did not disrupt the negatively charged cellular 
membrane due to either an inability to attain close proximity between negatively 
charged liposomes and negatively charge surface of pDNA complexes to initiate 
fusion or an inability to adopt the non-bilayer structure needed for fusion.  Therefore, 
even if the complexes were taken-up by cells, they may not escape endosomal 
compartments.  Incorporation of DOPE into the formulation resulted in a significant 
increase in membrane disruption, which correlated with an increase in gene 
expression.  This indicated that the presence of the fusion lipid DOPE has a more 
significant role in interaction with cellular membranes and transfection efficiency 
than the surface charge of the complexes (Wiethoff, C.M. et al., 2004).  Guo and Lee 
also demonstrated that the fusiogenic lipid DOPE was crucial for the endosomal 
escape and therefore transfection efficiency of anionic complexes (Guo, W. and L. 
Rj, 2000). 
Another important observation is that at although pDNA is not fully 
neutralized or condensed by the cationic lipid at low charge ratios (percentage pDNA 
available for interaction with the picogreen reagent was 50-80% with LD and 60-
90% with LPegD), high gene expression was obtained whereas at higher 
complexation rate (less than 20% available pDNA at charge ratio 3-4) gene 
expression was lower.  Although it is believed that full condensation of pDNA is 
necessary for efficient transfection, Sakurai and co-workers reported that the release 
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of pDNA from the complexes once inside the cell is one of the most crucial steps in 
determining optimal cationic lipid to pDNA charge ratio as it might be difficult for 
pDNA to be released from very compact complexes especially at high charge ratios.  
This theory could explain the low gene expression at high charge ratios for LD and 
LpegD complexes but does not justify the high gene expression for LPD complexes 
in which pDNA is well condensed at all charge ratios as shown by picogreen 
intercalation and light scattering data.  
2.5.3. Transfection versus toxicity 
In order to assess the relationship between toxicity and transfection efficiency, 
the cytotoxic effect of LD, LpegD and LPD complexes were determined at different 
charge ratios using MTT test.  Cellular damage caused by the three systems was 
relatively small compared to untreated cells as cell viability remained above 70% 
even at high charge ratios.  It had been reported that toxicity is closely related to 
cationic lipid/pDNA charge ratios (Lv, H.T. et al., 2006) and is more pronounced at 
high charge ratios due to the high positive zeta potential of the complexes (Sakurai, 
F. et al., 2000b)  
However, the cell viability data of LD and LpegD complexes showed no 
significant difference in cell viability between complexes prepared at different 
lipid/pDNA charge ratios, which implied that the reduced gene expression at high 
charge ratios was not due to toxicity.  Slightly higher cell viability was observed with 
LpegD complexes (75-85%) compared to LD complexes, perhaps because the 
presence of PEG chains shifted some of the positive charge of the cationic lipid.  In 
contrast to LD and LpegD, LPD complexes were associated with a trend to lower 
 114 
 
cell viability (albeit still not beyond the 70% viability level) with an increase in 
cationic lipid/pDNA charge ratios, possibly due to the presence of free liposomes in 
sample at high charge ratios (Lv, H.T. et al., 2006).  Xu and co-workers showed that 
removal of free liposomes from LD complexes prepared at high charge ratios 
resulted in reduction of toxicity (Xu, Y. et al., 1999).  However in another study, the 
purification of LPD complexes from free liposomes resulted not only in reduced 
toxicity, but also reduced transfection efficiency (Li, S. et al., 1998).  In terms of 
transfection efficiency, the reduction in cell viability at high charge ratios did not 
seem to affect the level of gene expression as cell viability remained above 70% 
(Masotti, A. et al., 2009).  Overall, the charge ratios selected for this study did not 
cause excessive cellular damage. 
2.5.4. Conclusion 
In conclusion, the trends in gene expression achieved using LD and LpegD 
complexes were similar with lower pDNA condensation at low (+/-) charge ratio 
giving higher gene expression, which was attributed to ready release of pDNA from 
the complex once inside the cells.  In contrast, LPD complexes showed similar gene 
expression as LD and LpegD complexes despite the high compaction of pDNA at all 
charge ratios.  Complexes prepared at (+/-) charge ratio 1 appeared to give the 
highest transfection efficiency except for the LPD system, which was effective at all 
charge ratios.  For LD and LpegD systems formation of stable complexes after 
charge ratios 1-2 resulted in reduction in transfection efficiency.  The parameters that 
may affect transfection such as size, charge and complexation efficiency were 
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specific to the lipid composition used and it was not possible to determine the main 
parameter that governs transfection. 
The data presented in this chapter illustrated the importance of characterising 
pDNA complexes at physiological salt concentration as the presence of high ionic 
strength resulted in a remarkable change in the physicochemical properties of the 
complexes.  The lipids used here will be used to compare the differences between 
pDNA and siRNA formulation in terms of physicochemical characteristics and 











3. Chapter 3 In vitro delivery of 





siRNA targets have been identified in various diseases such as cancer, viral 
infections, and neurodegenerative disease (Shrivastava, N. and A. Srivastava, 2008) 
and as the attractiveness of siRNA as a therapeutic tool is increasingly recognised, 
there is an imperative need to develop efficient delivery systems for clinical 
application.  When searching for potential siRNA delivery carriers, it is only logical 
to first investigate those with proven efficacy in delivering pDNA.  Among those are 
cationic lipids, which show great promise as carriers due to their low toxicity and 
ease of production (Wu, S.Y. and N.A. Mcmillan, 2009). 
Although both pDNA and siRNA are polynucleotides and therefore face 
similar physical barriers to their delivery, structural differences between siRNA and 
DNA as well as differences in their method of action, are likely to be responsible for 
differences in formulation (Gary, D.J. et al., 2007, Spelios, M. et al., 2010, Marty, R. 
et al., 2009b).  The size and electrostatic charge of siRNA are much lower than that 
of pDNA, and siRNA is more susceptible to degradation by nucleases (Mahon, K.P. 
et al., 2010).  siRNA acts primarily in the cytoplasm (Morille, M. et al., 2008, De 
Fougerolles, A. et al., 2007), it does not require nuclear targeting which is an 
important barrier in pDNA delivery (Wasungu, L. and D. Hoekstra, 2006, Thomas, 
M. et al., 2007).  The physicochemical differences between siRNA and pDNA may 
affect the interaction between the nucleic acid with the delivery vectors and this, 
along with the different site and mechanism of action, may affect their functionality.   
The previous chapter described the physicochemical properties of three 
cationic lipid/pDNA complexes; LD, LpegD and LPD and attempted to define the 
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relationship between the properties of the formulations and gene transfection 
efficacy.  No single physicochemical property (size, charge or condensation 
efficiency) was predictive of gene expression efficiency, but it is possible that the 
characteristics of the dominating population of complexes (detectable by the 
characterization methods) might not be the biologically active component.  
3.1.1. siRNA assays using respiratory epithelial cells in vitro  
In addition to the Calu-3 cell line utilised in Chapter 2, the A549 cell line was 
used to assay gene knockdown, to determine whether there is a difference in 
transfection efficiency between different cell lines.  This cell line is one of the most 
characterised and widely used in vitro systems for studying the alveolar epithelial 
function.  This human adenocarcinoma-derived cell line forms cell layers with 
characteristic alveolar type II cell morphology.  Type II cells are more numerous 
than Type I cells, and have distinct functions such as oxidative metabolism of drugs 
in the lung and production of surfactant (Foster, K.A. et al., 2000).   They are 
believed to differentiate into Type I pulmonary epithelial cells, which cover 96% of 
the surface area of the pulmonary epithelium (Steimer, A. et al., 2005).  Their 
endocytic properties have been well characterized which makes them a potential 
target for drug delivery of macromolecules.  A549 cell lines have been shown to 
have many type II cell characteristics and they have been widely used to study 
alveolar drug uptake, metabolism, and gene delivery (Steimer, A. et al., 2005). They 
are also considered as an accepted model in pulmonary toxicity studies, and unlike 




At the time of this thesis, only one study compared transfection efficiency of 
pDNA and siRNA using the CDNA:DOPE lipidic formulation in Hela cell line 
(Spagnou, S. et al., 2004).  The findings of this study showed that pDNA and siRNA 
required different (+/-) charge ratios for optimal transfection, but this has not been 
investigated systematically with the formulation physicochemical properties linked 
to functional transfection.  In addition the media in which the particle size of siRNA 
complexes was determined was different from the media used in transfection.  
Therefore, in this work, it was hypothesized that the factors that influence 
transfection efficiency such as formulation type, charge ratio, physicochemical 
properties might have a different effect on pDNA and siRNA transfection efficiency. 
3.1.2. Aim and objectives 
The aim was to compare the siRNA formulations with equivalent formulations 
using pDNA using the same three systems characterized for pDNA delivery.  
Formulations were evaluated in terms of their physicochemical properties and their 
delivery to obtain a biological effect.  The specific objectives of this chapter were to: 
 Measure the physicochemical properties of cationic lipid-siRNA formulations 
and compare these to the results obtained for the same formulations with 
pDNA, 
 Develop assay methodology to measure the effect of siRNA delivery in vitro 
by measuring GADPH knockdown, 
 Measure the transfection efficiency of cationic lipid-siRNA formulations, 
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3.3.1. GAPDH siRNA and negative control siRNA 
GAPDH (glyceraldehyde 3-phosphate dehydrogenase) siRNA, which targets 
the abundant ubiquitously expressed housekeeping gene GAPDH was used to 
determine gene knockdown in cell cultures.  This siRNA efficiently reduces both the 
mRNA and protein levels of GADPH in human, mouse and rat cell lines.  A non-
specific negative control siRNA, which is a non-targeting sequence, was used as 
baseline from which to determine the siRNA silencing effect.  The control was 
employed to identify nonsequence-specific effects of GAPDH siRNA as well as the 
toxicity of the delivery vectors. 
3.3.2. Preparation of cationic liposomes/siRNA complexes  
Cationic liposomes were prepared in the same way as described in 2.3.2.  The 
three cationic liposomes based systems were used to complex siRNA; 
DOTAP:DOPE (1:1 molar ratio), DOTAP:DOPE:DMPE-PEG5000 (1:1:0.05 molar 
ratio), and DOTAP:DOPE (1:1) Protamine to form LR, LpegR and LPR, complexes, 
respectively.   
siRNA and cationic liposomes complexes were prepared by sequentially 
diluting siRNA in non-supplemented cell culture media, then adding appropriate 
amounts of liposomes.  After vortexing, the mixtures were incubated for 30 min at 
room temperature to allow complex formation.  The amount of liposomes added was 
based on the desired +/- charge ratios (0.5, 1, 2, 3, 4, 6, 10, 12).  The +/- charge ratio 
was calculated as total number of positive charges on the DOTAP molecules divided 
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by the total number of negative charges on the nucleic acid (assuming 1µg siRNA 
contains 3nmol negatively charged phosphate groups and one DOTAP molecule 
contains one positive charge).  LPR complexes were prepared by the addition of 
protamine (1 mg/ml) to siRNA at a 2:1 mass ratio with 10 min incubation, followed 
by the addition of DOTAP:DOPE liposomes and incubation for 30 min to allow 
complexation.   
3.3.3. Characterization of cationic liposome/siRNA complexes  
3.3.3.1. SYBR green II intercalation assay 
SYBR green II reagent is a very sensitive fluorescent nucleic acid stain, which 
is more sensitive to dsRNA than dsDNA.  This reagent intercalates between nucleic 
acid base pairs and emits fluorescence at 497/520 nm and is used to quantify dsRNA 
at concentration as low as the picogram range.  The accessibility of this reagent to 
intercalation with siRNA base pairs in the lipid complexes was determined and used 
as a measure of degree of siRNA condensation in the cationic liposome. 
siRNA and cationic liposomes complexes were prepared at different charge 
ratios as described in 3.3.2.  SYBR green II 3X solution was prepared by diluting 
SYBR green II reagent 10000X 1 in 3000 times in HEPES buffer.  SYBR green II 
(100  μl,  3X  solution)  was  added  to  100  µl  of  the  formed  complexes  in  water  or  non-
supplemented cell culture media and the fluorescence was measured in sterile black 
96-well microplates at an excitation wavelength of 497 nm and emission wavelength 
of 520 nm using a Spectra Max Microplate spectrophotometer set at gain 40).  The 
fluorescence scale was calibrated such that the initial fluorescence of SYBR green II 
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(100 µl of 3X solution added to the well containing 100 µl water or non-
supplemented media) was set as background fluorescence.  The fluorescence 
obtained upon addition of naked siRNA in 100 µl non-supplemented media (50 
nM/100 µl; control) minus background fluorescence was set as the positive control 
(reference fluorescence). The amount of siRNA available for intercalation with the 
SYBR Green II was calculated by subtracting the values of background fluorescence 
from those obtained for each measurement, and expressed as a percentage of the 
control according to the following formula: % free siRNA = 100 x (fluorescence of 
cationic lipid:siRNA complexes/fluorescence of control). 
3.3.3.2. Light scattering and zeta potential 
The prepared siRNA complexes were placed into UV cuvettes containing 
phenol red-free non-supplemented cell culture media and then inserted in 
Brookhaven instrument ZETAplus particle sizer to measure the particle size and zeta 
potential.  The reported hydrodynamic diameters and zeta potentials represent the 
average values of five readings taken at 10 s intervals. 
For the zeta potential measurements, inconsistent readings were obtained, 
probably due to the low concentration of the complexes in the sample and due to 
high cost of siRNA higher concentrations could not be increased.  Therefore the 
particle size and polydispersity of the complexes in DMEM were determined only in 
phenol red-free non-supplemented cell culture media. 
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3.3.4. The optimisation of transfection conditions for the positive control 
The commercial transfection agent, Lipofectamine employed as a positive 
control for pDNA transfection experiments (section 2.3.6) has not been optimised for 
siRNA delivery in Calu-3 cells.  Therefore the aim of this experiment was to 
determine the transfection conditions that will provide maximum gene silencing 
while maintaining an acceptable level of cell viability.  The critical parameters that 
were optimized included the amount of transfection reagent, the duration of complex 
exposure to cells and the time allowed for protein knockdown to occur (incubation 
time). 
Calu-3 cells were cultured as described in section 2.3.5 with the incubation 
conditions in the following experiments being 37ºC and 5% CO2.  
siRNA/lipofectamine complexes were prepared by diluting siRNA in non-
supplemented cell culture media then adding the indicated amounts of lipofectamine.  
After vortexing, the mixtures were incubated for 30 min at room temperature to 
allow complex formation.  Cells that were seeded in a 96-well plate at a seeding 
density of 1x104 cells per well in normal media (10% FBS), and that were incubated 
for 24 hours before the transfection experiments were performed. The medium was 
removed from these cells and siRNA/lipofectamine (50 nM siRNA per well) 
complexes made in serum free DMEM-12 medium at different concentrations were 
added to the cells.  At appropriate times, the complexes were removed and replaced 
with normal growth medium (10% FBS) to maximize cell growth and prevent 
potential cytotoxicity.  The cells were then incubated for either 48 or 72 h, before 






Cells were exposed to the complexes prepared using different amounts of lipid for 
either 6 or 24 h.  GAPDH silencing was determined at both 48 and 72 hours post-
transfection.   
 
3.3.5. Determining protein knock down and toxicity using KDalert assay 
kit 
The KDalert GAPDH assay measures the conversion of NAD+ to NADH by 
GAPDH in the presence of phosphate and glyceraldehyde-3-phosphate (G-3-P).  The 
production of NADH under these conditions results in a fluorescence increase and a 
colour change in the samples.  Under the recommended assay conditions, the rate of 
NADH production is proportional to the amount of GAPDH enzyme present.  Thus 




The culture medium was aspirated from transfected cells and the KDalert Lysis 
Buffer  (200  µl)  was  added  to  each  well   for  20  min  at  4°C.     Cell   lysate  (10  μl)  was  
transferred to the wells of a black 96-well  plate  and  90  μl  of  KDalert  Master  Mix  was  
added to each sample at approximately the same time.  The increase in fluorescence 
of the samples over 4 min was measured at room temp (excitation/emission 
wavelengths  of  520/585  nm).       Efficiency  of  transfection  was  expressed  as  ‘percent  
gene   silencing’   with   respect   to   controls   (cells treated with the same amount of 
transfection reagent complexed to negative Control #1 siRNA to ensure that the 
decrease in protein levels was due to specific gene silencing not to the toxicity of the 
transfection agent).  Other controls included untreated cells and cells treated with 
naked siRNA.  The percent remaining gene expression for a given transfection 
condition was determined from the ratio of the fluorescence increase for samples 
transfected with GAPDH siRNA to the fluorescence increase for samples transfected 
with Negative Control #1 siRNA.  The level of gene knock down was calculated 
from the % remaining expression, according to the equation:  % knockdown= 100 - 
(100  x  Δfluorescence GAPDH  /Δfluorescence Negative control siRNA) 
3.3.6. Transfection of bronchial epithelial cell line, Calu-3 
GAPDH siRNA or negative control siRNA/lipid complexes LR, LPR and 
LpegR were prepared in DMEM-12 at different charge ratios (0.5 to 12) as described 
above.  Complexes were then added to the Calu-3 cells for 6 hours (final siRNA 
concentration 50 nM/100 µl).  After that time, complexes were removed and 
replaced with serum containing media and the cells were then incubated for 72 hours 
before measuring GAPDH enzyme activity using the KDalert assay.   
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3.3.7. Transfection of alveolar epithelial cell line, A549 
A549 cells (passages 104-120) were subcultured in 162 cm2 flasks in RPM-
1640 media supplemented with gentamycin (0.1% v/v), L-glutamine (5% v/v), non-
essential amino acids (5% v/v), and foetal bovine serum (10% v/v).  Cells were left 
to grow at 37°C in a humid atmosphere containing 5% CO2.  Every second day the 
medium was changed and once the cells reached 80-90% confluency, they were 
trypsinised using 1 ml of trypsin-EDTA (0.25%) solution before being passaged on 
or plated for experimentation.  The A549 cells were transfected as described above 
and the level of GAPDH activity was measured 72 hours after transfection using the 
KDalert assay.   
3.3.8. The effect of serum on gene silencing efficiency  
In order to investigate the stability of the siRNA complexes in the presence of 
serum, A549 cells were transfected with LPR and LpegR complexes prepared at 
charge ratio of 10:1 in the presence and absence of foetal bovine serum.  
Transfection was carried out as described above, except that after the preparation of 
the complexes in serum-free media, 5% or 20% FBS was added to the complex mix, 
which was then added to A549 cells.   
3.3.9. Data analysis and statistics 
A statistical package for social sciences (SPSS version 11.0) software was used 
to perform Unpaired t-test and One-way ANOVA and Post-Hoc   Tukey’s   tests.    
Statistically significant differences were assumed when p values were less than 0.05.   
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Unpaired t- test was performed to compare the difference in gene silencing 
between complexes containing GAPDH siRNA and complexes containing negative 
control siRNA. 
One-way ANOVA and Post-Hoc  Tukey’s   tests  were   performed   to   determine  
whether there was a significant difference in gene silencing between the three lipidic 




3.4.1. SYBR green II intercalation assay  
SYBR green II intercalation assays were employed to determine the degree of 
complexation of siRNA by the cationic vectors in LR, LpegR and LPR complexes 
prepared in transfection media DMEM.  Complexation efficiency of lipofectamine a 
commercial transfection reagent was used as a positive control.  Upon addition of 
lipofectamine to siRNA significant quenching of SYBR green II fluorescence was 
observed as compared with naked siRNA, which indicated efficient complexation 
and formation of stable complexs as shown with a decrease in percentage free siRNA 
from 100% (naked siRNA) to 15% and remained constant despite the increase in the 
amount of lipid (Figure 3.1A).  LR complexes caused a significant decrease in 
percentage of free siRNA at ratios ranging from 0.5 to 2  (down to ~50% at ratios 
2).  However, at higher ratios (6-10) the percentage of free siRNA available for 
intercalation increased (Figure 3.1B).  LpegR complexes displayed low 
complexation efficiency at all ratios (Figure 3.1C).  In the case of LPR complexes, a 
significant decrease in percentage free siRNA was observed at charge ratio 0.5 
(down to 20 % free siRNA), which then increased to 40-50% and remained 

















Figure 3.1  SYBR green II intercalation assay for A) Lipofectamine/siRNA B) LR 
C) LpegR and D) LPR complexes prepared in DMEM.  Complexes were prepared at 
the indicated charge ratios and the percentage of siRNA in the sample that is 
available for intercalation with SYBR Green II gel stain was determined.  Naked 
siRNA was used as control and represents 100% free siRNA (n=3, mean ±SEM). 
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3.4.2. Particle size and polydispersity of siRNA complexes 
After the addition of the cationic lipids to siRNA, the mean particle size 
generally increased from that of the original DOTAP:DOPE liposomes which was 
typically 150-160 nm to reach a maximum at charge ratio 2 (~600 nm) then decrease 
with the increasing charge ratio (down to 200 nm at charge ratio 10) (Figure 3.2).   
The smallest complexes were observed at ratios ranging between 6 and 12 (<200 
nm).  High particle size polydispersity was observed at low charge ratios then 
decreased as the charge ratio increased but the decrease was only significant at ratios 
ranging between 6 and 12. 
LpegR complexes had similar particle size and polydispersity compared to LR 
complexes, with an initial increase in the particle size after the addition of the 
cationic lipids to siRNA, from 130-140 nm (size of the original liposome) to reach a 
maximum of 400-450 nm at the charge ratios 1-2, and then the size decreased with 
the increasing charge ratios down to a minimum of 100 nm at ratios ranging between 
6 to 12 (Figure 3.3).  The polydispersity of the system was high at low ratios (0.5-4) 
then significantly decreased from charge ratio of 6 upwards.  The LPR complexes 
had a fairly stable particle size (200-250 nm) irrespective of the change in cationic 
lipid/siRNA charge ratios (Figure 3.4).  Hopwever, the polydispersity displayed a 
trend similar to the one observed with LR and LpegR, i.e., it was high at low charge 







Figure 3.2  The changes in the particle size and size distribution of LR complexes as 
a function of the cationic lipid:DNA/siRNA charge ratio.  The diameters (nm) and 
polydispersity of the complexes were determined 45 min after their preparation in 










Figure 3.3 The changes in the particle size and size distribution of LpegR complexes 
as a function of the cationic lipid:DNA/siRNA charge ratio.  The diameters (nm) and 
polydispersity of the complexes were determined 45 min after their preparation in 






Figure 3.4 The changes in the particle size and size distribution of LPR complexes 
as a function of the cationic lipid:DNA/siRNA charge ratio.  The diameters (nm) and 
polydispersity of the complexes were determined 45 min after their preparation in 
serum-free cell culture media.  (n=3, mean ±SEM). 
 
3.4.3. Optimisation of the transfection conditions 
As GAPDH activity reduction might be reduced not only by the silencing 
effects of the GAPDH siRNA but also by non-specific silencing and cell death, a 
non-specific siRNA (negative control) was used to normalise the gene silencing 
induced by GAPDH.  GAPDH activity in arbitrary fluorescence units was 
determined in cells transfected with either GAPDH siRNA or negative control 
siRNA complexes.  After determining GAPDH activity in cells treated with GAPDH 
siRNA relative to negative control siRNA, the percentage specific GAPDH 
knockdown was determined at charge ratios where the reduction in GAPDH activity 
was significant as described in 3.3.5.  
 134 
 
When Calu-3 cells were transfected with complexes containing 1 µl 
Lipofectamine, no significant gene silencing was observed regardless of the exposure 
time or incubation time (Figure 3.5).  No significant gene silencing compared to 
negative control siRNA was observed with either lipofectamine 2.5 or 5 l when the 
cells were exposed to the complexes for only 6 hours and then incubated for 48 hours 
to allow gene silencing to occur (Figure 3.5A).  Increasing the exposure time to 24 
hours resulted in 50-60% gene silencing at both amounts of Lipofectamine, but was 
associated with 70-90% cell viability when 2.5 l Lipofectamine was used and less 
than 50% cell viability when 5 l Lipofectamine was used.  With 2.5 l 
Lipofectamine, significant gene silencing (50%) was achieved after 72 hours post-
transfection (Figure 3.5B) regardless of the exposure time and cell viability remained 
above 80%.  On the other hand when 5 l was used the results were unexpected with 
6 hours incubation time resulting in insignificant gene silencing with approximately 
70% cell viability and 24 hour exposure resulted in significant gene silencing (more 
than 50%) but with less than 60% cell viability.  Therefore it was assumed that the 
reduction in GAPDH activity was associated with some level of toxicity.  From the 
above data it appeared that using 2.5 l, 72 hours transfection duration gave the most 
favorable results regardless of the exposure time 6 or 24 hours.  However, when 










Figure 3.5 The optimization of siRNA transfection in Calu-3 cells using 
Lipofectamine.  GAPDH gene silencing (bar) and cell viability (line) were 
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3.4.4. Transfection of Calu-3 cells with siRNA 
Calu-3 cells transfected with LR (Figure 3.6A) or LpegR complexes (Figure 
3.6B) at low charge ratios ranging from 0.5 to 6, showed no significant difference in 
GAPDH fluorescence between GAPDH siRNA and negative control siRNA 
indicating inefficient GAPDH silencing (Unpaired-t-test, p0.05) except at charge 
ratio 3.  At higher charge ratios 10 to 12 a significant reduction in fluorescence was 
observed in cells treated with GAPDH siRNA relative to cells treated with negative 
control siRNA (Unpaired-t-test, p<0.05).  With the LPR complexes, a significant 
reduction in fluorescence in cells treated with GAPDH siRNA as compared to those 
treated with negative control was observed starting from charge ratio of 6 upwards 
(Figure 3.6C).  The percentage GAPDH knockdown was determined at charge ratios 
where reduction in GAPDH activity was significant (Figure 3.6D). The percentage 
GAPDH silencing obtained with either LR or LpegR complexes at charge ratios 3, 
10 and 12 was comparable (Unpaired-t-test, p<0.05) to that obtained with 
Lipofectamine complexes (positive control) and (up to 50%). On the other hand, 
LPR complexes were as effective as Lipofectamine complexes in inducing GAPDH 
silencing starting from a charge ratio of 6 with 45-50% knockdown (Figure 3.6D).  
Using One-way Anova test, there was no significant difference (p>0.05) in the levels 
of GAPDH knockdown between the three systems at each charge ratio except at 


























Figure 3.6  GAPDH activity in arbitrary fluorescence units in Calu-3 cells measured 
72h post-transfection with GAPDH and negative control siRNA complexes; A) LR, 
B) LpegR, C) LPR, D) Percentage specific GAPDH silencing for the three 
complexes (n=3, mean ± SEM).  *Statistical significance as per independent t-test 
(p<0.05) **(p<0.01).  
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3.4.5. Transfection of A549 cells with siRNA 
LR (Figure 3.7A) and LpegR complexes (Figure 3.7B) at charge ratios ranging 
from 4 to 10 produced significant (Unpaired-t-test, p<0.05) reduction in fluorescence 
in A549 cultures treated with GAPDH siRNA compared to those exposed to negative 
control siRNA.  At other charge ratios, GAPDH siRNA and negative control siRNA 
resulted in similar levels of fluorescence indicating no specific GAPDH silencing 
(Unpaired-t-test, p>0.05).  LPR complexes at charge ratios 4-12 resulted in an 
important decline in fluorescence in cells treated with GAPDH siRNA compared to 
negative control siRNA suggesting specific GAPDH knockdown (Figure 3.7C). 
When percentage GAPDH silencing was determined, LR complexes showed 
the highest GAPDH silencing at charge ratios 6 and 10 with (up to 70%) and were as 
effective as the positive control (Lipofectamine/siRNA complexes) (Figure 3.7D).  
Whereas the LpegR complexes achieve the same levels of gene silencing at charge 
ratios ranging from 10 to 12 and much lower gene silencing was observed at charge 
ratios of 4 and 6 (20-30%).  LPR complexes on the other hand, displayed high 
GAPDH silencing at all charge ratios ranging from 4 to 10 with up to 80% 
knockdown.  When the three systems were compared in terms of GAPDH silencing 
efficiency at each charge ratio, both LPR and LR complexes induced significantly 
higher GAPDH silencing than LpegR complexes at charge ratios 4 and 6 (p<0.05, 
One-way Anova).  In addition LPR complexes had a higher GAPDH knockdown 


















Figure 3.7  GAPDH activity in arbitrary fluorescence units in A549  cells measured 
72h post-transfection with GAPDH and negative control siRNA complexes; A) LR, 
B) LpegR, C) LPR, D) Percentage specific GAPDH silencing for the three 




3.4.6. Cell viability 
Since the levels of GAPDH activity per cell are constant in untransfected cells 
and in cells transfected with negative control siRNA, GAPDH activity in negative 
control siRNA-transfected  cells  (Δfluorescence Negative) can be used as an indicator 
of cell number, or of relative viability, under the influence of transfection carriers 
(cationic lipids).  Therefore, in cells transfected with negative control siRNA, the 
higher the fluorescence (GAPDH activity) the less toxic the transfection conditions.  
Toxicities of the effective formulations were calculated using the following equation: 
%   Cell   viability=   100x   (Δfluorescence Negative   control/Δfluorescence   untreated  
cells).  
In both cell lines, LR complexes there was no significant reduction in cell 
viability in comparison to untreated cells at the effective charge ratios  (3, 10 and 12 
in Calu-3 cells , 6 and 10 in A549 cells) (Figure 3.8A).  Similarly, LpegR complexes 
did not cause a decrease in Calu-3 cell viability at the effective charge ratios (3, 10 
and 12 for Calu-3 cells, 4-12 for a549 cells) (Figure 3.8B). In the case of LPR 
complexes,  there were no significant toxicity at the effective charge ratios (6-12 in 
Calu-3 cells, 4-10 for a549 cells)not toxic except at charge ratios 4 (Calu-3 cells) and 
12 (A549 cells) (Figure 3.8C).  Significant reduction in cell viability was observed 













Figure 3.8 The percentage of cell viability in Calu-3 and A549 cells after 
transfection with A) LR, B) LpegR, and C) LPR complexes prepared at the indicated 
cationic lipid/siRNA charge ratios.  Data represent the mean of 3 experiments with 3 
replicates in each experiment (n=3, mean±SEM).  *Significant difference from 
control (100% cell vaibility) as per t-test (p 0.05). 
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3.4.7. The effect of serum on the gene silencing efficiency 
The addition of 5% FBS had no effect on the gene silencing efficiency of 
LpegR complexes, but it resulted in 29% reduction in GAPDH silencing induced by 
LPR complexes (Figure 3.9).  When transfection was performed in the presence of 
20% FBS, there was approximately 40-45% decrease in GAPDH silencing induced 
by either LpegR or LPR complexes.  However despite the significant reduction in 
gene silencing in comparison to 0% FBS, LPR complexes maintained acceptable 
levels of gene silencing (40-45%) even at high serum concentration (20% FBS). 
 
 
Figure 3.9. GAPDH activity measured after 72h exposure of A549 cells transfection 
with GAPDH and negative control siRNA complexes: LpegR and LPR at the 
indicated FBS concentrations. Data was presented as percentage GAPDH silencing 





Cationic lipid-mediated delivery of siRNA faces many of the same challenges 
as delivery of pDNA, from internalization to endosomal escape (Grayson, A.C. et al., 
2006) and once inside the cell the complexes should dissociate to release the nucleic 
acids from the vector system (Gary, D.J. et al., 2007).  Despite these similarities, 
formulation with siRNA might be quite different to pDNA formulation.  Although 
both self-asSEMble by electrostatic forces, pDNA is more than a few hundred-fold 
larger than siRNA, suggesting that they might have different optimal formulations.  
In this study several properties of cationic lipid/siRNA complexes that might affect 
the gene silencing activity were evaluated in comparison with the properties of 
cationic lipid/pDNA with the objective of identifying an optimal system for siRNA 
delivery. 
3.5.1. Complexation efficiency as a function of charge ratio 
An essential feature for transfection efficiency is complexation and packaging 
of nucleic acid to result in small particle size and protect from nuclease attack 
(Collins, E. et al., 2007).    SYBR green II intercalation data revealed that a 
significant portion of siRNA in the complex formulations was accessible to 
intercalation with the dye indicating low binding.  The three lpidic systems were less 
efficient in complexing siRNA as compared to pDNA.  Lipofectamine/siRNA 
complexes were used as a control to confirm the suitability of the SYBR green II 
intercalation assay for determining condensation efficiency.  Indeed Lipofectamine 
efficiently bound the siRNA (more than 85% bound siRNA was observed) and 
despite increasing the amount of lipid, percentage free siRNA.  The LPR system 
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resulted in the highest complexation (85%) at charge ratio 0.5, which decreased to 
40-50% at higher ratios.  Interestingly, when condensation efficiency of 
siRNA/protamine complexes without the cationic lipid was determined, up to 85% 
compaction was obtained which was similar with compaction obtained with the LPR 
complex at charge ratio 0.5, but as more lipid was added the condensation efficiency 
decreased to 50% and remained constant all charge ratios.  The reason of this was 
unclear.  With the LPD system in the previous chapter, pDNA condensation by 
protamine was not affected as more lipid was added.   
The difference in complexation efficiency between pDNA and siRNA can be 
explained by the differences in structure and distribution of negative counter ions 
around the nucleic acid.  Li and co-workers (2011) showed that double stranded 
siRNA was more resistant to condensation compared with double stranded pDNA 
and this was due to differences in the geometry of charge arrangement.  In another 
study it was found that for siRNA complexes, a larger (+/-) charge ratio than that 
used for pDNA delivery was required to achieve efficient gene silencing (Spagnou, 
S. et al., 2004, Zhang, Y. et al., 2010).  This was associated with resistance to 
complex formation due the rotational and translational degrees of freedom associated 
with siRNA in the bulk being greater than that of long DNA which created a large 
barrier for complex formation as the siRNA shifts from the bulk state to the confined 
complexed state.  In addition, siRNA has lower adhesion energy per unit length than 
pDNA, plus there are differences in electrostatic repulsion between pDNA compared 
to siRNA strands.  Other studies reported that the much more rigid and shorter 
structure of siRNA (21-23 nucleotides versus several kilobases for pDNA) prevented 
lipid-induced condensation (Spelios, M. et al., 2010) and that siRNA requires much 
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higher +/- charge ratio to achieve the degree of compaction that can be achieved with 
pDNA complexes at much lower ratios (Zhang, Y. et al., 2010, Marty, R. et al., 
2009b).  Surprisingly, in the current study, it was shown that despite increasing +/- 
charge ratio, there was no significant improvement in condensation and siRNA was 
assumed to be bound to the cationic carrier in a such a way that parts of it remained 
exposed to intercalation with the SYBR green II reagent.  
3.5.2. Particle size as a function of charge ratio 
siRNA formed smaller particle size complexes than pDNA under physiological 
salt conditions.  Unfortunately, direct comparison cannot be made because siRNA 
complexes were prepared in high ionic strength solution while pDNA complexes 
were prepared in water then transferred into high ionic strength solution.  This 
variation in method of preparation was adopted because it has been shown previously 
that using cell culture medium rather than water for siRNA/lipid complex formation 
significantly enhanced gene silencing (Spagnou, S. et al., 2004).  The major 
difference observed in particle size between the two complexes may be either due to 
the small size of the siRNA molecule and low tendency to aggregation (Li, L. et al., 
2011) or simply due to difference in the preparation method.  
LR and LpegR complexes displayed relatively large particle size  and 
polydispersity at low charge ratios in particular 1-2 zone , which then decreased as 
the charge ratio increased. LPR was the only exception where the particle size 
remained fairly constant despite the change in cationic lipid/pDNA charge ratio.  
This was attributed to the use of a constant protamine/siRNA mass ratio to condense 
siRNA before the addition of the cationic lipid.  This correlated with SYBR green II 
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data, as the percentage of condensation was the same at all charge ratios.  The 
significant   decrease   in   the   polydispersity   at   charge   ratios   ≥6   for   all   three   systems  
indicated a fairly homogenous size distribution was formed undert these conditions; 
this accords with previous studies which showed that high ratio cationic lipid/siRNA 
complexes, the system becomes more homogenous due to complete neutralization of 
the negative charge of siRNA.  However, in the current study, decrease in the 
particle size and polydispersity data  didn’t  correlate  with the low complexation data.    
There was no clear explanation for this but it is possible that SYBR-green II assay 
method did not give a clear description of the siRNA/cationic lipids complexation 
and should be combined with another technique such as gel electrophoresis to have 
an accurate complexation assay.  Similarly, Zhang and co-workers (2010) also 
reported that PEGylated DC-Chol/DOPE could not cause full siRNA gel retardation 
even at a (+/-) charge ratio of 15 where the complexes had a small particle size (500 
nm) and positive surface charge.  Unfortunately, due to lack of suitable equipment in 
our   laboratory,   the  zeta  potential  of   siRNA  complexes  wasn’t  measured  and   it  was  
assumed based on previous studies (Desigaux, L. et al., 2007, Zhang, Y. et al., 2010) 
that at high +/- charge ratios siRNA/cationic lipid complexes will be mainly 
positively charged.  
3.5.3. Gene silencing efficiency of siRNA complexes: 
After the physicochemical characterization of the siRNA complexes, their gene 
silencing activity was determined in two different cell lines.  Use of the bronchial 
epithelial Calu-3 cell line, which was used for pDNA transfection studies in the 
previous chapter, allowed direct comparison between pDNA and siRNA complexes.  
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Transfection conditions of Calu-3 cells using the commercial transfection reagent 
lipofectamine have not been determined previously, therefore, prior to the use of the 
LR, LPegR and LPR complexes to deliver siRNA, transfection of siRNA using the 
positive control formulation Lipofectamine was optimized.  The second cell line used 
was the alveolar epithelial cell line A549, which has been commonly used for pDNA 
transfection experiments and has also used in siRNA transfection studies (Lu, J.J. et 
al., 2009). Optimisation of the positive control Lipofectamine was not necessary as 
the manufacturer provides a recommended protocol.  
3.5.3.1. Gene silencing efficiency and physical properties of the complexes 
This study showed that siRNA complexes were most effective at high charge 
ratios where they had a homogenous size distribution, small particle size (200-300 
nm) and in which siRNA was not efficiently condensed.  Generally, it is believed 
that the size of the complexes should be 50 nm to 200 nm for efficient internalization 
by endocytic processes (Gao, H. et al., 2005).  However, despite that LR and LpegR 
complexes prepared at lower charge ratios of 4 to 6 had a similar size as complexes 
prepared at higher ratios  (10-12), the former complexes were inactive in GAPDH 
silencing whereas the latter resulted in significant knockdown.  Spagnou et al (2004), 
using a different cationic lipid, also demonstrated that there was no significant 
difference in GAPDH knockdown between complexes of small size (50-100 nm) and 
larger aggregates (200-600 nm).  Similarly LPR complexes showed no significant 
difference in size at the different charge ratios, but a significant difference in gene 
silencing was observed.  All these observation indicated that the gene silencing 
function of siRNA complexes is not dependent on the particle size of the complexes.  
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Once inside the cell the complexes should be able to release siRNA from the vector 
system to exert its function (Gary, D.J. et al., 2007).  Therefore the less efficienct 
binding of siRNA observed in this study even at high charge ratios could be 
beneficial in facilitating siRNA dissociation from the lipidic system and enhancing 
gene silencing activity.  On the other hand, it could present a disadvantage of 
exposing siRNA to interaction with polyanions as well as attack by nucleases in vivo.   
In addition, despite having low complexation efficiency, at low charge ratios, siRNA 
complexes were still inactive at these ratios, which suggested that even if low 
complexation could be beneficial in enhancing gene silencing efficiency, it is not a 
major determinant of successful gene silencing.  
3.5.3.2. Gene silencing and cytotoxicity in Calu-3 vs A549 cells 
GAPDH silencing induced by LR, LPR and LpegR complexes in A549 cells, 
showed similar trends to Calu-3 cells in terms of protein knockdown activity 
increasing with the increase in (+/-) charge ratios.  For all three lipid formulation 
systems, protein silencing was more potent in A549 cells at high charge ratios (10-
12) cpercentage GAPDH knockdown was higher in A549 cells than in Calu-3 cells.  
For example, LPR complexes prepared at charge ratio 10 resulted in more than 80% 
GAPDH silencing in A549 cells in comparison with 50% in the Calu-3 cell line.  
Electrostatic neutralization between the cationic lipids of siRNA complexes and 
anionic lipids of the endosome is believed to be involved in the release of the nucleic 
acid in the cytoplasm after the cationic lipid fuse with the cell membrane of the 
endosome.  Thus difference in the number of negative charges on endosomal 
membrane in different cell lines might explain differences in optimal charge ratio 
(Sakurai, F. et al., 2000b).  
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With cationic lipid/pDNA complexes, reduction in cell viability was minor 
because the +/- charge ratios used were lower that the ones used in siRNA studies 
and therefore cytotoxicity did not play a major role in determining the optimal 
charge ratio (2.5.3).  With siRNA, the +/ - charge ratios used were much higher than 
those used with pDNA, which enhanced gene silencing efficiency but could be a 
cause for concern for cell viability.  In both cell lines none of the three systems were 
toxic at the effective charge ratios.  In contrast, significant toxicity was observed 
with LR complexes at charge ratio 12 in A549 cells; this was probably the cause of 
the reduced GADPH silencing at those ratios.  Toxicity at high cationic lipid/nucleic 
acid charge ratio was attributed to an increase in the amount of free cationic 
liposomes (empty liposomes).   
3.5.3.3. Effect of serum on gene silencing 
Although low compaction of siRNA even at high ratios was beneficial in vitro 
transfection  and  didn’t  seem  to  inhibit  the  gene  silencing  activity,  it  was  important  to  
see how these systems will behave under transfection conditions similar to in vivo.  
Serum has been associated with inhibition of transfection efficiency of pDNA and 
siRNA complexes (Zhang, Y. and T.J. Anchordoquy, 2004, Simberg, D. et al., 
2005).  Serum proteins interact with the charged transfection complexes and may 
either result in the dissociation of the nucleic acid from the carrier or block 
association with cellular membrane as the complexes become negatively charged.  
As a result, most transfection studies are done in the absence of serum (Aljaberi, A. 
et al., 2005, Salvati, A. et al., 2006).  The presence of serum in vivo is inevitable 
therefore the gene silencing efficiency of siRNA complexes was also investigated in 
the presence of serum.  This is especially pertinent for siRNA as  it’s  phosphodiester  
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backbone is considered to be more sensitive to hydrolysis than pDNA and therefore 
more susceptible to nucleases (Mahon, K.P. et al., 2010, Ming, X. et al., 2011). 
Zhang and co-workers (Zhang, Y. et al., 2010) reported that the presence of 
10% FBS did not affect the uptake and gene expression activity of pDNA/DC-
Cholesterol:DOPE complexes, while it completely inhibited the gene silencing 
efficiency of siRNA delivered using the same system .  In this study, LPR and 
LpegR complexes were selected to investigate the effect of serum, as they are known 
to be more stable than the LR complexes in the presence of anionic molecules.  
Pegylation has been used to reduce interaction between negatively charged 
molecules in serum and the siRNA complexes and it has been shown to improve the 
in vivo circulation time of siRNA (Zimmermann, T.S. et al., 2006, Santel, A. et al., 
2006).  Gene silencing data showed that LpegR complexes were not affected by the 
presence of 5% serum, but as the amount of serum increased to 20% gene silencing 
was reduced by 40%.  On the other hand gene silencing of LPR complexes decreased 
in the presence of 5 and 20% but remained relatively high (60% silencing at 5% 
FBS, and 40% at 20% FBS) compared to LpegR complexes although this was not 
due to more resistance to serum but to the higher gene silencing efficiency of LPR 
complexes.  This data indicated that LpegR and particularly LPR are promising 
formulations for gene delivery in vivo, as the complexes were not completely 
deactivated by the presence of high concentration of serum (20%). 
3.5.4. Delivery of pDNA versus siRNA 
Luciferase expression in Calu-3 cells induced by LD and LpegD complexes 
was found to decrease as the +/- charge ratio increased and was highest at low ratios 
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0.5-2 (2.4.4).  At these ratios, pDNA complexes formed large polydisperse 
aggregates (3-4 m) that had low condensation efficiency (50-80% non-condensed 
pDNA).  In contrast, at the same charge ratios, LR and LpegR were completely 
inactive in inducing GAPDH silencing and only became active at higher charge 
ratios tested (10-12).  The active siRNA complexes had a very small particle size 
(200 nm) and had very low complexation efficiency.   The LPD complexes resulted 
in similar levels of luciferase expression irrespective of the charge ratio, which 
correlated with high condensation (20 % non-condensed) at all ratio, whereas LPR 
complexes gene silencing efficiency was dependent on increasing charge ratios 
despite similar condensation efficiency at all ratios.  Overall these data showed that 
pDNA and siRNA need to be formulated differently as the compositions that worked 
for  pDNA  didn’t  work  for siRNA.  In agreement with the recently reported findings 
of Zhang and co-workers (2010), increasing the +/- charge ratio increased the uptake 
of siRNA/lipid complexes until it reached plateau at ratio of 5 whereas with pDNA 
increasing charge ratios (4) resulted in a drop in internalization efficiency and was 
associated with poor endosomal escape of pDNA.  Thus pDNA transfection was 
effective at low charge ratios while siRNA was more effective when delivered using 
high ratios.   
3.5.5. Conclusion 
In conclusion, the data presented here elucidated the parameters that affect 
siRNA versus pDNA delivery in vitro using three different cationic-lipidic systems.  
It was found that what the optimal physicochemical characteristics for pDNA 
delivery were not optimal for siRNA and that these characteristics varied between 
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the different cationic carriers tested.  This dissimilarity in optimal formulation could 
be associated with the possibility that different formulations enter the cells through 
diverse pathways, which will be investigated in the next chapter.  The other 
explanation could be that there is a minor population of complexes not detected by 
physical characterization that are responsible for the biological activity, as it is 
assumed that only the pDNA of a small percentage of complexes reaches the nucleus 
to exert its effect.  Similarly with siRNA it has been shown that only a small fraction 
of the dose is sufficient to almost completely inhibit protein expression (Spelios, M. 
et al., 2010).  In terms of siRNA formulation, LPR and LpegR complexes, which to 
our  knowledge  haven’t  been  investigated  previously  for  siRNA  delivery,  were  found  
to be effective carriers for potent GAPDH knockdown at their optimal charge ratios.  
These non-toxic carriers could also function in the presence of serum and therefore 
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4.1.  Introduction 
Recently it became evident that the mode of internalisation of siRNA has a 
major influence on the kinetics of its intracellular trafficking and biological 
effectiveness (Rejman, J. et al., 2005, Detzer, A. et al., 2008).  In order to optimise 
and improve the efficacy of transfection using non-viral vectors such as cationic 
lipids, it is therefore important to define fully the mechanisms by which cell entry 
and intracellular trafficking of these complexes occur.  There are few published 
studies that address the uptake mechanism of siRNA-cationic lipid complexes 
(lipoplexes) and these studies do not provide conclusive findings regarding the exact 
uptake pathway.  A variety of factors have been reported to be influential, including 
the cell type (Douglas, K.L. et al., 2008), particle size (Rejman, J. et al., 2004, Lai, 
S.K. et al., 2008), surface charge (Harush-Frenkel, O. et al., 2008, Resina, S. et al., 
2009) and the chemistry of the delivery vector (Elouahabi, A. and J.M. Ruysschaert, 
2005, Khalil, I.A. et al., 2006).  Thus, there is limited knowledge about the uptake 
mechanisms and the intracellular processing that lead to gene silencing by siRNA.  
In this Chapter, the LPR and LpegR lipoplexes, which were identified as promising 
systems in the preceding work, were investigated to try to elucidate their delivery 
mechanisms. 
To date, most data on the uptake mechanism of non-viral delivery complexes 
comes from studies using DNA.  It is generally considered that DNA delivery 
mediated by lipoplexes or polyplexes is via endocytosis (Felgner, J.H. et al., 1994, 
Hoekstra, D. et al., 2007, Labatmoleur, F. et al., 1996, Zuhorn, I.S. et al., 2002a, 
Khalil, I.A. et al., 2006, Friend, D.S. et al., 1996, Godbey, W.T. et al., 1999).  
Although it is recognized (through the work presented in this thesis and that of 
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others) that pDNA complexes have different physicochemical properties from those 
of siRNA complexes, it may be hypothesized that siRNA entry would also be taken 
up through endocytosis.  Endocytosis is a broad term as multiple endocytotic 
pathways have been described (Conner, S.D. and S.L. Schmid, 2003, Lamaze, C. and 
S.L. Schmid, 1995), but the common feature of all such pathways is the uptake of 
macromolecules in transport vesicles.  These endocytotic vesicles differ in the 
composition and size as well their intracellular trafficking and are subcategorised 
into three well-described endocytic pathways that are distinguished according to their 
differential sensitivity to pharmacological inhibitors (Table 4-1).   
In terms of DNA delivery, the clathrin-mediated pathway has been shown to be 
the main route for entry of DNA lipoplexes (Rejman, J. et al., 2005, Zhou, X.H. and 
L. Huang, 1994), whereas the caveolae pathway has been involved in the uptake of 
DNA/polypeptides complexes (Rejman, J. et al., 2005)) and protein transduction 
domains such as trans-activator of transcription protein (TAT) (Ferrari, A. et al., 
2003, Fittipaldi, A. et al., 2003).  It is important to consider that genes internalised 
through the clathrin-mediated pathway end up in lysosomes, which provide a 
degradative environment, thus for successful delivery of biologically active genes, 
lysosomal escape and release in the cytoplasm is crucial.  In this context, caveolae-
mediated endocytosis represents a more attractive pathway for gene delivery due to 
the absence of lysosomal internalization, thus avoiding this degradative route 
(Ferrari, A. et al., 2003, Harris, J. et al., 2002).  However, this process is considered 
slow and the caveolae have a small phase volume meaning that it is limited as a 
primary uptake route.  The third major endocytosis route is macropinocytosis and 
this is gaining increased interest as a route for gene delivery because it allows higher 
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levels of uptake, avoidance of lysosomal compartments and, due to the leaky nature 
of the macropinosomes, escape into the cytosol is easier (Wadia, J.S. et al., 2004).  
This mechanism has been demonstrated to be involved in the uptake of pDNA 
complexed to peptides (Kaplan, I.M. et al., 2005, Nakase, I. et al., 2004). 
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Table 4-1  Description of the three major endocytic pathways and the chemicals 
used to inhibit them. 
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4.1.1. Aim and objectives 
The aim in this Chapter was to elucidate which of the endocytosis pathways 
was involved in the uptake of the best performing formulations in terms of gene 
silencing efficiency, toxicity profile and reproducibility (3.5.3.2). To achieve this, 
methodologies originally designed to study the uptake of DNA complexes were used.  
The objectives of the chapter were to: 
 Visualise the intracellular localization of LPR and LpegR lipoplexes in A549 
cells.  This was studied using fluorescently labelled siRNA and lipids. 
 Interrogate the transfected A549 cells for co-localization of the lipoplexes 
with fluorescent markers of the individual internalization pathways, 
 Evaluate the effect of endocytosis inhibitors on gene silencing efficiency 


























Alexa Fluor-488 and 633 transferrin Invitrogen Ltd, UK 
BODIPY-Lactosylceramide (BODIPY-
LacCer) 
Invitrogen Ltd, UK 
Endocytosis inhibitors:  
chloropromazine, nystatin, amiloride, 
cytochalasin D 
Sigma-Aldrich Ltd, Dorset, UK 
DAPI Sigma-Aldrich Ltd, Dorset, UK 
NaCl, HEPES, pH 7.4, CaCl2, MgCl2, D-
glucose, sodium borohydride, Triton-X-
100, paraformaldehyde 






4.3.1.   siRNA complex localization studies 
To follow the cellular internalization of LPR and LpegR complexes in A549 
cells, either a fluorescent Cy3-GAPDH siRNA or DOPE-N-carboxyfluorescein was 
included in the initial siRNA/lipid complex formulation to identify location of 
siRNA or liposome respectively.  Cells were incubated with the formed fluorescent 
siRNA complexes at a (+/-) ratio of 10 (as described in chapter 3) for 2 h, following 
which internalization and subcellular localization were examined by confocal 
microscopy as described below.   
Glass microscopy coverslips were sterilized in 60% hydrochloride acid in 
ethanol, and then washed three times with ultrapure water before a wash in 100% 
ethanol and drying in a laminar flow cabinet.  Once dry the coverslips were placed 
into each well of a 24-well plate.  A549 cells were seeded on top of the coverslips at 
a seeding density of 1x105 cells per well and incubated overnight (37°C, 5% CO2).  
On the day of experiment, the complexes LPR and LpegR were prepared as 
described in chapter 3 (siRNA: 500 nM, N/P ratio: 10/1).  However, either 
fluorescent red Cy3-GAPDH siRNA or fluorescent green DOPE-N-
carboxyfluorescein liposomes were substituted in order to form fluorescent 
complexes.  Cell culture media was removed and replaced with 500 µl of fluorescent 
LPR or LpegR complexes in RPMI-1640 for 2 h (37°C, 5% CO2).  After this time 
the media was removed and the cells washed with PBS solution before fixing with 
500 µl of 4% paraformaldehyde (PFA) in PBS for 15 min.  PFA was then removed 
and 500 µl of 0.2% Triton-X-100 was added for 15 min to permeablise the 
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membrane before replacement with 500 µl 1mg/ml sodium borohydride for 15 min.  
Finally, 500 µl of 0.001 mg/ml DAPI was added to stain the nucleus, which was left 
for 2 min, removed then washed three times with PBS.  To mount the coverslips, 
10µl Mowiol was added to the glass slides, and the cover slips were carefully 
removed from each well with tweezers, dipped in clean water and then placed on the 
Mowiol with care to avoid air bubble formation. After leaving to dry overnight at 
room temperature, the coverslips were examined using a Leica TCS SP2 Confocal 
Microscope at different magnification using an oil immersion objective (40x and 
60x).  These methods were performed in the dark.  
4.3.2.  Temperature adjustment 
To determine whether the delivery of siRNA lipoplexes is an energy-dependent 
process, the effect of lowering the temperature on the uptake of siRNA lipoplexes 
was examined.  A549 cells were pre-cooled to 4°C before for 1 h before transfection 
with Cy3-labeled LPR and LpegR complexes for 2 h at the same temperature.  After 
removal of the complexes, cells were fixed and observed under a confocal 
microscope as described above. 
The effect of lowering the temperature on gene silencing efficiency was also 
determined.  One hour before transfection, A549 cells were incubated at different 
temperatures (4°C, 10°C, 37°C) then exposed to fluorescent LPR and LpegR 
complexes for 6 h at these temperatures.  After removal of complexes, the cells were 
incubated (37°C, 5% CO2) in RPMI-1640 media for 72 h and assayed for GAPDH 




4.3.3. Colocalization of siRNA complexes with Alexa Fluor 488-
transferrin and BODIPY-LacCer 
4.3.3.1. Colocalization with Alexa Fluor 488-transferrin   
Colocalization studies were performed to investigate whether fluorescent LPR 
and LpegR complexes colocalized with Alexa Fluor 488-transferrin, hence 
demonstrating clathrin-mediated uptake.  Red Cy3-GAPDH siRNA was used to 
prepare fluorescent LPR and LpegR complexes (500 nM GAPDH siRNA, (+/-) ratio 
of 10).  A549 cells were seeded on microscopy coverslips in 24-well plates overnight 
(37ºC, 5% CO2).  After incubation, the media was removed and the cells were co-
incubated with 300 µl of fluorescent LPR or LpegR complexes (500 nM GAPDH 
siRNA, N/P: 10/1) and 20 µl of Alexa Fluor 488-transferrin (1 mg/ml) for 2 h (37ºC, 
5% CO2).  A 5 min gap was allowed between the addition of the complexes and 
transferrin.  After incubation, cells were washed with PBS before fixation and 
examination by confocal microscopy. 
4.3.3.2. Colocalization with BODIPY-LacCer 
Co-localisation studies were performed to investigate whether fluorescent LPR 
and LpegR complexes colocalised with BODIPY-LacCer, hence demonstrating 
caveolae-mediated uptake.  The experiment was carried out as described in section 
4.3.3.1 except that the cells were first washed with cold media and exposed to 1 ml 
of 1.5 µM Bodipy LacCer for 30 min at 10°C to enhance accumulation of BODIPY-
LacCer on the cell membrane. LPR and LpegR complexes in warm media were then 
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added to the cells and incubated for 2 h (37ºC, 5% CO2) before fixation and 
examination by confocal microscopy. 
4.3.4. Optimisation of endocytosis inhibitors concentrations 
Endocytosis inhibitors were chosen for their reported selectivity for each of the 
pathways under study.  However under the experimental conditions, the 
concentration of each inhibitor to be used was optimized based upon efficiency of 
pathway disruption and toxicity.  Hence the most efficient and least toxic 
concentrations of inhibitors were determined according to the MTT toxicity assay 
and markers of the major endocytosis pathways. 
4.3.4.1. MTT screening of the endocytosis inhibitors  
A549 cells were seeded at a seeding density of 1x104 cells/well in a 96-well 
plate and incubated for 24 h (37°C, 5% CO2).  On the day of the experiment, the 
medium was removed and 100 µl mixtures of serum free-RPMI-1640 media and 
inhibitor test solutions at different concentrations, was added to each well as follows:  
chlorpromazine (1-50 g/ml) for 30 min and 1 h, nystatin (1-100 g/ml) and 
amiloride (1-20 g/ml) for 1 and 2 h.  The control wells were treated identically 
without the inhibitors.  For each concentration 6 replicates were performed per 
experiment.  After the incubation time, the inhibitor solutions were removed and 100 
µl of 0.5 mg/ml MTT solution was added to the wells for 3 h (37 °C, 5% CO2).  
After this time, the MTT solution was then removed and replaced by 100 µl of 
isopropanol and stored at 4°C for approximately 90 min.  The absorbance of the 
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resulting samples was measured at 570 and 650 nm using a SpectraMax Microplate 
Spectrophotometer.   
The effect of potassium depletion on cell viability was also determined by 
performing potassium depletion as described by Larkin et al (1983).  Briefly, A549 
cells were washed with potassium-free buffer (140 mM NaCl, 20 mM Hepes, pH 7.4, 
1 mM CaCl2, 1 mM MgCl2 and 1 mg/ml D-glucose), followed by a wash with 
hypotonic buffer (potassium-free buffer diluted with ultrapure water 1:1 v/v).  The 
cells were then washed three times with potassium-free buffer.  The cells were then 
exposed to potassium depleting buffer for 2, 4 and 6 h after which time the MTT 
assay was carried out as described above.  The control represented cells treated with 
potassium containing buffer.  
4.3.4.2. Inhibition of transferrin uptake via the clathrin-mediated endocytosis 
In order to determine the minimum concentration of chlorpromazine that 
would inhibit the clathrin-mediated pathway Alexa Fluor 633-transferrin, known for 
being internalised via this pathway, was added to A549 cells pre-treated with 
increasing concentrations of chlorpromazine (0, 4, 8 and 10 g/ml). A549 cells were 
seeded at a seeding density of 1x105 cells/well into a 24-well plate containing 
sterilized glass microscopy coverslips and incubated overnight (37°C, 5% CO2).  
After this time, the media was removed and replaced with a 1 ml mixture of cell 
culture medium and chlorpromazine solution to give a final concentration of 4, 8 and 
10µg/ml chlorpromazine per well.  The control well contained RPMI-1640 media 
without the inhibitors.  The plate was then incubated for 1 h (37°C, 5% CO2), after 
which time the inhibitor solutions were removed and then replaced with 300µl of 20 
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µg/ml fluorescently labeled transferrin solution in RPMI-1640.  The cells were 
incubated for 1 h (37°C, 5% CO2) before cell fixation and evaluation of fluorescent 
transferrin uptake by confocal microscopy.  The same experiment was carried out to 
examine the effect of the endocytosis inhibitors; nystatin (25µg/ml), amiloride 
(3mM) and Cytochalasin D (10 µg/ml) on the internalization of fluorescently labeled 
transferrin. 
To determine if the clathrin-mediated pathway was inhibited by potassium 
depletion, the internalization of Alexa Fluor 633-transferrin was examined following 
potassium depletion as described in section 4.3.4.1.  As a control, cells were treated 
with a buffer containing 10 mM KCl.  Alexa Fluor 633-transferrin (20 µg/ml) was 
then incubated with cells for 1 h (37ºC, 5% CO2), before fixation and analysis by 
confocal microscopy. 
 
4.3.4.3. Inhibition of BODIPY-LacCer via caveolae-mediated endocytosis 
To optimise the concentration of the caveolar endocytosis inhibitor nystatin, a 
BODIPY labeled lactocylceramide (BODIPY-LacCer) was used. It has been reported 
that this sphingolipid is mainly internalised via a caveolaoe-mediated mechanism 
(Singh et al., 2003).  The experiment was conducted as described in section 4.3.4.2, 
except that nystatin at different concentrations; 10, 20 and 25µg/ml, was used.  After 
incubation, the nystatin solutions were removed and the cells washed with cold 
RPMI-1640 media, before the addition of 1 ml of 2 µM BODIPY-LacCer solution 
and incubation for 1 h at 10ºC.  After this time the cells were incubated at 37ºC for 5 
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min to stimulate uptake of BODIPY-LacCer followed by fixation and examination 
using confocal microscopy. 
4.3.4.4. Effect of endocytosis inhibitors on the cell viability after 7 h exposure.  
The MTT was performed to assess the toxicity of the selected effective 
concentration of endocytosis inhibitors (see above) that would be used for the 
transfection experiments.  The cells were exposed to the inhibitors for 7 hours 
(equivalent to the duration of the whole transfection experiment) and then assayed 
for cell viability.  The endocytosis inhibitors; nystatin (25 µg/ml), cytochalasin D (10 
µg/ml) and amiloride (8 µg/ml) at the concentrations used showed more than 85% 
cell viability. 
4.3.5.  Gene silencing in A549 cells with siRNA complexes after inhibition 
of endocytic pathways 
4.3.5.1. Inhibition of the clathrin-mediated endocytosis 
A549 cells were seeded into 96-well plates at a seeding density of 1x104 cells 
per well and incubated overnight (37ºC, 5% CO2). The cells were then exposed to 
chlorpromazine 7.5 µg/ml for 1 h and transfected with LPR or LpegR complexes 
(50nM siRNA, N/P charge ratio 10/1) for 6 h (37ºC, 5% CO2).  In order to rule out 
the possibility that inhibitors might disturb complexation of siRNA with lipids when 
it is present in transfection solution, the transfection was carried out in two ways; in 
the presence or absence of the inhibitor.  After incubation, the complexes were 
removed and replaced with supplemented RPMI-1640 (10% FBS) with or without 
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the inhibitor solution.  The cells were incubated for 3 days (37ºC, 5% CO2) before 
measurement of gene silencing and cell viability using the KDalert assay.  
For potassium depletion, A549 cells were treated as described above.  LPR and 
LpegR complexes in potassium-free buffer were added to the cells for 6 h incubation 
(37ºC, 5% CO2).  After incubation, the complexes were removed and replaced with 
supplemented RPMI-1640 (10% FBS) and the cells cultured for 72 h before 
measurement of gene silencing and cell viability. 
4.3.5.2. Inhibition of caveloae and macropinocytosis 
Using similar methods to those described in the preceding section, the cells 
were pretreated with inhibitors of non-clathrin pathways (i.e. caveolae and 
macropinocytosis): nystatin (25 µg/ml), amiloride (8 µg/ml) and cytochalasin D (10 
µg/ml) in serum-free culture media for 1 h (37ºC, 5% CO2).  Cells were then 
transfected with LPR or LpegR complexes (per well 50 nM siRNA, (+/-) charge ratio 
of 10) for 6 h (37ºC, 5% CO2) in the presence or absence of the inhibitor.  After 
incubation, the complexes solutions were removed and replaced with supplemented 
RPMI-1640 (10% FBS) and cells cultured for 72 h (37ºC, 5% CO2) before 
measurement of gene silencing and cell viability. 
4.3.6. Gene silencing in A549 cells after combined inhibition of endocytic 
pathways 
A549 cells were treated with combinations of two or three endocytosis 
inhibitors for 1 h (for clathrin and non-clathrin pathways); (7.5µg/ml chlorpromazine 
+ 25µg/ml nystatin), (7.5µg/ml chlorpromazine + 8µg/ml amiloride), (25µg/ml 
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nystatin + 8µg/ml amiloride) and (7.5µg/ml chlorpromazine + 25µg/ml nystatin + 
8µg/ml amiloride).  Chlorpromazine was used at a lower concentration (7.5µg/ml) 
due to the high toxicity caused by the 10µg/ml chlorpromazine combined with the 
other inhibitors.  Subsequently, LpegR complexes (50nM siRNA, N/P charge ratio 
10/1) were added to the cells and incubated for 6 h in the presence of the 
combinations of inhibitors (37ºC, 5% CO2).  After incubation, the complexes were 
removed and replaced with supplemented RPMI-1640 (10% FBS) and cells cultured 
for 3 days (37ºC, 5% CO2) before measurement of gene silencing and cell viability. 
4.3.7. Data analysis and statistics 
All data is expressed as mean ± standard error of the mean SEM.  Statistical 
analysis was performed in SPSS, version 16.0, using One-way ANOVA and Student 
























4.4.1. siRNA complexes subcellular localization 
Both LPR and LpegR complexes effectively delivered siRNA to the cytoplasm 
of A549 cells (Figure 4.1).  Two hours post-transfection, Cy3-labelled GAPDH 
siRNA delivered by both lipidic formulations accumulated in the cytoplasm and 
specifically formed a spot like pattern of distribution at the periphery of the nucleus.  
There was no apparent difference between the localization pattern of LPR or LpegR 
complexes. 
The localization of red fluorescence in the perinuclear region raised the 
question whether the fluorescence represents the siRNA on its own or associated 
with the lipid.  For this LPR and LpegR complexes were prepared using both labeled 
siRNA (Cy3-GAPDH) and labeled lipid (Carboxyfluorescein-DOPE:DOTAP) and 
the distribution of red and green fluorescence were observed.  Confocal images 
showed that in as little as 2 hours post-transfection some of the free siRNA was 
detected while the rest of siRNA and lipid co-localised giving rise to a yellow 
fluorescence (Figure 4.2). 
4.4.2. Functional siRNA complexes uptake is temperature-dependent 
Confocal microscopy images (Figure 4.3) showed that the uptake of the 
fluorescently labeled LpegR (A) and LPR (B) complexes was inhibited at low 
temperatures (4°C).  In cells transfected at 37°C (Figure 4.1), red dots which 
represent fluorescent siRNA complexes were observed in the cytoplasm in the 
perinuclear region whereas when transfected at 4°C the red dots appeared on the cell 
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membrane rather than the cytoplasm while when transfected at 4°C the red dots 
seemed to be on the cell membrane not the cytoplasm. 
 
 
Figure 4.1  Confocal images of fluorescent LPR and LpegR complexes in A549 cells 
2 h post-transfection.  Red fluorescence represents Cy3-GAPDH siRNA in the 
complexes.  Blue DAPI stain was employed to highlight the nucleus. 
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DAPI CF-lipid Cy3-siRNA  Overlay 
    
    
Figure 4.2  Colocalization of Cy3 siRNA (red) and CF-DOTAP:DOPE (green) in A549 cells after 2 hour incubation with fluorescent 





Figure 4.3  Confocal images of Cy3-GAPDH siRNA in A549 cells at 4°C.  A549 cells 
were transfected with LpegR (A) and LPR (B) complexes for 2 hours at 4°C.  The 
fluorescent complexes were prepared using red Cy3-GAPDH and blue DAPI was used 
to highlight the nucleus. 
 
 
In order to investigate the effect of lowering temperature on gene silencing 
efficiency, A549 cells were transfected with LPR and LpegR complexes at decreasing 
temperatures to inhibit the energy-dependent endocytosis.  The level of GAPDH gene 
silencing mediated by either LPR or LpegR complexes was significantly (p<0.05, 






80% reduction at 4ºC (Figure 4.4A).  Cell viability (Figure 4.4B) under any of these 






Figure 4.4  A) Gene silencing efficiency and B) cell viability of A549 cells incubated 
with LPR and LpegR complexes at different temperatures for 6 h. Cells were incubated 
at the indicated temperatures for 1 h pre-transfection and during transfection then 
incubated at 37ºC post-transfection.  Gene silencing and cell viability were measured 
after 72 h using KDalert assay (n=3, mean±SEM). * Statistical significance (p<0.05, 
unpaired t-test). 
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4.4.3. Optimisation of endocytosis inhibitors concentrations 
4.4.3.1. MTT screening of endocytosis inhibitors 
When A549 cells were exposed to chlorpromazine at different concentrations for 
30 or 60 min, a concentration dependent toxicity was observed, with chlorpromazine 
concentrations  ≤10  µg/ml   for   either   30   or   60  minutes exposure maintaining good cell 
viability compared to control (Figure 4.5A).  However, higher concentrations (25 and 50 
µg/ml) significantly reduced cell viability to less than 40% (p<0.05, unpaired t-test).  
There was no significant increase in toxicity between the 30 min and 1 hour exposure 
time for all concentrations (p>0.05, unpaired t-test).  Similarly when A549 cells were 
exposed to nystatin (Figure 4.5B) and amiloride (Figure 4.5C) for 1 or 2 h, cell viability 
remained above 80% at the concentration range used.  No significant difference was 
observed between cell viability after 1 or 2 h exposure for all concentrations (p>0.05, 
paired t-test).  
Depleting cells from potassium for different durations (2, 4 and 6 h) did not have 
any effect on cell viability when compared to control cells (p>0.05, paired t-test) treated 


























Figure 4.5  Percentage viability of A549 cells after incubation with different 
concentrations of inhibitors; A) chlorpromazine, B) nystatin, C) amiloride and  D) 
potassium depletion.  Results are expressed as a percentage of the viability of untreated 
cells or cells treated with potassium containing buffer in the potassium depletion 
experiment (Data represent mean±SEM, n=3).  *Statistically significant (p<0.05, 
unpaired t-test). 
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4.4.3.2. Inhibition of transferrin uptake via the clathrin-mediated pathway 
In A549 cells treated with 4 µg/ml chlorpromazine (Figure 4.6B), transferrin 
internalization was similar to that observed in untreated cells (Figure 4.6A) marked by a 
similar amount of red fluorescence.  However as the concentration of chlorpromazine 
was increased to 8 µg/ml, there was a reduction in transferrin internalization as seen by 
the reduced red fluorescence in comparison with untreated cells (Figure 4.6C).  Strong 
inhibition of transferrin internalization was observed when cells were treated with 10 
µg/ml chlorpromazine (Figure 4.6D).  Based on these findings and the MTT test results, 
chlorpromazine at 10 µg/ml concentration was selected as the optimal concentration to 
inhibit clathrin-mediated endocytosis without causing significant toxicity.  This comes in 
accordance with the literature as most studies used chlorpromazine at this concentration 
to effectively inhibit clathrin pathways (Rejman, J. et al., 2004, Lu, J.J. et al., 2009, Lai, 
S.K. et al., 2008).  In A549 cells treated with non-clathrin inhibitors nystatin, 
cytochalasin D and amiloride, transferrin internalization was indistinguishable from that 
observed in untreated cells (Figure 4.7).  This confirms that the uptake of transferrin via 
the clathrin pathway is specifically inhibited by chlorpromazine at the concentrations 
tested. 
Depletion of cellular potassium that specifically inhibits uptake via clathrin-
mediated endocytosis reduced the uptake of transferrin in A549 cells following 2 h 
exposure, as compared to control cells treated with potassium containing buffer (Figure 
4.8).  Therefore this method can be effectively and safely used to inhibit the uptake via 





Figure 4.6  Uptake of Alexa Fluor 633-transferrin in A549 cells pre-treated with 
chlorpromazine. Confocal microscopy analysis following cell exposure to 
chlorpromazine at different concentrations: A) 0 µg/ml, B) 4 µg/ml, C) 8 µg/ml, D) 10 
µg/ml.  Cells were incubated with the inhibitor for 1 h before the addition of transferrin.  
Blue DAPI stain was used to highlight the nucleus.   
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Figure 4.7  Uptake of Alexa Fluor 633-transferrin in A549 cells pre-treated with non-
clathrin inhibitors:  Confocal microscopy analysis following cell exposure to A) no 
inhibitors, B) 25 µg/ml nystatin, C) 10 µg/ml cytochalasin D, D) 8µg/ml amiloride.  
Cells were incubated with the inhibitors for 1 h before the addition of transferrin.  Blue 





Figure 4.8  Uptake of Alexa Fluor 633-transferrin in A549 cells exposed to (A) 
potassium containing buffer and (B) potassium depletion.  Blue DAPI stain was used to 
highlight the nucleus. 
 
 
4.4.3.3.Inhibition of BODIPY-LacCer via the caveloae-mediated endocytosis   
Nystatin at 10 µg/ml was ineffective at inhibiting BODIPY-LacCer internalization, 
when compared to untreated cells (Figure 4.9).  However as the concentration was 
increased to 20 µg/ml or 25 µg/ml, a significant reduction in internalized BODIPY-
LacCer was observed.  In accordance with these findings, MTT assay data 25 µg/ml 









Figure 4.9  Uptake of BODIPY-LacCer in A549 cells pre-treated with nystatin.  
Confocal images of uptake in cells treated with different concentrations of nystatin:  (A) 
0 µg/ml, (B) 10 µg/ml, (C) 20 µg/ml, (D) 25 µg/ml.  Cells were incubated with the 
inhibitor for 1 h before the addition of green BODIPY-LacCer.  Blue DAPI stain was 










4.4.3.4. Effect of endocytosis inhibitors after exposure to cells for a duration equivalent 
to the duration of transfection experiment 
From the previous section, when chlorpromazine 10 µg/ml was incubated with 
cells for 30 or 60 min, it did not cause a significant effect on cell viability.  However 
after 7 h exposure (i.e., the duration of a transfection experiment), it caused more than 
80% reduction in cell viability compared to untreated cells.  Chlorpromazine at 7.5µg/ml 
concentrations appeared less toxic with more than 60 % cell viability after 7 h exposure 
to cells (Figure 4.10) and was used for the transfection experiments.  The other 
inhibitors were non-toxic even after a 7-hour incubation with cells. 
 
 
Figure 4.10  Viability of A549 cells treated for 7 h with endocytosis inhibitors.  
Treatments were: nystatin (25 µg/ml), cytochalasin D (10 µg/ml), amiloride (8 µg/ml) or 
chlorpromazine (7.5 µg/ml – low, and 10 µg/ml).  Cell viability was measured using the 
MTT assay and results are expressed as a percentage of the viability of untreated cells 
(Data represent mean±SEM, n=3).  *Statistically significant (p<0.05, unpaired t-test). 
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4.4.4. Role of Clathrin-mediated endocytosis in the uptake of functional 
siRNA 
The colocalization of siRNA complexes with markers of the clathrin-mediated 
endocytosis was studied.  The cellular localization of fluorescent siRNA LpegR 
complexes was compared to that of fluorescent Alexa Fluor 488-transferrin, which is a 
selective marker of clathrin-mediated endocytosis.  Co-localization of siRNA complexes 
with the pathway markers would suggest that they share the same uptake pathway.  
When A549 cells were co-incubated with Cy3-labeled siRNA complexes (LPCy3-R and 
LpegCy3-R) and Alexa Fluor 488-transferrin, for 2 hours, overlap between the green 
labeled siRNA complexes and the red labeled transferrin was seen in the cells as yellow-
orange fluorescence which indicated co-localization of the both the LPR and LpegR 














    
 
Figure 4.11  Co-localization of Cy-3 labeled LPR and LpegR complexes with Alexa Fluor 488-transferrin in A549 cells.  Cells were 
co-incubated with fluorescent siRNA complexes and transferrin (green) for 2 h prior to analysis by confocal microscopy.   Blue 
indicates DAPI-stained nucleus. 
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The inhibition of the clathrin-mediated pathway did not affect gene silencing 
mediated by LPR and LpegR complexes.  The effect of clathrin-mediated endocytosis 
inhibition on gene silencing was first determined using the potassium depletion method.   
In A549 cells depleted from potassium, gene silencing mediated by either LPR or LpegR 
complexes was not affected, as there was not a significant difference in the percentage 
GAPDH knockdown between cells treated with potassium buffer and cells depleted from 
potassium (Figure 4.12A).  The cell viability of the transfected cells after K+ depletion 
was also determined using KDalert assay and was found to be in the range of 75-85% 
(Figure 4.12B).   
The effect of clathrin pathway inhibition on gene silencing was further tested using 
chlorpromazine.  In cells pre-treated with chlorpromazine (7.5µg/ml) for 1 hour then 
transfected with LPR complexes in the absence of the inhibitor, the gene silencing 
efficiency was not affected compared to control (no inhibitors)  (Figure 4.13A).   To 
confirm the result, the transfection was carried out in the presence of the inhibitor at the 
same time as the siRNA complexes.  Despite getting a significant (p<0.05, unpaired t-
test) 50% reduction in gene silencing efficiency compared to control, there was more 
than 80% reduction in cell viability (Figure 4.13B).  The same experiments were carried 
out using a different siRNA complex, LpegR and there was no significant difference in 
gene silencing efficiency between untreated cells and cells treated with chlorpromazine 
for 1 hour only or for 7 hours (Figure 4.13C).  However, as observed with LPR 
complexes, cells transfected in the presence of chlorpromazine (7 hours), showed a 
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significant (p<0.05, unpaired t-test) reduction in cell viability (~50%) as compared to the 





Figure 4.12  (A) Gene silencing efficiency and (B) cell viability of A549 cells after 
exposure to potassium depletion and subsequent transfection with LPR and LpegR 
complexes.  Cells transfected in the presence of potassium were used as control.  Gene 
silencing and cell viability were determined 72 h post-transfection by KDalert assay.  











Figure 4.13  A) Gene silencing and B) cell viability of A549 cells after pre-treatment 
with chlorpromazine and subsequent transfection with LPR complexes, as well as C) 
Gene silencing and D) cell viability after transfection with LpegR complexes.  Cells 
were exposed to chlorpromazine for 1 h, followed by incubation with complexes for 6 h 
in the absence (grey bars) or presence (white bars) of the inhibitor.  Control represent 
cells transfected with LPR or LpegR complexes without treatment with inhibitors at all 




4.4.5. Role of Caveolae-mediated endocytosis and macropinocytosis in the 
uptake of functional siRNA 
siRNA complexes did not co-localize with markers of the caveolae-mediated 
endocytosis.  A549 cells were co-incubated with the marker of the caveolae-mediated 
endocytosis BODIPY-LacCer and siRNA complexes.  Confocal analysis showed that 
there was no overlap between the red siRNA complexes (LPCy3-R and LpegCy3-R) and 
the green BODIPY-LacCer (Figure 4.14).  
Inhibition of the caveolae and macropinocytosis pathway did not affect gene 
silencing mediated by LPR and LpegR complexes.  In the presence of the caveolae 
enodcytosis inhibitor nystatin (25 µg/ml), GAPDH knockdown mediated by both LPR 
and LpegR complexes and percentage cell viability remained at levels comparable to 
untreated controls (Figure 4.15A and 4.16A).  Similarly, the presence of the 
macropinocytosis inhibitor amiloride before or during transfection did not diminish gene 
silencing and did not affect cell viability either.  This finding was verified using another 
drug cytochalasin D, which inhibits both caveolae-mediated endocytosis and 
macropinocytosis.  There was no significant reduction in GAPDH silencing mediated by 
LPR complexes after treatment with the inhibitor (Figure 4.15A), but a statistically 
significant (p<0.05, unpaired t-test) reduction in cell viability was observed during both 
1 and 6 h exposure to the inhibitor (Figure 4.15B).  LPegR complexes resulted in ~30% 
reduction in gene silencing when the inhibitor was present during the whole transfection 
duration (Figure 4.16A), but it was linked with an 80% reduction in percentage viable 
cells as compared to cells not treated with cytochalasin D (Figure 4.16B). 
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Figure 4.14  Colocalization studies of LPeg-Cy3-R complexes with BODIPY-LacCer in A549 cells.  Cells were first incubated with 
BODIPY-LacCer (green) for 30 min at 4°C, followed by incubation with Lpeg-Cy3-R complexes for another 90 min at 37°C prior to 










Figure 4.15  A) Gene silencing and B) cell viability of A549 cells when exposed to 
LPR complexes after pretreatment with inhibitors of non-clathrin mediated 
endocytosis.  Pre-treatment with nystatin 25 µg/ml, amiloride 8 µg/ml or 
cytochalasin D 10 µg/ml for 1 h, followed by transfection with LPR complexes in the 
absence (grey bars) or presence of the inhibitor (white bars) for 6 h.  Gene silencing 
and cell viability were measured 72 h post-tranfection using KDalert assay.  Data 
represent the mean of three independent experiments (mean±SEM).  *Statistically 










Figure 4.16  (A) Gene silencing and (B) cell viability of A549 cells when exposed to 
LpegR complexes after pretreatment with inhibitors of non-clathrin mediated 
endocytosis.  Pre-treatment with nystatin 25 µg/ml, amiloride 8 µg/ml or 
cytochalasin D 10 µg/ml for 1 h, followed by transfection with LpegR complexes in 
the absence (grey bars) or presence of the inhibitor (white bars) for 6 h.  Gene 
silencing and cell viability were measured 72 h post-tranfection using KDalert assay. 
Data represent the mean of three independent experiments (mean±SEM).  




4.4.6. The effect of combined inhibition of endocytosis pathways on the 
gene silencing efficiency of siRNA complexes  
In the previous sections, the effect of a single inhibitor on gene silencing was 
determined.  In this section the combined effect of two or more inhibitors was 
investigated to determine whether the different endocytosis pathways compensated 
when one of the pathways was inhibited.  A549 cells were exposed to a combination 
of two or three inhibitors of the endocytosis pathways and subsequently transfected 
with LpegR complexes in the presence of inhibitors.   None of the combinations of 
two inhibitors showed any significant reduction (p> 0.05, One-way-Anova, Tukey’s)  
in the gene silencing as compared to untreated cells (Figure 4.17A).  However the 
percentage of viable cells after exposure to two inhibitors was significantly reduced 
by 50% (p<0.05, One-way   Anova,   Tukey’s),   except   with   the   nystatin+amiloride  
combination where the cell viability was not affected (Figure 4.17B).  
When A549 cells were exposed to a combination of the three inhibitors 
chlorpromazine +nystatin + amiloride, there was a significant 40% inhibition of 
GAPDH gene silencing as compared to control (p<0.05, One-way Anova, Tukey’s)    
(Figure 4.17A). However triple inhibitor combination proved to be toxic and 
significantly decreased cell viability by 60%  (p<0.05, One-way   Anova,   Tukey’s) 
(Figure 4.17B).  A statistically significant difference in gene silencing between cells 
treated with nystatin+amiloride and those treated with 
nystatin+amiloride+chloropromazine was observed, but again this difference was 








Figure 4.17  A) Gene silencing and B) cell viability of A549 cells after pre-treatment 
with combinations of the endocytic inhibitors.  Pre-treatment for 1 h, followed by 
transfection with LpegR complexes in the presence of the inhibitors.  Gene silencing 
and cell viability were measured 72 h post-tranfection using the KDalert assay. (Data 
represent mean±SEM, n=3).  Statistically significant (*p<0.05, *** p<0.001, One-




The first step in gene delivery is the intracellular uptake of the gene delivery 
complex therefore knowledge of the uptake mechanisms of non-viral gene carriers is 
essential for the development of improved vectors. Early studies indicated that 
cationic lipid-mediated pDNA delivery occurs through endocytosis, although there is 
contradictory evidence regarding the exact endocytic pathways (Khalil, I.A. et al., 
2006).  Some reports showed that DOTAP:pDNA lipoplexes entered via the clathrin 
pathway (Rejman, J. et al., 2005, Rejman, J. et al., 2006), while others showed that 
distinct lipidic formulations follow different endocytic pathways; for example pDNA 
complexed to the lipid Lipofectamine-LTX entered via the clathrin-mediated 
endocytosis, while pDNA/DMRIE-C complexes followed the caveolar pathway in 
the same cell line (Wong, A.W. et al., 2007).  However, to date only a few studies 
have investigated the mechanisms involved in the uptake of siRNA/lipid complexes 
(Schroeder, A. et al., 2010).  Therefore, the aim of this work was to provide a novel 
insight into the pathways that are involved in the internalization of siRNA lipoplexes 
and to discern which pathways led to efficient gene silencing, also known as 
‘’functional  siRNA  uptake’’. 
4.5.1. Peri-nuclear localization of siRNA complexes 
The first indication of the probable uptake mechanism for siRNA complexes 
was obtained by confocal microscopy studies; LPR and LpegR complexes were 
shown to enter the cytoplasm within 2 hours of transfection.  This is consistent the 
gene silencing data in Chapter 3 and indicated that at the effective charge ratios, 
siRNA uptake was observed.  When confocal microscopy was performed using 
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fluorescently labelled Cy3-GAPDH siRNA in LPR or LpegR complexes, a spot-like 
distribution of siRNA was observed in the cytoplasm at the periphery of the nucleus.  
This stippled pattern provides evidence of the entrapment of siRNA in perinuclear 
vesicles (Lu, J.J. et al., 2009).  Furthermore, as early as 2 hours post-transfection 
some of the siRNA had already dissociated from the cationic lipid and localized in 
the cytoplasm at the perinuclear region.  This localization may represent sites of 
siRNA processing or sites where the RISC complex resides (Berezhna, S.Y. et al., 
2006).  Studies have shown that perinuclear localization is associated with high 
levels of gene silencing suggesting that siRNA is directed to these regions to interact 
with RISC to induce RNAi (Lavigne, C. and A.R. Thierry, 2007, Veldhoen, S. et al., 
2006, Billy, E. et al., 2001, Chiu, Y.L. et al., 2004).   
4.5.2. siRNA complexes uptake is temperature-sensitive 
To characterize the uptake mechanism of functional LPR and LpegR 
complexes further, uptake and transfection experiments were carried out at low 
temperatures.  Confocal analysis showed that at a low temperature (4ºC) LPR and 
LpegR complexes no longer localized to the perinuclear regions but remained on the 
cellular membrane indicating uptake inhibition.  GAPDH silencing greatly decreased 
when transfection was performed at 4-10ºC as compared to 37ºC.  These findings 
suggest the involvement of an endocytic uptake pathway as low temperature has 
been shown to reduce the flexibility and fluidity of cellular membranes and block all 
of the endocytosis pathways (Haylett T, T.L., 1991, Wiliam A. Dunn, A.L.H., And 
Nathan N. Aronson, 1980).   Studies using a number of different delivery methods 
have consistently found that siRNA was internalised by some form of endocytosis 
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(Veldhoen, S. et al., 2008, Lavigne, C. and A.R. Thierry, 2007, Detzer, A. et al., 
2008), however, it has not been shown which particular endocytosis pathway leads to 
successful siRNA delivery i.e. efficient gene silencing. 
4.5.3. The uptake of LPR and LpegR complexes is clathrin-dependent 
In order to determine by which routes LPR and LpegR complexes enter the 
cells, colocalization of internalized complexes with fluorescent uptake pathways 
markers transferrin and BODIPY-lacCer was investigated. Both LPR and LpegR 
complexes co-localized with transferrin which is known to be taken up mainly by 
clathrin-mediated endocytosis.  This indicated that both types of complex utilized the 
clathrin-meditated pathway.  This is in agreement with a study by Lu and co-
workers, who showed that 95% of siRNA lipoplexes enter the cells via the clathrin 
pathway (Lu, J.J. et al., 2009).   In addition, Rejman and co-workers (2004) showed 
that the uptake pathway of fluorescent nanoparticles was size dependent and reported 
that nanoparticles of less than 200 nm diameter entered mainly via the clathrin route; 
this corresponded with the LPR and LpegR complexes in this study which had 
particle sizes of less than 200 nm.  In contrast, no colocalization was observed 
between either types of complex with the caveolae pathway marker BODIPY-lacCer, 
therefore excluding caveolae-mediated endocytosis as an entry route for these siRNA 
complexes in this cell line.   
 199 
 
4.5.4. Functional siRNA uptake is non-clathrin, non-caveolae mediated 
and does not depend on macropinocytosis 
The uptake and intracellular processing are important factors in transfection 
efficiency. However, it has been shown recently that effective cellular uptake does 
not necessarily equate to effective transfection (Ming, X. et al., 2011, Lu, J.J. et al., 
2009).  This study investigated the uptake pathways that led to the most effective 
gene   silencing,   termed   here   as   ‘functional   siRNA   uptake’.      This   was   done   by  
examining the effect of blocking the major endocytic pathways on the gene silencing 
efficiency of siRNA complexes using endocytosis inhibitors.  Cells were treated with 
various inhibitors to differentiate clathrin-dependent from clathrin-independent 
endocytosis.  Before these studies were possible, it was necessary to optimize the 
concentrations of each inhibitor and select the most effective in blocking the uptake 
pathway with minimal toxicity to the cells. 
Despite the supposition that clathrin-mediated endocytosis has been shown to 
be the major entry pathway for DNA lipoplexes (Rejman, J. et al., 2005, Zhou, X.H. 
and L. Huang, 1994, Friend, D.S. et al., 1996, Zuhorn, I.S. et al., 2002a), the findings 
of this study suggested that that the uptake of siRNA complexes via this pathway 
failed to produce functional GAPDH silencing as the gene silencing efficiency was 
unaffected by the inhibition of the entry pathway by either chloropromazine or 
depletion of cellular potassium.  Any partial reduction in gene silencing was 
associated with toxicity due to the combined effect of inhibitors and lipoplexes. 
The caveolae pathway is another option for functional siRNA uptake as it has 
been shown to play a critical role in the uptake of DNA polyplexes (Rejman, J. et al., 
2005, Van Der Aa, M.a.E.M. et al., 2007). In addition, Detzer and co-workers (2008) 
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suggested that phosphothioate-stimulated siRNA uptake may occur through the 
caveolar pathway.   In the present study, functional siRNA delivery was not via the 
caveolar endocyotsis since gene silencing mediated by LPR and LpegR complexes 
was not imunpaired in the presence of nystatin.  This result is in agreement with the 
co-localization studies, in which no colocalization was detected between internalised 
siRNA complexes and the caveolae pathway marker BODIPY-LacCer in A549 cells.   
Macropinocytosis is another well-defined non-clathrin uptake pathway and 
recently has been considered as an entry route for gene delivery vectors in particular 
peptides such as octaarginine peptide (Khalil, I.A. et al., 2006) and TAT peptide 
(Kakudo, T. et al., 2004, Kaplan, I.M. et al., 2005, Nakase, I. et al., 2004, Wadia, 
J.S. et al., 2004). This pathway provides some advantageous aspects such as a higher 
capacity for the uptake of macromolecules, the avoidance of lysosomal degradation 
and the ease of escape from macropinosomes because of their relatively leaky nature 
(Khalil, I.A. et al., 2006).  However, in this study, the inhibition of macropinocytosis 
by amiloride had no effect on the gene silencing efficiency mediated by LPR or 
LpegR complexes.  These results were further confirmed when no effect was seen in 
the presence of cytochalasin D, which blocks both caveolae and macropinocytosis 
without affecting clathrin-mediated pathways.  Some reduction in gene silencing 
mediated by LpegR complexes was observed in the presence of cytochalasin D, but 
tyhis was attributed to toxicity.  Thus, neither caveolae nor macropinocytosis could 
be considered as a main uptake pathway of the functional siRNA/lipid complexes.   
As no single endocytotic pathway could be identified as the principal route of 
functional siRNA delivery by the use of individual inhibitors, the possibility of 
interaction between the pathways with regard to uptake was investigated.  A study by 
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Luhmann and co-workers (2008) suggested that Poly-L-Lysine-g-PEG-DNA 
complexes entered cells by several endocytic pathways and that transfection 
efficiencies were increasingly abolished when two or three pathways are inhibited as 
compared to inhibition of one pathway.  Other investigators have similarly concluded 
that not one single pathway was responsible for uptake, e.g. several pathways were 
reported to be involved in the uptake of siRNA mediated by a novel peptide MPG 
peptide (Veldhoen, S. et al., 2006).  Lu and co-workers (2009) estimated that an 
siRNA complexed to the commercial lipid Dharmafect was internalized by both 
clathrin (50%) and caveloar (20%) pathway but that none of the pathways led to 
functional gene silencing.   In the present study, when two inhibitor combinations 
were used to inhibit two different pathways at the same time, gene silencing 
mediated by LpegR complexes was not diminished.  A strong inhibition of gene 
silencing was observed when all three pathways (clathrin, caveolae and 
macropinocytosis) were blocked but this was associated with excessive cellular 
toxicity (70% cell death) which invalidated the finding; i.e. was not possible to 
distinguish whether the gene silencing inhibition was due to blockage of the uptake 
pathways, or as appears more likely, due to significant reduction in cell viability.  
These findings illustrate that the effect of inhibitors on cell viability is a major 
limitation to their use in studying uptake mechanisms.  Despite using optimized 
concentrations, there is still a narrow concentration range between effectiveness and 
toxicity, especially during longer incubation times.  Furthermore, the toxicity of 
inhibitors increased in the presence of siRNA complexes compared to when cells 
were exposed to inhibitors alone.  It is important, therefore, to look at the effect on 





The uptake mechanism that led to effective gene silencing was found to be 
temperature sensitive, indicating that it is probably energy-dependent.  In addition, it 
was shown that entry via the clathrin-mediated pathway occurred, but was not 
necessary for function, as blockade of this pathway had no effect on gene silencing 
efficiency.  It appeared that the siRNA complexes that led to efficient gene silencing 
must enter the cells via a pathway that is not clathrin, caveolae nor 
macropinocytosis-dependent as the inhibition of all the investigated pathways had no 
effect on gene silencing.  This other uptake pathway may be either another 
unconventional endocytotic pathway or passive diffusion.  Recent work by Ming and 
co-workers (2011) showed that antisense oligonucleotides (ODN) lipoplexes entered 
the cells via both endocytic and non-endocytic pathways, but it was the latter that 
accounted for gene silencing activity.  Lu and co-workers (2009) showed that despite 
most siRNA lipoplexes (95%) entering cells via endocytosis it was the 5% that 
entered through a different pathway that resulted in the majority of functional 
siRNA.  They suggested that the minor uptake pathway was passive diffusion 
through the cellular membrane as gene silencing was significantly blocked at low 
temperature and by cholesterol depletion using nystatin.  Passive diffusion provides 
the advantage of avoiding endosomal compartment and therefore siRNA can directly 
enter the cytoplasm and result in effective gene silencing.  The findings of the 
current study are consistent with these reports, although the gene silencing efficiency 
was not affected by cholesterol depletion.  However, the punctuate distribution and 
temperature sensitivity do not exclude the involvement of an endocytic pathway 
which has yet to be characterised.  It should be remembered that interpretation of 
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these findings is problematic because experiments have focused on the three well-
characterized types of endocytotic pathways and yet many aspects of these and other 
pathways remain unclear.  Nonetheless this study has provided insights into the 
uptake pathway of functional siRNA mediated by two cationic lipid systems and 




























The delivery of nucleic acids represents a powerful therapeutic tool for the 
treatment of a broad range of diseases including those of pulmonary origin (Gill, 
D.R. et al., 2004). Therefore extensive efforts have been made in order to develop an 
optimal delivery vector that allows the transfer of these nucleic acids to their target 
cells.. Non-viral delivery of pDNA has progressed over the years with the continuous 
discoveries of new delivery agents.  So far for pulmonary diseases, there has been a 
total of eight clinical trials concerning aerosol delivery of gene carriers to the lungs, 
and all these pertain to cystic fibrosis (Griesenbach, U. and E.W. Alton, 2009) and 
only very few gene transfer vectors have been aerosolised to the lungs of patients.  
One of these trials uses the non-viral cationic lipid system Genzyme lipid 67A 
(GL67A) complexed to pDNA (Alton, E.W.F.W. et al., 1999) and has been shown 
that cationic-lipid-mediated CFTR gene transfer can significantly influence the 
underlying chloride defect in the lungs of patients with cystic fibrosis.  A more 
recent one consist of cystic fibrosis gene pGT-1 complexed to DMRI:DOPE lipid but 
results are still pending (The U.S. National Institutes Health).  Although, cationic 
lipids represent a major class of non-viral delivery vectors and to date more than 100 
cationic lipids have been designed, most are under in vitro conditions, with a 
relatively few tested in vivo (Marty, R. et al., 2009a) The process of nucleic acid 
delivery remains unclear and there is ongoing work to develop an optimal system for 
in vitro and in vivo use.   
As discussed in chapter 1, since the discovery of RNA interference, the 
popularity of siRNA as a therapeutic agent has increased tremendously and the 
attention from gene therapy has deviated to gene silencing. siRNA has been 
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delivered using different cationic lipid carriers, some of which have begun to be 
evaluated in the clinic (Schroeder, A. et al., 2010).  Despite considerable advances in 
this field, there is still a need to develop safe and effective delivery systems for 
siRNA.  Previously, most of the cationic lipids shown to be effective for pDNA 
delivery have been used for siRNA delivery.  However a study in 2004 showed that 
optimal lipid-based transfection agents for siRNA differ from those of pDNA 
(Spagnou, S. et al., 2004).  Gary et al (2007) reviewed the differences between 
polymer-based siRNA and pDNA delivery and highlighted the fact that siRNA 
delivery approaches can benefit from the wealth of information on pDNA delivery.  
The limited information regarding transferability of vector design between pDNA 
and siRNA therefore warrants a study of their physical properties and function in 
order to help identify the key requirements for siRNA delivery.   
Before looking at the differences between siRNA and pDNA formulation, it is 
essential to understand what the characteristics of an optimal delivery system in 
general are.  Many researchers have investigated the optimal physical properties that 
lead to efficient lipid-mediated delivery of pDNA as reviewed by Barteaux et al 
(2008) and a few have looked at siRNA (Spagnou, S. et al., 2004, Desigaux, L. et al., 
2007, Zhang, Y. et al., 2010).  A review of the available literature so far indicates a 
lot of contradiction and differences in the optimal characteristics for high 
transfection efficiency.  These variations have been associated with the use of 
different delivery systems, different cell lines and different characterization media.  
This   study’s approach to tackle this issue was to compare three types of cationic 
lipid-based formulations of pDNA and siRNA, under the same experimental 
conditions, in order to enable correlation of physicochemical properties and delivery 
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efficiency, and to determine whether the same rule applies to all types of complexes.  
A number of unresolved questions arose from the findings of this study and are 
discussed below. 
In addition, investigating the uptake mechanism and the intracellular fate of 
pDNA and siRNA/lipid complexes allows us to gain further information on how to 
design a delivery system that will provide optimal results. Much work has been done 
in the field of uptake mechanisms of pDNA complexes, with debatable results, but 
generally it is agreed that pDNA/lipid complexes enter the cells via endoyctosis 
(Rejman, J. et al., 2005, Elouahabi, A. and J.M. Ruysschaert, 2005, Luhmann, T. et 
al., 2008).  However, at the time of this study there was only one report by Lu et al 
(2009) that attempted to characterise the uptake pathway of siRNA/lipid complexes. 
Research in the field of uptake pathways of siRNA in general, and siRNA/lipid 
complexes in particular, is still in its infancy.  Thus, this thesis investigated the 
involvement of major endocytic pathways in the uptake of siRNA/lipid complexes.  
5.2. Correlation between the physicochemical properties and 
transfection efficiency of pDNA complexes 
The aim of this chapter was to set ground for working with siRNA, as in order 
to compare between the two nucleic acids it is important to use the same systems, 
cell line and experimental conditions.  Despite some slight modifications to the 
protocols, the cationic lipid-based systems used in this study have already been 
employed to deliver pDNA but were not compared directly under one study. Nor 
have they been prepared and characterised in the same media and at the same +/- 
charge ratios in previous studies (Yang, J.P. and L. Huang, 1998, Birchall, J.C. et al., 
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1999, Kim, J.K. et al., 2003, Coulman, S.a.B., David; Anstey, Alexander; Gateley, 
Chris; Morrissey, Anthony; Wilke, Nicolle; Allender, Chris; Brain, Keith; Birchall, 
James C, 2006). By taking into consideration all three systems, results showed no 
obvious correlation between physical properties and gene expression efficiency i.e. 
transfection efficiency.  However if looking at the systems individually, high 
transfection was related to negative or low zeta potential, low condensation 
efficiency and a large particle size (micron range) for LD and LpegD complexes.  
However, when looking at the LPD complexes, high transfection correlated with a 
high positive charge, high condensation efficiency, and despite showing significant 
differences in particle size, there was no significant difference in gene expression 
levels.  These differences led to the suggestion that the LPD complexes might have 
either a different uptake mechanism or a different endosomal escape mechanism and 
pDNA release mechanism due to the presence of protamine.  One the other hand, 
protamine has not been shown to be involved in transfection as pDNA complexed to 
protamine is inactive in inducing transfection and this was associated with the 
inability to enter cells or inability to escape endosomes (Collins, E. et al., 2007).  On 
the other hand, one has to consider the possibility that due to the heterogeneity of the 
pDNA/lipid complexes in physiological media, the physical characterisation methods 
used were not detecting a minor population of complexes that is functional and 
resulted in efficient gene expression.  Before incubation in the transfection media, 
complexes were first made in water and characterised.  Results showed that in water 
the condensation ability, size and charge correlated with the general three-zone 
colloidal stability pattern discussed in chapter 2.  After incubation in physiological 
media, complexes formed large aggregates and lost the particle size trends observed 
in water. In addition, the physical characteristics of LPD complexes in water 
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matched those of gene expression levels, so it can be assumed that the population of 
complexes that did not form aggregates are responsible for effective transfection.   
It is also important to highlight the significance of characterising the 
complexes in the media used for transfection as characterisation in water or low salt 
concentration solution might give misleading results.  Many studies have 
characterised pDNA or siRNA complexes in water and performed transfection 
experiments in cell culture media which has a high ionic strength not taking into 
account any changes in complex characteristics upon change of media (Eastman, S.J. 
et al., 1997, Nchinda, G. et al., 2002, Wiethoff, C.M. et al., 2004, Spagnou, S. et al., 
2004, Zhang, Y. et al., 2010).  For example Birchall et al. (2000) who designed the 
LPD system argued that this system would provide compact, small, homogenous 
complexes but did not show the effect of high ionic strength of media on the physical 
characteristics.   The use of high ionic strength media reflects the in vivo situation, 
which may lead to a poor control on the stability of the complexes once exposed to 
physiological conditions.  
5.3. Difference between siRNA and pDNA complexes 
5.3.1. Physical properties 
In these studies, siRNA was complexed to the same systems as pDNA and 
showed significantly different physical properties, particularly with the condensation 
data.  siRNA complexes showed much lower condensation than pDNA complexes, 
especially the LPR system, which contains both a polycation and a cationic lipid.  
This was explained by the fact that pDNA is much larger than siRNA and possesses 
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a molecular topography that allows it to condense into nanoparticles, whereas siRNA 
molecules are only 21-23 nucleotides in length and have a rigid structure and do not 
condensate even upon interaction with a cationic carrier (Gary, D.J. et al., 2007).  
Recent work has shown that by increasing the +/- charge ratio, cationic lipids 
were able to compact siRNA at ratios higher than those used to condense pDNA, but 
these studies used different lipidic systems and different methods of characterizing 
complexation. For example, gel electrophoresis (Zhang, Y. et al., 2010), which 
reflects binding more than condensation, and the ethidium exclusion assay 
(Desigaux, L. et al., 2007) can tell you different things.  In addition the study by 
Desigaux and colleages did not show the standard deviation and did not mention the 
number of experiments performed so it does not indicate the reproducibility of the 
system.  The findings of the current study contradicted these finding as even with 
increasing the charge ratio to 20 (data not shown), siRNA was still accessible to the 
intercalation dye. That raised a suspicion about the suitability of using SYBR-green 
II intercalation assay to determine complexation efficiency, but when siRNA was 
complexed to either protamine without lipids, and the commercial transfection 
reagent Lipofectamine, high condensation was observed.  Thus it validates the 
suitability of the data.  Nonetheless, careful interpretation of the intercalation assay is 
required because exclusion of the intercalating dye not only suggests condensation 
but can also indicate charge neutralisation.  Therefore even if siRNA was not 
accessible to the dye when complexed to protamine or Lipofectamine, it does not 
necessarily indicate condensation.  With the three lipidic systems studied it is likely 
that siRNA is loosely bound to the cationic lipids, which makes it easier for the 
intercalating dye to compete with the lipid and gain access to the nucleic acid. In 
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addition, the presence of the neutral lipid DOPE might have caused weaker binding 
between siRNA and the cationic lipid.  This weak binding could be beneficial in 
terms of ease of release of siRNA once the complexes enter the cells, but is also a 
disadvantage in vivo as the complexes might de-asSEMble easily upon interaction 
with negatively charged plasma proteins before reaching their target cells. 
In terms of particle size, although siRNA complexes were prepared in cell 
culture media (high ionic strength) the complexes were much smaller than pDNA 
complexes  (nanorange) and followed the three-zone model, when negative or 
positive charge are in excess the complexes have a small particle size (150-200 nm) 
and at neutral charge (positive charges almost equal negative charges) large 
aggregates were observed (500-700 nm).  This comes in agreement with recent 
studies (Desigaux, L. et al., 2007, Zhang, Y. et al., 2010).  The only exception to the 
particle size change was the LPR system that had the same small size regardless of 
the amount of lipid used (+/-charge ratio), and this can normally be associated with 
pre-complexation of the nucleic acid with protamine.  
5.3.2. Transfection efficiency 
The finding of these studies showed that the optimal charge ratios for pDNA 
transfection in Calu-3 cells were inefficient for siRNA transfection.  siRNA 
complexes for all three systems were only active in inducing protein knockdown at 
higher charge ratios.  The characteristics of the effective siRNA complexes were a 
small size with low polydispersity, a positive charge and a low complexation 
efficiency.  However, effective gene silencing cannot directly be associated with 
these physical properties because in the case of the LPR systems, complexes showed 
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no difference in particle size and complexation at the different charge ratios but 
displayed differences in gene silencing efficiency.  The main conclusion from these 
studies was that what was effective for pDNA was ineffective for siRNA complexes, 
regardless of the lipidic system used. 
At the effective ratios for each system, about 50% GAPDH protein knockdown 
in Calu-3 cells was observed.  The protein knockdown was also determined in a 
different cell line, the alveolar A549 cells previously used in the transfection 
efficiency studies to verify the reproducibility of the results in different cells.  
Surprisingly, the percentage protein knockdown was higher and reached up to 80-
90% at some charge ratios.  This showed that A549 cells were more transfectable 
than Calu-3 cells. One explanation for this is the difference in the negative charge of 
the endosomal membrane and again this highlights the fact that efficient gene 
silencing is also dependent on the target cells.  Cell lines represent an important tool 
for screening new therapeutics, which has the advantage of shorter experimental 
times, and being less labour extensive than primary cultures or animal use.  However 
there is a concern about how well results can be based on cell lines that do not 
accurately reflect the in vivo situation.  In order to mimic the in vivo situ, this study 
looked at the effect of serum on the gene silencing efficiency of the complexes.  LPR 
and LpegR complexes at a charge ratio of 10 were judged to be most effective due to 
the reproducibility of protein knockdown. The presence of protamine and PEG 
chains has been reported to enhance stability, which may have aided in complex 
stability in serum (Hong, K. et al., 1997).  Data showed that despite some inhibition 
of protein knockdown at high serum concentration, complexes were still active and 
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resulted in up to 50% protein knockdown, in particular the LPR complexes.  
Therefore, these systems might have the potential for in vivo usee.  
Overall all these data led to the conclusion that despite being complexed to 
identical cationic systems, the resulting siRNA and pDNA complexes were 
significantly different in terms of complexation efficiency, particle size and 
biological activity. Therefore what worked for pDNA did not work for siRNA.  In 
addition, factors that affected pDNA transfection efficiency were different from 
those that affected siRNA delivery.  This suggested that although siRNA delivery 
can benefit from ideas and knowledge developed in the pDNA delivery field, it is 
better to look to siRNA as a different molecule and aim to further investigate the 
factors that influence gene-silencing efficiency. 
5.4. The involvement of endocytic pathways in the uptake of siRNA 
complexes 
At the time of this work, there was only one study that investigated the 
involvement of different endocytic pathways in the uptake of siRNA/lipid 
complexes. Lu and colleagues used the commercial cationic lipid based siRNA 
transfection agent called DharmaFECT1, and proposed that even if siRNA 
complexes were mainly internalised via an endocytic pathway (clathrin and non-
clathrin dependent), a small portion of complexes that were biologically active 
entered via a minor pathway which was affected by changes in temperature and 
cholesterol depletion. They suggested that this pathway is passive diffusion.  The 
findings of the present study showed that LPR and LpegR complexes were 
internalised via clathrin-mediated endocytosis, but the inhibition of this mechanism 
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had no effect on gene silencing efficiency, which correlated with the data reported by 
Lu and colleagues.  Molecules that enter through the endocytic pathway end up in 
early endosomes maturing into lysosomes where degradation takes place. Therefore 
there it is possible that most of the complexes are degraded in the endosomes unless 
they escape, making this uptake process unfavourable for siRNA complexes.  
However, the protein knockdown activity of both LPR and LpegR was completely 
inhibited by reduction in temperature suggesting an energy-dependent process 
(Haylett T, T.L., 1991, Wiliam A. Dunn, A.L.H., And Nathan N. Aronson, 1980).  
Furthermore, in confocal microscopy studies, fluorescent siRNA complexes 
displayed a punctuate distribution in the peri-nuclear region, suggesting a vesicular 
entrapment of the complexes.  All these findings led to the conclusion that functional 
siRNA entered cells through a temperature-dependent pathway which was clathrin 
and caveloae-independent and did not involve macropinocytosis.  This pathway 
could be a yet unknown receptor-mediated endocytosis and complexes that entered 
through this route avoided the endosomal pathway and therefore remained 
biologically active.  There is a small chance that passive diffusion could be involved 
as hypothesised by Lu and colleagues, but they justified their theory by the inhibitory 
effect of both temperature and cholesterol, which affect cellular membrane integrity.  
However the current data only showed temperature dependence and cholesterol 
depletion had no effect on protein knockdown efficiency.  In addition, the dotted-like 
distribution of fluorescent complexes suggested a vesicular entrapment.    
Determining the nature of vesicles in which siRNA was internalised could provide 
further information on the uptake pathway.  The difference in the uptake mechanism 




5.5. Future challenges 
The above discussion drew attention to a few areas that need further 
consideration in order to develop an optimal siRNA formulation for in vivo use.  
These include (a) investigating the effect of serum on the physical properties and 
stability of the LPR and LpegR and the effect of increasing pegylated lipid 
concentration on serum inhibition, (b) quantitative analysis of the uptake of siRNA 
complexes would provide a more clear picture on the involvement of each endocytic 
pathway, (c) differentiating between endosomes from other vesicles by fluorescent 
staining in order to gain more information on the nature of the vesicles involved in 
siRNA complexes uptake, (d) optimising the formulation of siRNA into a dry 
powder for in vitro delivery to monolayers of differentiated lung cell lines with 


































































0 2000 4000 6000 8000 10000 12000










Figure A.2  MTT calibration curve to determine the optimal Calu-3  cells’   seeding  
density for MTT test.  The experiment was carried out three times with n=12 each 
time (n=3, mean ± STD). 
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Figure A.3  Bio-Rad protein assay standard curve using, the standard protein (bovine 
gamma-globulin). (n=3, mean ± STD). 
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